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ABSTRACT 
Barth syndrome (BTHS) is an X-linked disease characterized by cardio- and skeletal 
myopathy, hypotonia, growth delay, neutropenia, and 3-methylglutaconic aciduria. Patients 
have mutations in the TAZ gene on chromosome Xq28 (G4.5) most of which are presumed to 
result in a loss-of-function of the protein product, tafazzin (TAZ). As TAZ is involved in the 
remodeling of the phospholipid, cardiolipin (CL), the resultant lipid profile in the absence of 
its function shows decreased CL levels, accumulated monolyso-CL, and the remaining CL 
contains an altered acyl chain composition. Unfortunately, the lack of an antibody against 
endogenous TAZ has prevented a detailed cell biologic and biochemical characterization of 
the endogenous protein. This in turn has impeded a molecular understanding of the protein’s 
role in BTHS pathogenesis. Here, we have developed three mouse monoclonal antibodies 
capable of detecting endogenous TAZ in mammals. A complicating aspect of mammalian 
TAZ research is the presence of many predicted alternatively spliced variants, of which only 
the hTAZ –exon5 was able to fully restore aberrant CL profile in the Saccharomyces 
cerevisiae Δtaz1 mutant. Importantly, each TAZ antibody has the ability to detect every 
predicted isoform as determined by epitope mapping. Our results also show that only one 
isoform of TAZ is normally expressed in human fibroblasts, HEK293 Flp-In cells, amd 
mouse heart and liver, despite the reported detection of mRNA corresponding to multiple 
splice variants.  
Using mouse tissues, 293 Flp-In cells, and immortalized fibroblasts derived from 
healthy and BTHS patients, we demonstrate that mammalian TAZ is a highly protease-
resistant and localized to the mitochondria where it associates non-integrally with 
membranes and assembles in a range of complexes. Like its yeast counterpart, TAZ in 
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humans and rodents associates with the IMS-facing leaflets of the inner and outer 
mitochondrial membrane, Finally, using a novel mammalian BTHS cell culture model 
established via TALEN-mediated genome editing, we demonstrate that the loss-of-function 
mechanisms for two pathogenic alleles, R57L and H69Q, when overexpressed in tazTALEN 
cells, are the same as originally modeled and defined in yeast. Thus, our results reveal that 
tazTALEN cells can serve as a convenient platform to systematically dissect the loss-of-
function mechanisms that underlie other BTHS variants, especially those that cannot be 
modeled in yeast due to lack of conservation. Combined with the generation of antibodies 
against endogenous TAZ, this work provides a major leap forward in our ability to 
characterize this enigmatic protein, to assign and discern the functions of TAZ and its 
numerous variants, and to study its role in CL metabolism. 
 
Advisor: Steven M. Claypool, Ph.D. 
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 The signature mitochondrial phospholipid cardiolipin plays an important role in 
mitochondrial function,and alterations in cardiolipin metabolism are associated with 
human disease. Topologically, cardiolipin biosynthesis and remodeling are complex. 
Precursor phospholipids must be transported from the ER, across the mitochondrial outer 
membrane to the matrix-facing leaflet of the inner membrane, where cardiolipin 
biosynthesis commences. Post-synthesis, cardiolipin undergoes acyl chain remodeling, 
requiring additional trafficking steps, before it achieves its final distribution within both 
mitochondrial membranes. This process is regulated at several points via multiple 
independent mechanisms. Here, we review the regulation and topology of cardiolipin 
biosynthesis and remodeling in the yeast Saccharomyces cerevisiae. Although cardiolipin 
metabolism is more complicated in mammals, yeast have been an invaluable model for 
dissecting the steps required for this process. 
 
KEYWORDS 
cardiolipin, remodeling, mitochondria, yeast, regulation, lipid trafficking  
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CCCP, carbonyl cyanide 3-chlorophenylhydrazone; CDP-DAG, CDP-diacylglycerol; CL, 
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intermembrane space; OM, outer membrane; PA, phosphatidic acid; PG, 






The unique phospholipid cardiolipin (CL) is required for the efficiency of a 
number of mitochondrial processes (1). CL is unique for a number of reasons: 1) unlike 
most other phospholipids which are synthesized in one or a few cellular locations, then 
disseminated throughout a cell’s membranes, CL by and large remains in the 
mitochondrion, its site of synthesis; 2) CL is essentially a lipid dimer; it consists of two 
phosphate headgroups, which are attached by a glycerol moiety, and four acyl chains; and 
3) after its synthesis, CL undergoes acyl chain remodeling, where acyl chains are 
removed by a lipase and replaced by a transacylase or acyltransferase, resulting in the 
establishment of only a few molecular forms of CL in a cell or tissue. Surprisingly, the 
acyl chain specificity of the lipase has never been demonstrated (2), and the transacylase 
tafazzin has no acyl chain specificity (3), although tafazzin from Drosophila has been 
shown to preferentially catalyze transacylation reactions on curved membranes leading to 
the establishment of CL with unsaturated acyl chains, which were proposed to decrease 
lipid disorder in areas of high curvature (4). Curiously, the final molecular form of CL 
varies between organisms and even between cell types within the same organism. 
CL serves the cell in multiple capacities: it associates with all the major proteins 
of the mitochondrial respiratory chain and thereby increases the efficiency of electron 
flow and ADP/ATP exchange (5-12), modulates the catalytic activities and stability of 
interacting proteins (7, 12-15), is critical for the biogenesis of mitochondrial proteins (12, 
16, 17), facilitates mitochondrial fission/fusion (18-20), and is involved in the 




In addition to the importance of CL in promoting and maintaining normal 
mitochondrial function, alterations in CL metabolism have been associated with ischemia 
and reperfusion, heart failure, diabetic cardiomyopathy, and Barth syndrome (24-28). 
Barth syndrome is caused by mutations in tafazzin (TAZ1), and patients present with 
cardio- and skeletal myopathy, neutropenia, 3-methylglutaconic aciduria, and abnormal 
mitochondria (24, 29). 
Much of the knowledge of CL biosynthesis and remodeling comes from studies in 
yeast.  In addition to the “usual” advantages of using yeast as a model system (30, 31), 
yeast are viable in the absence of CL and CL precursor phospholipids (32-36) whereas in 
higher eukaryotes CL is required for life (37).  Although CL biosynthesis and remodeling 
are highly conserved between yeast and higher eukaryotes, there are still a few 
differences. There are no orthologs of Gep4p, the phosphatidylglycerolphosphate (PGP) 
phosphatase, or Cld1p, a CL lipase, in higher eukaryotes (2, 32). However, the 
phylogenetically unrelated PTPMT1 performs the same function as Gep4p (37); and a 
calcium-independent phospholipase A2 has been implicated as a CL lipase (38-40), 
although its exact role in CL remodeling remains nebulous (41). Additionally, only the 
tafazzin-mediated CL remodeling pathway exists in yeast, while additional remodeling 
enzymes have been identified in mammals (reviewed in (1)). Thus, while yeast have been 
useful in dissecting this process, the complexity of and multitude of players in 
mammalian CL remodeling suggest that there is still much to discover. 
With the recent characterizations of Cld1p, Gep4p and Tam41p (2, 32, 42), it is 




identified in yeast; however, many questions regarding the regulation of this process, as 
well as the topology and trafficking of CL and its precursors, remain (Figure 1.1). 
 
DELIVERYING PRECURSOR PHOSPHOLIPIDS TO THE IMM 
CL biosynthesis requires CDP-diacylglycerol (CDP-DAG), which is formed from 
phosphatidic acid (PA) and CTP by a CDP-DAG synthase (43). Yeast contain two CDP-
DAG synthases: Cds1p in the ER (44), and the recently characterized Tam41p in the 
mitochondrial inner membrane (IMM) (42).  
Although CDP-DAG (containing an NBD moiety) is able to be translocated from 
the ER to the IM in vitro, this process is inefficient (42). The very low abundance of CL 
in Δtam41 yeast (45, 46) suggests that if Cds1p-derived CDP-DAG contributes to CL 
biosynthesis, its role is very minor. Tam41p is peripherally associated with the matrix 
side of the IMM (Table 1) (42, 47).  Thus, Tam41p activity requires that its substrate, PA, 
be transported from the ER to the matrix-facing leaflet of the IMM. Phospholipid 
transport between the ER and mitochondrial outer membrane (OMM) was suggested to 
be mediated by the ER-mitochondria encounter structure (ERMES) complex which 
physically tethers the two organelles (48). Indeed, loss of any ERMES complex subunit 
(Mdm10p, Mdm34, Mdm12p, or Mmm1p) alters the mitochondrial phospholipid profile, 
including reducing CL (45, 48, 49). However, its direct role in phospholipid transport has 
recently been challenged (50, 51). Further, defects caused by the loss of a functional 
ERMES complex can be rescued by expressing an artificial ER-mitochondria tether, 
suggesting that the ERMES complex facilitates phospholipid transport by forming close 




(48, 50, 51). Notably, these studies focused on the transport of phosphatidylserine from 
the ER to mitochondria (and phosphatidylethanolamine to the ER after is decarboxylation 
in mitochondria). Thus, the mechanisms of PA and CDP-DAG transport from the ER to 
mitochondria, and the players involved, including a direct assessment of the role of the 
ERMES complex, remain to be discovered. 
To reach to the IMM, CL precursor phospholipids must traverse the OMM, but 
little is known about this process. Phospholipid exchange between leaflets of purified 
OMM vesicles is rapid, suggesting that proteins mediate this process. However, treatment 
with proteases or with sulfhydryl reactive compounds does not inhibit transbilayer 
movement across the OMM (52). 
PA is transported from the OMM to the IMM by the intermembrane space (IMS) 
resident protein, Ups1p (53). Mdm35p binds Ups1p, facilitating its import into the IMS 
and preventing its proteolytic degradation (54, 55). Although Ups1p/Mdm35p dimers can 
bind negatively charged phospholipids, only PA is transported in vitro, demonstrating the 
specificity of its transport activity. Ups1p is unable to dissociate from membranes 
containing physiological levels of CL. Thus, the higher amount of CL in the IMM is 
modeled to confer directionality of PA transport and the ability to limit CL accumulation 
(53). Once delivered to the IMM, PA must traverse to the matrix side of the IMM. This 
could be accomplished by an unidentified protein or alternatively, PA may redistribute to 








The first committed step of CL biosynthesis is the formation of PGP from CDP-
DAG and glycerol-3-phosphate by Pgs1p (36). While the topology of Pgs1p has never 
been formally investigated (Table 1), the presence of an NH2-terminal presequence, 
which is able to import the lacZ gene product to the matrix (58), suggests that Pgs1p is 
localized on the matrix side of the IMM. PGP is then dephosphorylated to 
phosphatidylglycerol (PG) by Gep4p, a protein that is peripherally attached to the matrix 
side of the IMM (32). In the final step of CL biosynthesis, PG and another CDP-DAG are 
condensed to form CL by Crd1p (34, 35). Characterization of the rat Crd1p homolog 
from liver indicates that it is an integral membrane protein and that its active site faces 
the matrix (59, 60).  
Exogenous inositol downregulates phosphatidylcholine and phosphatidylinositol 
biosynthesis through transcriptional repression via an inositol sensitive upstream 
activating sequence (UASINO) (61). Pgs1p activity is similarly reduced in the presence of 
inositol, but it contains a mutated, nonfunctional UASINO sequence (62) and PGS1 
mRNA levels are unchanged in the presence of inositol (63). Further, deletion of the 
UASINO-binding genes INO2, INO4, or OPI1 does not affect Pgs1p activity (64), 
suggesting its inositol-mediated regulation is independent of the INO2-INO4-OPI1 
circuit. Indeed, inositol increases Pgs1p phosphorylation, leading to its repressed activity, 
although the kinase(s) involved has yet to be identified (65). Independent from its 
inositol-mediated regulation, Pgs1p activity is increased under conditions indicative of 




phase, and its activity is higher in the presence of non-fermentable carbon sources and 
when cells contain functional mtDNA (63, 66, 67). 
Crd1p activity is similarly increased during stationary growth, in the presence of 
mtDNA, and in the presence of non-fermentable carbon sources, leading to increased CL 
levels (66, 68-72). This is not surprising considering the importance of CL in a myriad of 
mitochondrial functions (1); as mitochondrial biogenesis increases, CL levels 
concurrently increase. 
Crd1p activity can be additionally regulated by the matrix pH (73). Treatment of 
yeast with the protonophore CCCP (which disrupts the pH and electrical gradients across 
the IMM), but not the K+ ionophopre valinomycin (which disrupts the electrical gradient 
but does not affect the matrix pH), decreases Crd1p activity. A decrease in the matrix pH 
is indicative of less robust electron transport chain activity, coordinating the 
mitochondrion’s energetic requirements with CL biosynthesis. This is further exemplified 
by the decreases in CL levels that result from defects in respiratory complexes and/or 
bioenergetic function (73, 74). 
Interestingly, while steady state CL levels were reduced in Δtaz1 yeast, synthesis 
of CL was actually increased in the mutant, concurrent with MLCL accumulation (28).  
These observations led the group to suggest that de novo CL biosynthesis might be 
regulated by downstream CL acylation/remodeling. Crd1p’s activity might therefore be 
negatively regulated by its own product, and under conditions where CL is decreased or 
aberrantly acylated, the cell compensates by promoting CL biogenesis. 
CL biosynthesis is thus regulated via multiple independent mechanisms: by 




Crd1p activity; by CL, which may inhibit Crd1p activity; and by the capacity for 
oxidative phosphorylation, which affects Crd1p. 
 
REMODELING CL 
 CL remodeling is initiated by the lipase Cld1p in yeast (2), which removes an acyl 
chain from CL, generating MLCL. Taz1p performs an acyl-CoA independent 
transacylation reaction, transferring an acyl chain from a phospholipid to a 
lysophospholipid (generated by a phospholipase), regenerating CL (28, 75, 76). 
 Cld1p is located on the matrix-facing leaflet of the IM and does not traverse the 
membrane (69). Surprisingly, the localization of Taz1p is not the same as enzymes 
upstream in the pathway. In yeast, Taz1p was originally localized to the mitochondrial 
OMM (77), but was later shown to be present on both the inner and outer membrane, on 
leaflets facing the IMS (16, 25). Taz1p is an interfacial membrane protein; it contains 
residues that are embedded in, but not through, the membrane (Claypool 2006). 
Cld1p and Taz1p are localized to different sides of the IMM, and neither contains 
transmembrane domains, suggesting that an as yet unidentified protein(s) transports 
MLCL generated by Cld1p to the opposite side of the IMM and/or to the OMM. This 
trafficking of MLCL is expected to occur rapidly after CL deacylation as MLCL does not 
accumulate in yeast with a functional Taz1p (28, 69). That both Cld1p and Taz1p 
assemble into higher-order complexes (25, 68, 69), and that their binding partners have 
been, at best, partially defined, raises the exciting possibility that the protein(s) mediating 
MLCL translocation physically interacts with Cld1p, Taz1p, or both enzymes, although 




membrane leaflets have been identified for the plasma membrane, Golgi, and endosomes 
(78), considerably less is known about this process in the mitochondrion. CL 
redistribution between IMM leaflets has been observed (56, 60), but the protein(s) 
responsible has not been identified. So far, phospholipid scramblase 3 (PLS3) is the only 
mitochondrial protein suggested to facilitate transbilayer lipid trafficking (79), but this 
has not been formally demonstrated. Further, deletion of its predicted yeast ortholog, 
AIM25, in yeast does not result in MLCL accumulation (data not shown). Importantly, 
the translocation of phospholipids between membrane leaflets may not be facilitated by 
specific proteins, but instead non-specifically by the presence of numerous 
transmembrane proteins, as has been suggested for bacterial membranes and the ER (78, 
80, 81). 
Similar to Crd1p, Cld1p activity is upregulated in the presence of non-fermentable 
carbon sources. Cld1p expression increases in lactate-containing media, and is repressed 
in dextrose-containing media (69), suggesting that CL remodeling is coordinately 
regulated with biosynthesis. Cld1p is also regulated by changes in the electrochemical 
gradient, but through a different mechanism and with a different functional outcome than 
Crd1p regulation. While reduction of the matrix pH decreases Crd1p activity (73), Cld1p 
activity increases upon dissipation of the electrical potential (69). These differences may 
provide a mechanism by which CL biosynthesis and remodeling activity can be 
independently adjusted to fit the requirements of the mitochondrion. 
Cld1p is the only protein in the CL remodeling pathway whose activity is known 
to be regulated (Taz1p expression increases when yeast are grown in the presence of non-




Taz1p provides a potential point of regulation, MLCL levels remain unchanged and very 
low/absent unless Taz1p is non-functional (69), suggesting that the activity of the MLCL 
flippase and Taz1p is never limiting.   
 
ESTABLISHING THE FINAL DISTRIBUTION OF CL 
CL is enriched in the IMM, but is also present on the OMM (16). How it achieves 
its final distribution in yeast is still unclear. Intriguingly, the presence of a subpopulation 
of Taz1p on the OMM opens up the possibility that MLCL may be the lipid species 
trafficked from the IMM to the OMM, where it is then reacylated to form CL (16, 25). 
Phospholipid transfer between the OMM and IMM has been suggested to occur at 
contact sites between the two membranes (82, 83). Recently, the proteins comprising this 
complex (termed mitochondrial inner membrane organizing system, MICOS) have been 
identified (84-86). Loss of this complex results in abnormal cristae morphology and loss 
of cristae junctions. However, the effects on phospholipid transport, the import of the CL 
precursor PA, or the final distribution of CL, have yet to be studied in contact site mutant 
yeast strains. 
Currently, three proteins have been described that have the ability to 
traffic/redistribute CL in mammals: the mitochondrial creatine kinase (MtCK) (87), the 
mitochondrial nucleoside diphosphate kinase (NDPK-D) (87, 88), and phospholipid 
scramblase 3 (PLS3) (79). However, MtCK has no ortholog in yeast. Yeast also do not 
contain a mitochondrial-specific ortholog of NDPK-D, although a small portion of the 
yeast nucleoside diphosphate kinase, Ynk1p, localizes to mitochondria (89). However, if 




to redistribute CL between the IMM and OMM in mammalian mitochondria (79), but 
phospholipid transport between membranes is inconsistent with its role as a scramblase. 
Thus, it is likely that PLS3 instead coordinates with a CL transport protein, and the 
altered distribution of CL between the OMM and IMM when PLS3 is overexpressed 
reflects the increased availability of CL on the IMS-facing leaflet of the IMM. 
Three UPS isoforms exist in yeast, although a concrete function has yet to be 
assigned to Ups2p or Ups3p. It is tempting to speculate that, like Ups1p and PA (53), 
either of these proteins can transport CL (or MLCL) between the IMM and OMM. 
Interestingly, total CL levels in UPS2 and UPS3 mutants remain largely unaffected (90, 




While most, if not all, of the enzymes involved in CL biosynthesis and 
remodeling have been identified (at least in yeast), many questions remain. How CL 
precursors are trafficked, and how CL achieves its final distribution, remains 
incompletely resolved. The ERMES complex is undoubtedly important for the trafficking 
of phospholipids between the ER and OMM, but whether it directly transports 
phospholipids or simply mediates the apposition of the two membranes remains to be 
answered. OMM/IMM contact sites are potentially important for the movement of both 
CL precursors and CL itself between mitochondrial membranes, but this is currently an 
understudied aspect of CL metabolism. Additionally, the proteins mediating CL/MLCL 




identification. The regulation of CL precursor trafficking, except for the potential ability 
of CL to inhibit Ups1p/Mdm35p-mediated PA import, is unknown. Trafficking steps 
have the potential to regulate the flux of precursors through the CL pathway, but whether 
this is the case has yet to be determined. Further, compared to yeast (Figure 2 
summarizes modes of regulation identified in yeast), knowledge of these processes and 
their regulation in mammals is lacking. 
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FIGURE 1.1 The topology of CL biosythesis and remodeling. Phosphatidic acid (PA) is synthesized in the ER and translocates to mitochon-
dria in a process that is influenced by the ERMES (ER-mitochondria encounter structure) complex. Ups1/Mdm35p heterodimers transport PA 
from the OMM to the IMM, potentially at contact sites (established by MICOS complexes). PA is converted to CDP-diacylglycerol (CDP-DAG) 
by Tam41p on the matrix-facing leaflet of the IM. CDP-DAG is used to generate phosphatidylglycerolphosphate (PGP) by Pgs1p. PGP is 
dephosphorylated to phosphatidylglycerol (PG) by Gep4p. PG and another CDP-DAG are condensed to form unremodeled CL by Crd1p. CL is 
deacylated by Cld1p on the matrix-facing leaflet of the IMM, forming MLCL. Via an unknown mechanism, MLCL must flip to the IMS-facing 
leaflet of the IMM or be transported to the OMM to gain access to the transacylase Taz1p, which regenerates CL. Multiple rounds of 
deacylation/reacylation result in remodeled CL which is enriched in unsaturated acyl chains. CL achieves its final distribution on both leaflets of 
the IMM and OMM through currently ill-defined mechanisms. The depicted topology of Pgs1p has not been experimentally verified. Solid lines 
indicate known pathways. Dashed lines delineate potential but currently unknown phospholipid transport processes.
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FIGURE 1.2 Regulatory mechanisms of CL biosynthesis and remodeling. The CL biosyn-
thetic pathway is upregulated under conditions favoring mitochondrial biogenesis. In contrast, 
deficiencies in ERMES (ER-OMM), MICOS (OMM-IMM contact sites) complexes, and compo-
nents of the electron transport chain, as well as increased levels of inositol and reduced matrix 
pH, can all lead to a down-regulation of CL biosynthesis. Additionally, CL levels can be modu-
lated by Ups1p/Mdm35p-mediated PA transport. Similar to CL biosynthesis, growth of yeast on 
respiratory media also promotes CL remodeling by upregulating the activity and/or expression of 
enzymes in the remodeling pathway. Distinct from CL biosynthesis, dissipation of the electrical 
potential across the IMM, indicative of reduced OXPHOS capacity, increases Cld1p activity. 
Green boxes indicates conditions that promote CL biosynthesis and remodeling while red boxes 
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The human nuclear and mitochondrial genomes co-exist within each cell. While the 
mitochondrial genome encodes for a limited number of proteins, transfer RNAs, and 
ribosomal RNAs, the vast majority of mitochondrial proteins are encoded in the nuclear 
genome. Of the multitude of mitochondrial disorders known to date, only a fifth are 
maternally inherited. The recent characterization of the mitochondrial proteome therefore 
serves as an important step towards delineating the nosology of a large spectrum of 
phenotypically heterogeneous diseases. Following the identification of the first nuclear 
gene defect to underlie a mitochondrial disorder, a plenitude of genetic variants that 
provoke mitochondrial pathophysiology have been molecularly elucidated and classified 
into six categories that impact: 1) oxidative phosphorylation (subunits and assembly 
factors); 2) mitochondrial DNA maintenance and expression; 3) mitochondrial protein 
import and assembly; 4) mitochondrial quality control (chaperones and proteases); 5) 
iron-sulfur cluster homeostasis; and 6) mitochondrial dynamics (fission and fusion). 
Here, we propose that an additional class of genetic variant be included in the 
classification schema to acknowledge the role of genetic defects in phospholipid 
biosynthesis, remodeling, and metabolism in mitochondrial pathophysiology. This 
seventh class includes a small but notable group of nuclear-encoded proteins whose 
dysfunction impacts normal mitochondrial phospholipid metabolism. The resulting 
human disorders present with a diverse array of pathologic consequences that reflect the 
variety of functions that phospholipids have in mitochondria and highlight the important 
role of proper membrane homeostasis in mitochondrial biology. 
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MITOCHONDRIA AND DISEASE 
The mitochondrion is the primary generator of adenosine triphosphate (ATP) in 
eukaryotes. In addition to oxidative phosphorylation (OXPHOS), the mitochondrion is 
involved in a wide range of essential cellular processes. The organelle is the home for the 
tricarboxylic acid cycle, fatty acid beta-oxidation, iron-sulfur cluster biogenesis, a portion 
of the urea cycle, and steps in the porphyrin and pyrimidine biosynthetic pathways. 
Moreover, mitochondria have important roles in Ca2+ buffering and thus, Ca2+ signaling, 
are a major producer (a consequence of OXPHOS) and scavenger of reactive oxygen 
species (ROS), and are intimately involved in programmed cell death (1, 2). Finally, the 
mitochondrion directly contributes to cellular phospholipid metabolism by hosting 
machinery that can produce at least four distinct phospholipids: phosphatidic acid (PA), 
phosphatidylglycerol (PG), cardiolipin (CL), and phosphatidylethanolamine (PE). Given 
the myriad of roles the mitochondrion plays in maintaining cellular homeostasis, it is no 
surprise that defects in mitochondrial function lead to a broad spectrum of diseases (3). 
Mitochondrial disorders, first recognized in 1962 (4), are the most common 
source of inborn errors of metabolism (5-7). Primary mitochondrial disorders can be 
caused by mutation of genes encoded by either mitochondrial (mt)DNA or nuclear 
(n)DNA (but whose protein product resides in the mitochondrion). Thus, while the 
discovery of pathogenic mtDNA mutations in the 1980s greatly facilitated understanding 
of maternally-inherited OXPHOS disease (8, 9), the clinical and genetic heterogeneity of 
mitochondrial disease still complicates efforts to diagnose, manage, and treat affected 
patients (3, 10, 11).  
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Human mtDNA encodes 13 OXPHOS subunits, 22 transfer RNAs, and two ribosomal 
RNAs (12). In contrast, 99% of the mitochondrial proteome, which consists of over 1000 
proteins (11, 13-20), is encoded by the nuclear genome. Thus, not surprisingly, disorders 
that are caused by pathogenic mtDNA mutations (identified in 30 of the 37 mtDNA-
encoded proteins (21)) only comprise a fifth of the known mitochondrial diseases (22).  
Mitochondrial dysfunction is not only defined by specific defects in mtDNA or in 
OXPHOS-associated processes. Mutations in enzymes involved in any number of the 
mitochondrion’s essential functions can lead to mitochondrial disease. Genetic variants 
that drive mitochondrial pathophysiology have been broadly classified into six categories: 
1) OXPHOS-related (subunits and assembly factors) (23); 2) mtDNA maintenance and 
expression (24); 3) mitochondrial biogenesis (25); 4) mitochondrial quality control 
(chaperones and proteases) (26); 5) iron-sulfur cluster homeostasis (27); and 6) 
mitochondrial dynamics (fission and fusion) (28). These categories are delineated by the 
pathways in which the impacted proteins partake but do not predict in any way known, 
the clinical presentation caused by any given genetic mutation.    
Here, we propose that an additional class of genetic variant be included in the 
classification schema to acknowledge the role of defects in mitochondrial phospholipid 
metabolism as a cause of mitochondrial disease. This seventh class will encompass a 
small but notable group of Mendelian-inherited disorders that specifically impact normal 
mitochondrial phospholipid metabolism and thus highlight the important role of proper 
membrane homeostasis in mitochondrial physiology. PA, PG, CL, and PE have parts, if 
not all, of their biosynthetic pathways localized to the mitochondrion. Combined with the 
essential import of extra-mitochondrial phosphatidylcholine, phosphatidylserine and 
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phosphatidylinositol, the mitochondrion requires and maintains a highly articulated lipid 
trafficking network. Therefore, it is no surprise that disruption of mitochondrial 
phospholipid metabolism can lead to mitochondrial dysfunction.  
While the mitochondrion hosts a major PE biosynthetic pathway, to date, an 
inherited disease directly impinging on mitochondrial PE metabolism has not been 
demonstrated. As such, the biology of this important phospholipid will not be covered 
here. Instead, this review will only focus on those phospholipids which are impacted by 
mutations in genes encoded by the nuclear genome with defined or emerging roles in 
mitochondrial phospholipid metabolism. 
 
CARDIOLIPIN METABOLISM 
Mitochondrial membranes and asymmetry  
Each mitochondrion has two highly specialized membranes, the outer 
mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM), delineating 
two aqueous compartments, a dense internal matrix and an intermembrane space (IMS). 
Characteristic to mitochondrial membranes is a low phospholipid to protein ratio relative 
to other organelle membranes, high PC and PE content, cumulatively accounting for up 
to 80% of total lipid phosphorous, low amounts of sterols and sphingolipids, and 
enrichment of a unique phospholipid, CL (29).  
Commonly known as the signature phospholipid of mitochondria, CL is a 
phospholipid dimer that consists of a pair phosphatidic acids, each with two fatty acyl 
chains, bridged by a central glycerol moiety (30, 31). The presence of four acyl chains 
per molecule provides the opportunity for an incredible diversity of CL molecular forms 
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while the two phosphate groups confer upon the lipid a net -1 charge at physiological pH 
(32). CL, like PE and PA, is a non-bilayer forming phospholipid; these lipids have much 
smaller hydrophilic head group diameters than their hydrophobic acyl chains, making 
them cone-shaped. Non-bilayer lipids participate in membrane fusion events (33), 
facilitate membrane bending (34), and can impart order to surrounding lipids (35). This 
distinguishes them from bilayer forming lipids that have head groups and acyl chains that 
are of similar diameter.  
Each mitochondrial membrane has a distinct protein population and phospholipid 
composition (13-19, 36-40). In fact, the protein to phospholipid ratio differs significantly 
between the IMM and OMM, with the IMM being significantly more proteinaceous (41-
43). When purified, OMM and IMM vesicles have different shapes, structures, and lipid 
compositions (37, 44). Notably, the OMM has relatively less CL than the IMM (36, 45). 
Even within a membrane bilayer, there is asymmetry in the lipid composition between the 
two leaflets (42, 46-50). For instance, most of the associated PE and all of the low 
amounts of CL are on the cytoplasmic-facing side of OMM (46).  
The high protein to phospholipid ratio in the IMM reflects the sheer magnitude of 
essential processes that occur in its context. Embedded in the IMM is the OXPHOS 
system, three distinct translocation machineries (TIM22, TIM23, and OXA1), carrier 
proteins that mediate the flux of metabolites across the IMM, quality control proteases, 
and phospholipid metabolizing enzymes. In spite of this protein density, the IMM is an 
intact diffusion barrier that enforces the proton gradient generated by the electron 
transport chain. The stored power of the electrochemical gradient across the IMM is 
central to mitochondrial biology. Not only is it used as the source of energy for ATP 
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production and harnessed to drive numerous transport processes, but in fact, the 
electrochemical gradient is required for mitochondrial biogenesis itself (51). Therefore, 
maintaining a proper lipid composition is likely not only required to support the 
functionality of the numerous proteins and protein complexes embedded in the IMM but 
also to maintain its crucial barrier function. 
PA pools potentially used for CL production 
CL biosynthesis begins with PA, a common substrate in triacylglycerol and 
glycerolipid metabolism. Reflecting this central role, PA can be made in a multitude of 
ways. Worth mentioning from the outset is that the source of PA used for CL 
biosynthesis has yet to be experimentally established; given the apparent redundancy, we 
anticipate that more than one PA-producing pathway will be at play. 
De novo biosynthesis of PA is catalyzed by glycerophosphate acyltransferases 
(GPATs) that are localized to the mitochondrial OMM (GPAT1/2) (52-54) or ER 
(GPAT3/4) (55, 56). GPATs transfer acyl groups from acyl-CoA donors to the sn-1 
position of glycerol-3-phosphate generating lyso-PA (LPA). Whether and how the 
mitochondrial and ER GPAT isoforms contribute to mitochondrial phospholipid 
metabolism is currently unresolved. The LPA that is generated on either the OMM or 
within the mitochondria-associated membrane (MAM, (57, 58)) subcompartment of the 
ER can be acylated by LPA acyltransferases (LPAATs). In mammals, there are four 
LPAAT isoforms that differ in their tissue distribution and acyl-CoA specificities (some 
LPAATs can additionally acylate other lyso-lipids) (59-64). In addition to the defined 
LPAATs, other lyso-phospholipid acyltransferases are able to esterify LPA to some 
degree (65).  
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Another potential source of PA is mitochondrial phospholipase D (MitoPLD), a 
divergent member of the PLD superfamily localized to the OMM that can hydrolyze CL 
to PA in vitro (66). Similar to yeast, mammals can also produce PA via the 
dihydroxyacetone phosphate pathway in the peroxisome (67). All of the discussed 
pathways of PA synthesis are located outside of, or on the outside of, mitochondria. 
However, the recent identification of acylglycerol kinase (AGK) in the IMS suggests that 
PA may be produced inside the mitochondrion (16). AGK, previously termed MuLK for 
multi-substrate lipid kinase (68), phosphorylates diacylglycerol (DAG) and 
monoacylglycerol generating PA and LPA (68, 69). AGK activity is modulated by 
surface charge (via Mg2+) and stimulated, in a dose-dependent manner, by CL (68). 
Moreover, overexpression of AGK in the human prostate cancer PC-3 model results in 
increased mitochondrial PA although CL levels are unchanged (69). Thus, whether PA 
made by AGK inside of the mitochondrion can and does access the downstream CL 
biosynthetic machinery is unclear. 
Cardiolipin biosynthesis 
Upon gaining access to the matrix side of the IMM (discussed later), PA is 
converted to cytidine diphosphate-DAG (CDP-DAG) and pyrophosphate upon reaction 
with cytidine triphosphate (CTP; Figure 2.1). The reaction is catalyzed by CDP-DAG 
synthases (CDS), whose activities have been demonstrated in yeast ER and mitochondria 
(70, 71). It has been recently established that the conserved IMM resident Tam41p is the 
mitochondrial CDP-DAG synthase whose activity provides CDP-DAG for CL 
biosynthesis (72-74). Accordingly, CDS proteins in the ER provide CDP-DAG that is 
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used for phospholipid biosynthesis therein while TAMM41 supplies the CL pathway 
(29).  
Also localized on the matrix-facing leaflet of the membrane are downstream 
enzymes in PG and CL biosynthesis. The committed step of this pathway is catalyzed by 
phosphatidylglycerol phosphate (PGP) synthase (PGS1), which forms PGP from CDP-
DAG and glycerol 3-phosphate (75). After PGP is synthesized, it is rapidly 
dephosphorylated to PG by PTPMT1 (76, 77) of the protein tyrosine phosphatase family 
that shares no primary sequence similarity to the yeast PGP phosphatase, Gep4p (78). 
Notably, at steady state, PG is present at extremely low levels (1-2%) relative to the other 
major mitochondrial phospholipids (79), indicating that newly-synthesized PG is quickly 
consumed by downstream pathways. Finally, cardiolipin synthase (CLS), an integral 
IMM protein with its active site facing the matrix (80), condenses PG with another 
molecule of CDP-DAG to generate nascent unremodeled CL (81-83). 
Cardiolipin remodeling 
Cardiolipin biosynthetic enzymes exhibit no or only limited acyl chain specificity 
(81, 82, 84). The general lack of acyl chain specificity in CL biosynthesis is significant as 
it is in direct contrast to the observation that in any given tissue (except the brain (85)), 
there exists a dominant homogeneous molecular form of CL that is characterized by the 
incorporation of unsaturated fatty acyl chains (86) and molecular symmetry with respect 
to the two chiral centers of CL (87). In mammals, CL is predominantly composed of 
unsaturated 18-carbon linoleic acid (18:2). The enrichment in this particular species is 
exemplified by human heart where 18:2-linoleic acid constitutes up to 90% of the acyl 
chains in CL, yielding the abundant and stereotypical tetralinoleoyl-CL species (87, 88). 
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However, it is notable that the final acyl chain composition of CL in different tissues is 
not the same; this observation has led to the hypothesis that the final acyl chain 
composition of CL is tailored to the unique demands of its host tissue (85, 87, 89). 
As such, the generation of CL molecular species that accumulate at steady state 
requires the active remodeling of CL shortly after its de novo synthesis (90, 91). To 
initiate the remodeling process, a lipase removes an acyl chain from CL generating 
monolyso-CL (MLCL) that is subsequently re-acylated by one of several enzymes 
(Figure 2.2). Through a series of such reactions at each position in CL, a tissue-specific 
homogeneous pool of CL is generated that is characterized by molecular symmetry and a 
higher degree of acyl chain unsaturation. 
Phospholipases 
In yeast, the recently identified cardiolipin deacylase, Cld1p, initiates CL 
remodeling and preferentially catalyzes the hydrolysis of palmitic acid (16:0) from newly 
synthesized CL, forming MLCL (92, 93). In the absence of Cld1p, the acyl chain 
composition of CL shifts to palmitic acid (16:0) residues at the expense of palmitoleic 
(16:1) and oleic (18:1) acid moieties (92, 93). Cld1p associates with the matrix-facing 
leaflet of the IMM and lacks any membrane spanning segments (94), placing the 
initiation of CL remodeling on the same side of the IMM as its biosynthesis. 
Although there are no orthologs of Cld1p in higher eukaryotes, evidence points to 
Ca2+-independent phospholipases A2 (iPLA2) as being involved in mammalian CL 
remodeling. The PLA2 family of enzymes catalyzes the hydrolysis of membrane 
glycerophospholipids at the sn-2 position, generating free fatty acids and lyso-lipids. 
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Interestingly, all of the PLA2 isoforms capable of hydrolyzing CL in vitro have different 
specificities for CL molecular species (95).  
iPLA2g is membrane-bound, dually localized to the mitochondrion and 
peroxisome, and participates in CL metabolism (96). In the hearts and skeletal muscle of 
ipla2g-/- mice, CL levels are reduced and the acyl chain pattern is altered (97, 98). 
However, the absence of iPLA2g in taz knockdown mice does not prevent the 
accumulation of MLCL as predicted if iPLA2g functions immediately upstream of TAZ 
(99).  
Ablation of another mitochondrially-localized iPLA2 family member, iPLA2-VIA, 
in taz-/- flies, partially restores MLCL:CL ratios, a biochemical hallmark of TAZ 
dysfunction, and rescues male sterility (100-102). Still, the CL acyl chain pattern in 
single ipla2-via-/- flies is not significantly different from wild type (wt) flies, suggesting 
that like murine iPLA2g, iPLA2-VIA activity is not obligately required to initiate the 
remodeling process. Thus, which phospholipase(s) functions upstream of mammalian 
TAZ remains an open and important question. Once identified, basic biochemical and cell 
biological characterization will further establish the topology of CL remodeling. For 
instance, it is anticipated that the lipase(s) that initiates CL remodeling will reside in the 
same compartment as the enzyme that subsequently re-acylates MLCL; it is worthwhile 
to note that although iPLA2g localizes to the mitochondrion, its submitochondrial 
distribution has not been formally demonstrated. If the lipase and its substrate do not co-
localize, then appropriate trafficking steps of the lipid substrate (CL or MLCL) will be 
inferred. A consideration of the basic cell biology of the lipase(s) required for CL 
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remodeling is particularly relevant given that all three enzymes that can re-acylate MLCL 
reside in distinct cellular compartments. 
Trans/acyltransferases 
In mammals, there are at least three enzymes that have the capacity to re-acylate 
MLCL: TAZ, MLCL acyltransferase 1 (MLCLAT1), and acyl-CoA:lysocardiolipin 
acyltransferase-1 (ALCAT1), of which only TAZ is evolutionarily conserved from yeast 
to higher eukaryotes (103-106). All evidence to date indicates that the MLCL 
transacylase, TAZ, is responsible for the vast majority of physiological CL remodeling. 
TAZ deficiency is biochemically characterized by increased MLCL, the remodeling 
intermediate, decreased CL, both the substrate and product, and an abnormal acyl chain 
pattern of the remaining CL (101, 107-111). However, the mechanism by which TAZ 
establishes the steady state CL acyl chain composition is unresolved; TAZ catalyzes a 
reversible transacylation that exhibits no intrinsic acyl chain specificity, acts on acyl 
chains at both sn-1 and sn-2 positions, and can use any number of phospholipids and their 
lyso-derivatives as fatty acyl donors and acceptors, respectively (103, 112). Notably, 
heterologous expression of human TAZ in taz-/- flies or Dtaz1 yeast generates CL with 
acyl chain patterns typical of Drosophila melanogaster and yeast, respectively, and not 
humans (110, 113). This suggests that the characteristic fatty acid profile of CL may not 
be conferred by the substrate specificity of TAZ. Interestingly, recombinant fly TAZ can 
generate the physiologically-relevant tetralinoleoyl-CL species from MLCL but only 
under experimental conditions that promote non-bilayer membranes (114). This suggests 
that unique membrane physical states such as regions of high curvature, can confer upon 
TAZ acyl chain specificity. Other mechanisms that are hypothesized to play a role in the 
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TAZ-based establishment of CL molecular species include the specificity of enzymes 
immediately upstream of TAZ that initiate the remodeling process and thus dictate which 
substrates are available to TAZ (92), as well as the dietary intake of fatty acids (115).  
Presently, the submitochondrial localization of endogenous mammalian TAZ has 
not been documented. Yeast Taz1p associates with the IMS-facing leaflets of the OMM 
and the IMM as an interfacial protein (37, 111, 116). This is in sharp contrast to the 
deacylase, Cld1p that initiates CL remodeling and is localized to the matrix-facing IMM 
leaflet (94). Topologically, this means that MLCL produced on the matrix-side of the 
IMM in yeast has to flip across the membrane and/or be transported to the OMM, to 
access TAZ for remodeling (117). As TAZ is the only CL remodeling enzyme that is 
conserved in eukaryotes, it is anticipated that mammalian TAZ will be similarly localized 
in the organelle. Therefore, determining the submitochondrial localization of the 
upstream phospholipase in mammals will establish the CL and MLCL trafficking steps 
needed to access TAZ for remodeling (117).  
In mammals, MLCLAT1, which associates with the matrix side of the IMM 
(118), does not encounter the same problem of substrate access as TAZ. MLCLAT1 was 
originally identified in porcine liver mitochondria as a 74-kDa protein (104) that 
corresponds to the COOH terminus of the human trifunctional protein (TFP) alpha (a) 
(105). The TFP complex consists of a- and b-subunits that catalyze the last three steps of 
mitochondrial long-chain fatty acid beta-oxidation thus providing a significant source of 
cellular energy (118, 119). Pathogenic mutations in either TFP subunit are associated 
with beta-oxidation disorders, where patients suffer from cardiomyopathy and skeletal 
myopathy (120-122). Interestingly, recombinant TFPa is soluble when expressed alone, 
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in contrast to its partner TFPb, suggesting that it may contain a function independent of 
its association with TFPb that may be described by MLCLAT1 (123). Presently, the gene 
encoding MLCLAT1 has not been definitively determined. That MLCLAT1 is likely a 
splice variant of TFPa is suggested by the fact that knockdown using RNAi targeting the 
NH2-terminal portion of TFPa, absent in MLCLAT1, reduces TFPa, but not MLCLAT1 
mRNA levels (124). However, whether RNAi targeting a shared region between TFPa 
and MLCLAT1 can reduce the expression of both genes has not been established.  
Both recombinant human TFPa and MLCLAT1 can bind MLCL in vitro and are 
able to incorporate linoleoyl-(18:2), oleoyl- (18:1), and palmitoyl-(16:1) CoA into MLCL 
(105, 123, 124). When either protein is overexpressed in BTHS lymphoblasts, there is 
increased incorporation of linoleic acid in CL (105, 124). However, TFPa overexpression 
does not generate a CL profile that reflects its in vitro specificity. Thus, while TFPa 
and/or MLCLAT1 can participate in CL remodeling, especially in the absence of TAZ 
function when the levels of MLCL are high, the exact contribution of this 
acyltransferase(s) to physiological CL remodeling is unclear.  
Finally, ALCAT1 acylates MLCL and dilyso-CL in vivo and can use a number of 
lyso-phospholipids as acyl acceptors in vitro (125-127). Depending on the acyl acceptor, 
tissue type, and species, ALCAT1 has been described to preferentially incorporate long 
chain unsaturated fatty acyl chains or promiscuously accept all acyl-CoA derivatives 
(125, 127). As such, ALCAT1 lacks the specificity expected of an enzyme with a critical 
role in physiological CL remodeling. Notably, ALCAT1 resides in the ER MAMs (125, 
127). Therefore, for ALCAT1 to participate in CL metabolism, CL and/or MLCL must 
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travel from the IMM to at least the external leaflet of the OMM, if the active site of 
ALCAT1, which has not been determined, faces the cytosol. 
The absence of TAZ causes alterations in CL molecular species in every model 
tested to date (87, 92, 100, 101, 103, 107, 109, 110, 128-139). In contrast, the loss of 
MLCLAT1/TFPa or ALCAT1 does not consistently result in changes in the steady state 
acyl chain composition of CL (140-142). Thus, it is unlikely that either MLCLAT1/TFPa 
or ALCAT1 significantly contributes to the steady state CL acyl chain profile under 
normal conditions. These results further underscore the predominant role of TAZ in 
physiological CL remodeling 
Phospholipid trafficking steps required for CL metabolism 
Once made, PA must travel to the matrix side of the IMM to gain access to the CL 
biosynthetic machinery. If made in the ER, this requires movement of PA from ER to 
OMM, flipping between OMM leaflets, movement from the OMM to the IMM, and 
finally flipping to the matrix-facing IMM leaflet. Inter-organelle contacts have recently 
emerged as being critically important for mitochondrial phospholipid metabolism. In 
yeast, there are at least two distinct structures that contribute to the physical association 
of ER and mitochondria (Figure 2.3). The first described complex is the ER-mitochondria 
encounter structure (ERMES) (143). A second ER-mitochondria tether, the ER-
membrane protein complex (EMC), that is distinct from ERMES, was recently identified 
in yeast (144). When either EMC or ERMES subunits are missing, the number and length 
of ER-mitochondria contacts are reduced and mitochondria are unable to support growth 
on respiratory media (143-146). Also, a synthetic mitochondria-ER tether similarly 
rescues the defects caused by the absence of EMC or ERMES. While EMC may play a 
	  	  	  	  	  	   45 
more direct role in phospholipid trafficking (144), EMC and ERMES complexes likely 
have both overlapping and distinct functions in phospholipid transfer between the ER and 
mitochondria (144, 147).  
The ERMES subunits are conserved in fungi but not in metazoans. In contrast, the 
close apposition of ER and mitochondria is conserved (148). In mammals, 
IP3 receptor/GRP75/VDAC1-containing complexes (149), mitofusin-2 (150), and several 
other proteins have roles in ER-mitochondria tethering (151, 152). Moreover, the newly 
described EMC is conserved but its role in ER-mitochondrion tethering has only been 
tested in yeast. The diversity of players implicated in this inter-organelle association 
provides strong evidence of the physiological importance of such contacts. 
The existence of vacuolar and mitochondrial contacts, termed vCLAMPs (vacuole 
and mitochondrial patch), recently identified in yeast, further highlights the importance of 
inter-organelle associations for mitochondrial phospholipid metabolism (153, 154). 
Simultaneous deletion of ERMES and vCLAMP components is synthetically lethal. 
Deletion of vCLAMP and repression of ERMES impairs PA trafficking into 
mitochondria and results in a 40% reduction in CL levels (154). A recent report 
describing mitofusin 2-mediated contacts between mouse melanosomes (a lysosomal-like 
compartment in pigment cells) and mitochondria (155), suggests that there may be 
similar vacuolar-tethering mechanisms in mammals. 
Analogous to inter-organelle tethers, regions of close physical apposition between 
the IMM and OMM are important for lipid trafficking across the IMS (41, 156), although 
the underlying mechanism(s) is unknown. In addition, IMM-OMM contact sites have 
roles in energy transduction from the mitochondrial matrix to the cytosol (157) and 
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precursor protein import (158). MICOS (mitochondrial contact site and cristae organizing 
system) is a hetero-oligomeric protein complex that is embedded in the IMM but interacts 
with several distinct OMM proteins (159-163). Depletion of the conserved 
mitofilin/Fcj1p (yeast formation of cristae junction 1) subunit, which constitutes the 
MICOS core, results in an expanded IMM surface, dramatic loss of cristae junctions, and 
the remaining cristae are stacked, lamellar, and aberrantly disconnected from the OMM 
(159, 162, 164, 165). Recently, apolipoprotein O (APOO) and APOO-like protein 
(APOOL) were identified as potential subunits of the bovine MICOS complex (166). The 
IMS-facing APOOL specifically binds CL in vitro and its knockdown results in 
morphological phenotypes similar to yeast MICOS mutants (166). Thus, MICOS 
complexes are key determinants of cristae morphology that contain subunits capable of 
binding CL (159, 160, 162). Whether these two properties are leveraged in the context of 
phospholipid trafficking between the IMM and OMM is presently unclear although it is 
interesting to note that biochemically isolated IMM-OMM contact sites are enriched in 
CL (41, 43).  
The movement of PA from the OMM to the IMM is mediated by the IMS-resident 
Ups1p/PRELI-like proteins (167, 168). In vitro, the yeast Ups1p/Mdm35p dimer (169, 
170) binds numerous anionic phospholipids but only transports PA (167). The 
directionality of PA transport is likely conferred by the fact that Ups1p remains tightly 
bound to membranes containing physiological amounts of CL, leading to Ups1p’s 
subsequent degradation. These observations suggest a mechanism for regulating CL 
biosynthesis by limiting precursor trafficking between the two membranes when CL 
levels are bountiful (167). Whether transport of PA by the Ups1p/PRELI-like proteins 
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utilizes in some manner MICOS or is instead mechanistically distinct is at present 
unknown. 
Once PA is transported to the IMM, or if synthesized in this compartment by 
AGK, the transbilayer movement of PA to the matrix-leaflet is required for PA to gain 
access to the CL biosynthetic enzymes. How this is achieved is presently not known but 
could involve a specific protein or protein complex. However, the requirement for a 
specific PA transporter does not seem obligate as a transmembrane pH gradient is 
sufficient to disseminate PA across both IMM leaflets (171, 172).  
Since CL is made in the context of the matrix leaflet and can eventually be 
exposed on the OMM, mechanisms must be present to facilitate the movement of CL 
intra-mitrochondrially. Scramblases are Ca2+-dependent, ATP-independent bidirectional 
transporters that equilibrate lipids unevenly distributed across a bilayer (173). As such, a 
scramblase could serve to redistribute CL made on the matrix-side, between IMM 
leaflets. Alternatively, phospholipid translocation between membrane leaflets may not be 
mediated by specific proteins, but instead facilitated by the presence of numerous 
transmembrane proteins (especially in the context of the IMM) in a non-specific manner, 
as suggested for bacterial and ER membranes (174, 175).  
Albeit minor, CL is a normal constituent of the OMM and can traffic to the OMM 
following certain stimuli (176, 177). Phospholipid scramblase 3 (PLS3) is the only 
known mitochondrial scramblase (178-180) and in vitro, murine and human PLS3 
catalyze the Ca2+-dependent flip-flop of CL in proteoliposomes (180). However, it is 
unclear whether PLS3 functions in vivo as a CL scramblase or instead mediates the 
movement of CL from the IMM to the OMM. PLS3 overexpression increases 
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mitochondrial mass, CLS transcription, CL synthesis, and CL externalization to the OMM 
(179, 181). Conversely, overexpression of a catalytically-dead pls3 allele or PLS3 
knockdown reduces CL externalization following UV irradiation or rotenone poisoning, 
respectively (176, 181). How does PLS3 activity contribute to movement of CL to the 
OMM? If PLS3 is a true scramblase, then the equilibration of CL between the leaflets of 
the IMM may be required for the subsequent ability of CL to traffic to the OMM. 
Alternatively, PLS3 may instead directly participate in the movement of CL between 
mitochondrial membranes. Future studies are needed to clarify the role of PLS3 in this 
process. 
Another potential mechanism by which lipids can be transferred from the IMM to 
the OMM involves the NM23-H4/NDPK-D (nucleotide diphosphate kinase isoform D) 
(182). NM23-H4 is the only mitochondrially-targeted member of a family of NDPKs 
whose role in phosphotransfer is well-established. NM23-H4 has been additionally 
implicated in the trafficking of anionic phospholipids (in particular CL) between the 
IMM and the OMM (183). Interestingly, the levels of CL can functionally switch NM23-
H4 between phosphotransfer and lipid transfer modes (184). Normally, the lipid transfer 
mode is inhibited by anionic lipids, including CL, and the protein operates as a nucleotide 
kinase. However, when CL levels are low (due to mitochondrial dysfunction), NM23-
H4’s lipid transfer function is de-repressed and the protein cross-links the IMS-facing 
leaflets of the IMM and OMM. Subsequently, NM23-H4 facilitates the 
thermodynamically-unfavorable movement of negatively-charged lipids across the 
aqueous IMS.  
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While a role for both NM23-H4 and PLS3 in the stimulated externalization of CL 
on the OMM is clearly emerging, whether either or both enzymes participate in the 
routine processes of CL biosynthesis and remodeling is not known. Given its MAM-
residence, it is tempting to speculate that NM23-H4 and/or PLS3 may be involved in 
ALCAT1-based CL remodeling. 
 
PHYSIOLOGICAL FUNCTIONS 
Phospholipids play a myriad of roles in cellular and mitochondrial physiology that 
are beyond the scope of any single review. The following section is focused on recently 
discovered roles and guided by those physiological functions of mitochondrial lipids, that 
when disturbed, may contribute to human disease. Of note, the diversity of functions 
attributed to the discussed mitochondrial phospholipids is reflected by the vast array of 
pathogenic mechanisms that underlie this cohort of mitochondrial diseases. 
Phosphatidic acid  
The dynamic appearance and disappearance of PA on the OMM is a recently 
established determinant of mitochondrial fusion and fission. Overexpressed MitoPLD 
generates PA on the OMM, promoting mitochondrial fusion and subsequent aggregation 
(66), while loss of MitoPLD leads to fragmented mitochondria (185). PA generated by 
MitoPLD recruits the PA phosphatase, lipin-1. Lipin-1 dephosphorylates PA to DAG 
which stimulates mitochondrial fission while simultaneously removing the pro-fusogenic 
accumulation of PA on the OMM (185, 186). Interestingly, mitopld-/- flies (187) and mice 
(185, 188) have defects in the biogenesis of Piwi-interacting (pi)RNAs that have a role in 
providing a germline-specific defense against retrotransposon activity (189). Male 
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mitopld-/- flies are sterile, typical of flies lacking piRNAs (190), lose nuages (191), sites 
where piRNA production and processing is thought to occur, and have de-repressed 
retrotransposons in their testes (187, 188). Moreover, lipin-1-/- mice have elevated PA on 
the mitochondrial surface and significantly increased nuage formation (185). Genetic 
evidence therefore strongly supports a role for PA and/or DAG at the OMM in piRNA 
production (185). However, the exact role of MitoPLD with respect to the mitochondrial 
phospholipid pool is unclear.  
The importance of the dynamic regulation of PA on the OMM is further 
substantiated by the recent characterization of PA-PLA1 (192). In vitro, PA-PLA1, 
preferentially deacylates PA to LPA (193). PA-PLA1 overexpression or depletion in 
HeLa cells causes mitochondrial fragmentation and elongation, respectively (192). 
Interestingly, co-expression of PA-PLA1 and MitoPLD prevents the accumulation of PA 
on the OMM surface and the morphological defects associated with MitoPLD 
overexpression alone (192). Similar to mitopld-/-and lipin-1-/- mice, pa-pla1-/- mice have a 
defect in spermatogenesis that correlates with mitochondrial disorganization (192). 
Finally, diminution of ddhd2, a related iPLA1 family member with a similar specificity 
for PA as PA-PLA1, causes mitochondrial elongation in mouse embryonic fibroblasts 
(192). 
Phosphatidylglycerol 
Besides being a required intermediate in CL biosynthesis, PG is also a precursor 
for bis(monoacylglycerol)phosphate (BMP; (194)), a class of phospholipid that is highly 
enriched in late endosomes and lysosomes (195-197). While BMP is found in many 
tissues and cells, it is usually present at less than 1% of the total phospholipid mass (198, 
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199). BMP is a structural isomer of PG and is thought to function in the maintenance and 
regulation of endosomal/lysosomal membrane dynamics and cholesterol trafficking (200-
203). However, its exact biological role(s) is unresolved. 
Cardiolipin 
The absolute requirement of PG and/or CL for life is underscored by the 
observation that ptpmt1-/- mice die in utero before embryonic day 8.5 (76). Reflecting 
this importance, CL has a multitude of functional roles in mitochondria (Figure 2.4). CL 
is highly enriched in cardiac tissues making up 15-20% of the total phospholipid 
phosphorus mass of the heart (204, 205). Its relative abundance in cells and tissues with 
high energetic demands point to CL as being intimately involved in maintaining 
mitochondrial structure and function. Indeed, it interacts with numerous mitochondrial 
proteins, including all OXPHOS complexes and most mitochondrial solute carriers, and 
is often required for their functional reconstitution in liposomes (206-212). In addition, 
CL is proposed to function as a proton trap that helps funnel pumped protons towards the 
ATP synthase to generate ATP (32). An association with CL promotes the assembly of 
membrane proteins into oligomeric complexes (206, 213-217). Indeed, CL is important 
for the assembly and function of IMM and OMM translocases and thus, mitochondrial 
biogenesis (37, 218, 219). CL is also critically important for stabilizing respiratory 
supercomplexes (SC), supramolecular assemblies built from respiratory complexes I, III 
and IV (220). These SCs are thought to increase the efficiency of electron transfer 
between the respiratory chain components by substrate channeling mechanisms (221, 
222), thereby maximizing OXPHOS. Further, SC assembly shortens the distance traveled 
by mobile electron carriers, minimizing ROS leakage and reducing oxidative damage. 
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Finally, CL-binding stimulates the activity of dynamin-related GTPases with pivotal roles 
in IMM fusion and mitochondrial fission (223-225). All of these CL-supported functions 
have been discussed extensively in several excellent reviews (106, 226-231).   
Both apoptosis and mitophagy, a macro-autophagic process that is pre-emptive to 
cell death via apoptosis, are signaled in part by the externalization of CL to the OMM. 
The movement of CL to the OMM is thought to involve the scramblase PLS3 and/or 
NM23-H4 and may occur preferentially at IMM-OMM contact sites thought to be 
enriched in CL (41, 43). Overexpression of NM23-H4, but not a CL-binding mutant, 
increases apoptotic markers that may be ascribed to increased CL externalization on the 
OMM (184). CL on the OMM attracts and activates caspase-8 (177) and aids in pro-
apoptotic Bax insertion into and permeabilization of the OMM (232, 233). In 
preparations of giant unilamellar vesicles lacking CL, caspase-8 is unable to interact with 
vesicle membranes, a step necessary for caspase-8 activation and subsequent recruitment 
of tBid (234, 235). Yeast mitochondria lacking CL are protected from the bioenergetic 
perturbations normally induced upon incubation with tBid (236) underscoring the 
importance of CL for tBid function. Furthermore, CL peroxidation by cytochrome c 
promotes the release of a number of pro-apoptotic factors, including cytochrome c, 
following OMM permeabilization (237). Under conditions of mild mitochondrial 
dysfunction, CL is externalized on the OMM where it promotes the specific destruction 
of the mitochondrion by mitophagy (176). siRNA knockdown of the scramblase PLS3 or 
CL synthase CLS in neuronal cells, diminishes CL externalization and the number of 
mitochondrially-associated autophagic markers, and attenuates chemically-induced 
mitophagy (176). As CL externalization is important for both apoptosis and mitophagy, 
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there is likely to be a threshold level of mitochondrial damage (severity of insult and 
percentage of mitochondrial pool impacted) above which apoptosis is executed and 
below which the affected mitochondria are selectively removed. In addition, qualitative 
and/or quantitative differences in the CL exposed on the OMM may influence how this 
lipid signal is interpreted by the cell. 
Remodeled versus unremodeled CL 
While the role and functional consequence of MLCAT1-based remodeling is 
presently unresolved, TAZ- and ALCAT1-mediated CL remodeling are associated with 
very different physiologic outcomes.  In the absence of TAZ, the acyl chain composition 
of CL is significantly diversified and molecular symmetry is lost (87). Thus, TAZ has a 
preeminent role in dictating the final collection of acyl chains attached to CL under 
physiological conditions. The final acyl chain pattern of CL, which is tissue-specific, is 
thought to be critical for normal mitochondrial physiology by supporting some 
combination of the functions attributed to CL. However, Dcld1 yeast, which fail to 
initiate CL remodeling and accumulate normal amounts of unremodeled CL, have wt 
OXPHOS activity and normal mitochondrial morphology (92, 238). These results 
question the idea that TAZ-based CL remodeling produces “optimized” CL species that 
promote mitochondrial fitness, and instead suggests that CL remodeling may actually 
accomplish other physiologically important functions that either were not tested (92, 238) 
or have not yet been discovered. 
In contrast to TAZ-based CL remodeling, CL remodeled by ALCAT1 predisposes 
mitochondria to damage. In mouse myoblasts, ALCAT1 overexpression increases the 
amount of CL enriched with docosahexaenoic acid (22:6) at the expense of linoleic acid 
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(18:2) (140), consistent with alterations in CL species that are observed in aging rat 
hearts (the latter additionally contain 20:4 arachidonic acid (239)). The increased acyl 
chain unsaturation in these CL forms makes them peroxidation-prone and increases the 
susceptibility of mitochondria to undergo apoptosis (140, 239, 240). As such, ALCAT1 
seems to perform “pathogenic” remodeling of CL. Consistent with this, ALCAT1 
overexpression, also noted in mouse models of metabolic disease, increases the rate of 
ATP, and consequently, ROS production during oxidative stress (140). Conversely, 
ablation of ALCAT1 elevates tetralinoleoyl-CL content in the heart (140), prevents the 
onset of disease, increases insulin resistance, mitigates OXPHOS dysfunction by 
increasing complex I activity, restores mtDNA fidelity, alleviates fusion defects and 
associated mitochondrial fragmentation, and re-establishes mitochondrial quality control 
(140, 241-243). Combined, this suggests that CL remodeled by ALCAT1 may exacerbate 
and/or signal mitochondrial dysfunction in disease pathogenesis (242). 
 
EMERGING DISEASES OF MITOCHONDRIAL PHOSPHOLIPID 
METABOLISM 
With the recent application of next generation sequencing methodologies, new 
disease-causing genes are being implicated in mitochondrial disorders each year. For the 
remainder of this review, we describe a new category of mitochondrial disorder that is 
caused by nuclear defects that specifically alter mitochondrial phospholipid metabolism. 
We anticipate that the diseases discussed below represent the tip of the iceberg and that 
more disorders that impinge on mitochondrial phospholipid metabolism will be identified 
in the near future. 
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Tafazzin mutations leading to Barth syndrome 
Mutations in the gene that encodes the MLCL transacylase, TAZ, lead to Barth 
syndrome (BTHS) (244-246). BTHS is the founding member of this new class of 
mitochondrial disease and thus not surprisingly, is the best characterized. This X-linked 
multisystem disorder presents with cardiomyopathy, skeletal muscle weakness, 
neutropenia, growth retardation, and 3-methylglutaconic aciduria (3-MGA), and can be 
fatal if not diagnosed early (244, 247, 248) (one isolated case of BTHS in a female 
patient has been reported (249)). 3-MGA-uria is a heterogeneous group of syndromes 
characterized by an increased excretion of 3-methylglutaconic and 3-methylglutaric 
acids, breakdown products of leucine catabolism (250). Additional features such as 
isolated left ventricular noncompaction, ventricular arrhythmia, motor delay, exercise 
intolerance, poor appetite, fatigue, hypoglycemia, lactic acidosis, and hyperammonemia 
have also been described in BTHS patients (251, 252). Patient heart, liver, and skeletal 
muscle biopsies contain malformed mitochondria with tightly stacked or circular bundles 
of cristae (139, 244, 253, 254). In patient-derived lymphoblasts, mitochondria have 
dramatically reduced inner membranes, collapsed cristae, and are often fragmented (138, 
255). TAZ (G4.5) contains 11 exons, is localized on a gene-rich region on Xq28, and is 
highly expressed in cardiac and skeletal tissues (246). Pathogenic taz variants identified 
to date encompass splice site mutations, insertions, deletions, as well as missense and 
nonsense mutations (247) (a current list of known genetic variants is maintained by the 
Barth syndrome foundation; https://www.barthsyndrome.org/science).  
Efforts to understand BTHS pathogenesis are complicated by the complete lack of 
genotype-phenotype correlations. Patients with the same mutation, or even siblings 
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sharing the same mutation, can manifest with extremely disparate symptoms. A case in 
point is that of a 51 year old proband, the oldest BTHS patient reported, and his 3 year 
old grandnephew (256). Although they harbor the same mutation, the boy presented with 
cardinal manifestations of BTHS (including congestive heart failure that required a heart 
transplant at 11 months of age) while the great uncle was 43 years old when he was 
diagnosed with myopathy. These observations highlight the importance of modifying 
factors as key determinants in BTHS disease progression. 
Furthermore, links between different mutations and severity of disease have not 
been established for BTHS. Model organisms can help bridge this gap. Using a yeast 
BTHS model, 21 distinct pathogenic missense mutations have been modeled in yeast 
Taz1p and their loss-of-function mechanism defined. This effort has identified seven 
classes of BTHS mutant defined by their loss-of-function mechanisms (108, 111, 257). 
Briefly, the seven classes comprise of variants that are 1) nonfunctional truncated 
products resulting from frameshifts or aberrant splicing, 2) mislocalized within 
mitochondria and aggregation-prone, 3) aberrantly assembled, 4) catalytically dead, 5) 
hypomorphic alleles with residual transacylase activity, 6) unable to engage in stable 
productive assemblies, or 7) temperature-sensitive. Systematic analyses of pathogenic 
variants in this manner can provide important mechanistic insight into the clinical 
heterogeneity of BTHS. The next step in attaining this goal is to verify that the defined 
loss-of-function mechanisms are conserved in an appropriate mammalian model. Such a 
model is additionally needed to characterize pathogenic alleles that cannot be modeled in 
yeast due to a lack of conservation. 
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There are a number of BTHS models presently available. Importantly, every 
BTHS model has the characteristic biochemical defects that underlie BTHS – increased 
MLCL, decreased CL, and an abnormal acyl chain composition of the remaining CL. In 
addition to yeast, other cellular BTHS models include patient-derived fibroblasts (258), 
lymphocytes (87, 138), and iPSCs (135, 136), and taz-depleted rodent (131, 259, 260) 
and human cell lines (177). Animal models of BTHS include taz-depleted zebrafish (261) 
and mice (137, 262, 263), and taz-/- flies (132). 
Cellular models of BTHS show dysmorphic changes in mitochondrial 
morphology and energetic defects (131, 133, 255). In patient-derived lymphoblasts (133, 
138), iPSCs (136), and fibroblasts (258), there is low basal respiration, reduced 
membrane potential, and compromised coupling of OXPHOS. Respiratory SCs are 
decreased and there is a shift in SC assembly from large “respirasomes” to smaller, and 
presumably, less efficient SCs (133, 136, 264). Therefore, it is postulated that these 
alterations in respiratory chain assembly diminish respiratory efficiency and 
consequently, augment ROS production. While basal respiration is unaffected in the 
shRNA-inducible taz knockdown mouse, maximal uncoupled respiration is reduced; 
whether this reflects changes in respiratory SC stability has not been demonstrated (265). 
Enzymatic analyses of respiratory chain complexes using cardiomyocytes derived from 
the taz knockdown mouse indicate that complex III is impaired (265), suggestive of a 
similar bioenergetic dysfunction as noted in the cellular models. In taz-depleted mice 
(137, 262, 263) and zebrafish (261), cardiac defects are observed that recapitulate many 
of the relevant cardiac parameters noted in BTHS patients. With respect to zebrafish, taz 
knockdown severely impairs zebrafish development and the degree of cardiac 
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dysmorphology is proportional to the morpholino dose. In addition to impaired cardiac 
function, taz knockdown mice have abnormal skeletal muscle ultrastructure (132, 137) 
consistent with taz-/- flies that also have impaired muscle functions (131, 132). Recently, 
cardiomyocytes differentiated from BTHS patient iPSCs have been generated (135, 136). 
In these cells, there is structural destabilization of respiratory SCs that correlates with 
reduced respiratory complex activities (136). When wt cells are seeded onto engineered 
chips, they form sarcomeres and contract; in contrast, the ability of BTHS-derived 
cardiomyocytes to form organized sarcomeric arrays is severely impacted as is their 
contractility (135). Therefore, results from the myriad of BTHS models indicate that the 
lipid abnormalities that occur in the absence of TAZ result in OXPHOS dysfunction 
associated with SC destabilization. OXPHOS dysfunction increases the production of 
ROS and in sum, these impairments compromise heart development and function.   
As already discussed, the stimulated externalization of CL onto the OMM is an 
important event that can alternatively trigger apoptosis or mitophagy. It is thus notable 
that BTHS-derived lymphocytes are resistant to mitochondrial-dependent apoptosis due 
to an impaired ability to recruit and activate caspase-8 (133, 177). Interestingly, caspase-
8-/- mice die in utero and the embryos have heart abnormalities that include thin and 
disorganized trabeculae (266), phenotypes also observed upon taz depletion in utero 
(263). Thus, defects in caspase-8 activity may contribute to the cardiomyopathy in 
BTHS. The relative capacity of BTHS mitochondria to be consumed by mitophagy has 
not been reported. However, BTHS lymphocytes have more mitochondria that are 
individually less functional (133) suggesting that mitochondrial homeostasis may indeed 
be perturbed in BTHS and contribute to disease progression. 
	  	  	  	  	  	   59 
Importantly, the detailed biochemical and cell biologic characterization of the 
numerous BTHS models have begun to identify potential avenues for therapeutic 
intervention. For instance, suppression of mitochondrial ROS attenuates the energetic and 
functional decline caused by taz-depletion in rodent cardiac myocytes (260) and corrects 
the sarcomere organization and contractile function of induced BTHS cardiomyocytes 
(135). Genetic and/or pharmacologic targeting of the lipase that initiates CL remodeling 
in yeast, flies, and patient lymphoblasts prevents, to varying degrees, the mitochondrial 
dysfunction caused by the absence of TAZ and can additionally rescue the sterility of 
male taz-/- flies (92, 102, 238). These results suggest that the mitochondrial dysfunction 
stemming from TAZ deficiency is not likely due to reduced remodeled CL, but instead 
caused by the increased abundance of MLCL and/or the low total amounts of CL. As 
such, drugs that can scavenge mitochondrial ROS or prevent the accumulation of MLCL 
(inhibit the activity of the upstream deacylase(s); enhance the activity of other putative 
MLCL remodelers; augment a pathway that degrades MLCL) could be used to the 
potential therapeutic benefit of BTHS patients.  
DNAJC19 mutations leading to dilated cardiomyopathy with ataxia (DCMA) 
syndrome 
To date, only two mutations have been identified in DNAJC19 (DnaJ/Hsp40 
homolog, subfamily C, member 19) that are associated with DCMA (267, 268), an 
autosomal recessive disorder that presents with early onset dilated cardiomyopathy, non-
progressive cerebellar ataxia leading to motor delays, testicular dysgenesis, growth 
failure, and elevated levels of 3-MGA. Additional features include microcytic anemia, 
mild to borderline non-progressive mental retardation, hepatic steatosis, and occasional 
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optic atrophy (267-269). DCMA shares with BTHS certain clinical features including left 
ventricular noncompaction with spongey and trabeculated myocardium (269). However, 
unlike in BTHS, DCMA patients do not exhibit neutropenia or skeletal myopathy (245).  
DNAJC19 is on chromosome 3q26.33 (267). The gene consists of six exons and is 
ubiquitously expressed as a 525 bp transcript with a minor 435 bp form, lacking exon 4, 
in all tissues tested and control fibroblasts (267). The consanguineous Canadian 
Dariusleut Hutterite families all have an exon4 splicing defect while two Finnish brothers 
have a frameshift mutation resulting in a truncated protein (267, 268). Consistent with 
these mutations, only the shorter transcript is expressed in fibroblasts from one Hutterite 
patient (267) and DNAJC19 protein is not detected in fibroblasts derived from the 
Finnish siblings (268). Since there are only two genetic variants of DNAJC19 linked to 
DCMA, it is not possible to describe genotype-phenotype correlations in this disorder. 
Still, in a retrospective study of the Hutterite patients that all share the same mutation 
(269), 13 of the 17 patients developed dilated cardiomyopathy and 10 later died. 
Interestingly, three patients had resolved or stabilized cardiomyopathy and another four 
did not present with cardiac defects at all. Thus, there is significant clinical variability 
with respect to this particular DCMA allele. 
DNAJC19 is associated with the matrix-facing leaflet of the IMM via a predicted 
NH2-terminal transmembrane region (141) and contains a conserved DNAJ domain at the 
COOH terminus, in contrast to other conventional DNAJ-proteins with an NH2-terminal 
J-domain. DNAJ domain-containing proteins typically act as molecular chaperones for 
Hsp70/Hsp40s and prevent protein aggregation by aiding in the folding and assembly of 
newly synthesized proteins (270, 271). Sequence alignment indicates that DNAJC19 is 
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orthologous to yeast Pam18p, a constituent of the TIM23 import machinery (272). In 
yeast, the Pam18p and Mdj2p proteins are essential components of the TIM23 
translocation machinery (273), interacting with mitochondrial Hsp70p, Pam16p, and 
Tim44p to form the presequence translocase-associated motor complex (274-279). This 
subcomplex associates with the core TIM23 translocon (consisting of Tim23p, Tim17p, 
Tim50p and variably, Tim21p) and mediates import of precursors destined for the matrix 
in an ATP- and membrane potential-dependent manner (219, 280-284). Thus, DNAJC19 
may, like yeast Pam18p, stimulate the ATPase activity of mtHsp70 and stabilize 
mtHsp70 binding to incoming peptides. For an excellent review on mitochondrial protein 
translocation, refer to (51). 
Consistent with a role in protein import, DNAJC19 interacts with MAGMAS, the 
conserved mammalian ortholog of yeast Pam16p that is essential for development (285-
288). MAGMAS is structurally similar to DNAJC19 but peripherally associated with the 
matrix-leaflet of the IMM. The interaction between DNAJC19 and MAGMAS occurs via 
their reciprocal J-domains and is required to recruit DNAJC19 to the core TIM23 
translocon (289). MAGMAS then associates with TIM17, a subunit of the TIM23 core, to 
form the TIM23 translocation machinery (290, 291). Interestingly, there are three distinct 
forms of TIM23 translocon that incorporate different TIM17 isoforms and associate with 
either DNAJC15 (TIM17a; translocase A), another co-chaperone of the same Hsp40-type 
(292, 293), or DNAJC19 (TIM17b1 and TIM17b2; translocase Bs). Of the three versions 
of TIM23, translocase Bs are critical for basal mitochondrial biogenesis (e.g. OXPHOS, 
iron-sulfur cluster biogenesis, mtDNA copy number, and maintenance of mitochondrial 
membrane potential) while translocase A plays a dispensable, albeit supportive role when 
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translocase Bs are absent (291). In light of these results, defects in mitochondrial 
presequence protein import and consequently, mitochondrial biogenesis, may represent 
the mechanism of DCMA pathogenesis. 
Recently, however, human and murine DNAJC19 were found to additionally 
interact with PHB complexes (141). PHB complexes are large hetero-oligomeric 
complexes composed of PHB1 and PHB2 subunits (294) that are involved in cristae 
morphogenesis (295) and modeled to function as lipid scaffolds in the IMM, 
redistributing lipids (such as CL (296)) and delineating functional membrane domains 
(297). In yeast, Dphb1 is synthetically lethal with Dcrd1 highlighting the importance of 
conserved PHB complexes in CL metabolism (298). Interestingly, DNAJC19-depletion in 
HEK293T cells shifts the CL acyl profile to longer and less saturated chains; however, 
CL levels are unaffected and MLCL does not accumulate (141). Moreover, while a 
functional DNAJ-domain is not required for DNAJC19 to interact with PHB complexes, 
it is necessary to rescue the changes in CL molecular composition that occur upon 
DNAJC19 knockdown (141). In contrast, PHB2 knockdown results in the same three 
biochemical alterations that characterize BTHS (increased MLCL, decreased CL, and 
changes in CL acyl chain composition), although the increase in MLCL is significantly 
less than in TAZ knockdown cells (141). Concomitant knockdown of PHB2 or DNAJC19 
with TAZ does not alter the accumulation of MLCL that occurs upon depletion of TAZ 
alone, indicating that neither PHB complexes nor DNAJC19 are required to generate the 
substrate, MLCL, used by TAZ. Combined, these results suggest unexpected roles for 
both PHB complexes and DNAJC19 in CL remodeling and further indicate that their 
functions in this regard, are at least partially distinct. TAZ does not interact with PHB2 or 
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DNAJC19 directly (141). Thus, the ability of PHB/DNAJC19 complexes to define 
specific membrane domains, such as those with negative curvature, is postulated to 
confer acyl chain specificity to TAZ (114, 141). In the absence of such privileged 
domains, TAZ remodeling still occurs, it just lacks acyl chain specificity.  
In sum, it appears that DNAJC19 has dual functions in the regulation of CL 
remodeling and mitochondrial protein biogenesis (Figure 2.5). A key question that 
remains unresolved is whether both activities contribute to DCMA disease pathogenesis. 
Presently lacking is any information regarding the lipid profile and protein import 
functionality of mitochondria isolated from actual DCMA patients; such data is needed to 
better understand the underlying pathogenic mechanism. If similar alterations in CL are 
detected in DCMA patient cells, future studies will be needed to define how 
DNAJC19/PHB complexes regulate the collection of acyl chains attached to CL and 
relate these changes to mitochondrial dysfunction. This latter question is all the more 
interesting and relevant given that in yeast, flies, and mammalian cells, genetically and/or 
pharmacologically preventing production of MLCL by targeting the lipase that begins the 
remodeling cascade rescues the multitude of phenotypes attributed to TAZ deficiency 
(92, 102, 238). 
SERAC1 mutations leading to MEGDEL syndrome 
Evidence that PG, like CL, undergoes physiologically important remodeling was 
recently provided by the identification of serine active site containing 1 (SERAC1) 
mutations that cause autosomal recessive MEGDEL syndrome (3-MGA-uria, 
sensorineural deafness, encephalopathy, and neuroradiological evidence of progressive 
Leigh-like syndrome (299, 300). In addition to classical MEGDEL symptoms, an 
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increasing list of clinical phenotypes have been associated with SERAC1 mutations; 
infantile mitochondrial hepatopathy, psychomotor and developmental delay, bilateral 
optic nerve atrophy, myoclonic epilepsy, and microcephaly (301-304). Similar to BTHS 
and DCMA, MEGDEL patients have 3-MGA-uria and variable mitochondrial 
dysfunction.  
SERAC1 is located on chromosome 6q25.3 and the encoded protein resides in the 
MAM (299). SERAC1 is a predicted single-pass transmembrane protein that is 654 
amino acids long and translated from 17 exons into three isoforms (299). The protein is a 
member of the PGAP (post-GPI attachment to protein 1)-like protein domain family and 
contains an a/b-hydrolase fold and a highly conserved serine-lipase domain (299). To 
date, 18 different mutations have been described in 24 patients, many of which are 
frameshift, nonsense, or missense mutations within or upstream of the lipase domain 
(299, 301-307). Of note, a patient recently described with severe, early onset MEGDEL 
symptoms harbors compound frameshift and stop-gain heterozygous mutations upstream 
of the lipase domain (301). In contrast to patients with variants within the lipase domain, 
which may allow for a protein with residual activity, the production of truncated 
SERAC1 completely lacking the lipase domain from both alleles may account for the 
severity of the particular patient’s phenotype. 
SERAC1 is implicated in changing the acyl chain composition of CL’s precursor, 
PG.   Specifically, MEGDEL patient fibroblasts have elevated concentrations of PG-34:1 
and lower concentrations of PG-36:1; the acyl chain compositions of the other major 
phospholipid classes, with the notable exception of CL, are normal (299). The inability to 
convert PG-34:1 to PG-36:1 results in the accumulation of PG-34:1 and subsequent 
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incorporation of PG with these acyl chain species into CL. Thus, in MEGDEL patients, 
CL levels are normal but the acyl chain composition of CL is altered (299). As in the case 
of DNAJC19 deficiency, if and how normal levels of CL of abnormal acyl chain 
composition affects mitochondrial function is at present unclear. Notably, most 
MEGDEL patient tissues and fibroblasts exhibit OXPHOS dysfunction (299, 300, 302, 
303, 305-307), though the degree of impairment and the affected respiratory chain 
component(s) varies. Moreover, ROS production is increased and catalase levels 
decreased in fibroblasts derived from at least one MEGDEL patient (307); therefore, 
similar to BTHS, defective OXPHOS function may cause an imbalance in redox 
homeostasis in MEGDEL patients. However, additional basic work is required to define 
whether increased ROS production and reduced scavenging is a consistent feature 
associated with SERAC1 dysfunction, exactly how defective SERAC1 variably impairs 
OXPHOS, and if the changes noted in the acyl chain composition of CL in MEGDEL 
patients are detrimental to mitochondrial functionality. 
It is curious to note that endogenous TAZ, which is presumably functional in 
MEGDEL patients, is unable to correct the unusual CL acyl chains that accumulate in the 
absence of SERAC1 function. PG is a precursor of CL and therefore contributes directly 
to the collection of acyl chains associated with pre-remodeled CL. Since other 
phospholipids have normal acyl chain compositions in MEGDEL patients (299), in 
theory, TAZ should still be able to generate “normal” CL. One possible explanation for 
this discrepancy is that perhaps the CL that accumulates in MEGDEL patients is not a 
substrate for the lipase that functions upstream of TAZ to initiate CL remodeling.  
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While SERAC1 defects do not affect the abundance or acyl chain pattern of 
phosphatidylcholine, phosphatidylserine, or PE, it does significantly reduce levels of 
BMP (299), a lipid implicated in endosomal/lysosomal homeostasis and function (200) 
(Figure 2.6). BMP levels regulate cholesterol trafficking with low intracellular BMP 
causing accumulation of free cholesterol in late endosomes. Indeed, SERAC1 patient 
fibroblasts accumulate unesterified cholesterol (303, 305) and patient biopsies show 
dramatically disorganized striated muscle ultrastructure with abnormal mitochondria and 
lysosomal accumulation of neutral fat droplets (299, 302). It is presently not clear how a 
change in the acyl chain composition of PG translates into lower amounts of BMP 
especially since the molecular composition of BMP in MEGDEL patients is not altered 
relative to controls (299). Also unclear is how PG produced on the matrix side of the 
IMM gains access to SERAC1, which resides in the MAM. As our understanding of how 
SERAC1 regulates the acyl chain composition of CL and the production of BMP is in its 
infancy, future basic work is needed to develop assorted models designed to better 
understand these processes and how their disturbance cause the numerous MEGDEL 
syndrome phenotypes.   
Acylglycerol kinase mutations leading to Sengers syndrome 
Sengers syndrome is caused by the absence of the IMS-residing acylglycerol 
kinase (AGK) (20, 308, 309). Symptoms of Sengers syndrome may present at birth, 
childhood, or early adulthood and its clinical manifestations range from being severe, 
causing death in infancy, to mild, allowing survival into adulthood (309, 310). This 
autosomal-recessive disorder is characterized by congenital cataracts, hypertrophic 
cardiomyopathy, skeletal myopathy, exercise intolerance, lactic acidosis, and increased 
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urinary 3-MGA; though motor development is delayed, mental development of the 
affected individuals are normal (311). Hence, the phenotypic spectrum associated with 
Sengers syndrome substantially overlaps with both Barth and DCMA syndromes. 
Sengers syndrome was originally thought to be due to deficiencies in the level and/or 
function of adenine nucleotide translocase 1 (ANT1) (312). ANT1 is the heart/muscle 
isoform of the mitochondrial ADP/ATP exchanger that plays a fundamental role in 
OXPHOS by mediating the flux of ADP and ATP across the IMM (313). However, 
genetic analyses excluded mutations in the ANT1 gene; as such, it was subsequently 
proposed that transcriptional, translational, or posttranslational events might be 
responsible for the lower amounts of ANT1 observed in patient (312). Recently, two 
groups localized the defect via exome sequencing, not in or around ANT1, but instead to 
the AGK locus on chromosome 7q34 (20, 309).  
The AGK gene contains 17 exons and encodes for a 422 amino acid protein; it is a 
mitochondrial membrane-associated, multi-substrate lipid kinase that contains domains 
that are highly homologous to sphingosine kinase-2 as well as DAG kinase (68, 69, 314). 
When phylogenetic analyses of AGK were undertaken, sequence comparisons to other 
lipid kinases such as DAG, ceramide, and sphingosine kinases revealed that despite 
containing a highly conserved DAG kinase catalytic domain, human and murine AGK 
segregate to a unique branch and are not members of any previously described lipid 
kinase family (68).  
Like Barth and DCMA syndromes, genotype-phenotype correlations in Sengers 
syndrome are not readily apparent. For instance, there are Sengers syndrome patients who 
are nonsyndromic or do not develop lactic acidosis (315), and siblings who share the 
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same mutation but present with very different disease courses (one had the severe form of 
disease and died at 15 months of age while the other brother, at 3 years old, was without 
skeletal myopathy or physical limitations (316)). Thus, the etiology of Sengers syndrome 
is also likely to involve genetic modifiers that can significantly affect disease progression 
and severity. 
However, there is evidence that a genotype-phenotype correlation for Sengers 
syndrome patients potentially exists (308). Two forms of the syndrome have been 
described, a severe neonatal form that leads to infantile death (317) and a more benign, 
but chronic, form that has allowed survival into the fourth decade (310). The former 
disease type is always associated with homozygous AGK nonsense mutations while in the 
latter, patients usually harbor at least one splice site variant or a start codon mutation, but 
not doubly null/missense alleles (308). Presumably, aberrant splicing of the COOH 
terminal exons (in or after the DAG kinase domain) produces proteins with residual AGK 
activity while inactivation of the canonical start site allows for initiation at an 
alternative/cryptic start site (318). In support of this possible genotype-phenotype 
relation, the oldest surviving patients (>35 years) carry either heterozygous start site and 
stop codon mutations or a homozygous mutation affecting exon 15-16 splicing (310, 
319).  
A role for AGK in the assembly, stability and/or regulation of OXPHOS 
components such as ANT1 and complex I has been speculated (308, 320). OXPHOS 
defects in patient samples have been variable (20, 308, 309, 312, 315, 316, 320, 321). In 
the more severe cases, ANT1 and complex I levels are low and the mtDNA copy number 
reduced. However, in the milder cases, OXPHOS function is spared. Curiously, ANT1 
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levels are normal in undifferentiated myoblasts but are dramatically reduced upon 
myoblast differentiation (309). This observation is notable as it suggests that ANT1 
stability is compromised during muscle fiber differentiation in Sengers syndrome 
patients. While the exact molecular function of AGK is not known, its potential role in 
CL metabolism is consistent with the varied bioenergetic impairments, structurally 
abnormal mitochondria, and lipid and glycogen deposits in patient-derived skeletal and 
cardiac muscle (311, 316). A comprehensive phospholipid analysis has not been 
performed for Sengers syndrome cells and/or tissues. Therefore, whether the absence of 
AGK function correlates with disturbances in phospholipid metabolism has not yet been 
established. If AGK generates PA that contributes substantially to TAMM41’s substrate 
pool (Figure 2.1), then the absence of AGK function should significantly impact 
downstream PG and CL synthesis. Given the aforementioned results concerning the 
relative stability of ANT1 in undifferentiated versus differentiated myoblasts, the choice 
of cell/tissue to analyze is likely to be critically important in uncovering if and how AGK 
participates in mitochondrial phospholipid metabolism. Such information is anticipated to 
shed crucial light onto Sengers syndrome disease pathogenesis. 
Phosphatidic acid-preferring phospholipase A1 mutations leading to hereditary 
spastic paraplegia 
Mutations in the phospholipase A1 family members DDHD1 (322-324) and 
DDHD2 (325-329) have recently been linked to autosomal-recessive forms of hereditary 
spastic paraplegia (HSP). HSPs are an extremely heterogeneous group of inherited 
neurological disorders that are classified by patients who present with (complex HSP) or 
without (uncomplicated or pure HSP) neurological defects. Pure HSP is characterized by 
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progressive spasticity and weakness of the lower limbs. In complex HSP, spastic 
paraplegia is compounded with neurological and systemic abnormalities such as 
dementia, intellectual disability, ataxia, and neuropathy, amongst others (see (330) for 
comprehensive discussion of HSP and spastic paraplegia variants). Furthermore, there is 
varied disease onset, progression, and “functional plateaus” (a point at which there is 
very little further disability) between the HSPs and as such, there is very little genotype-
phenotype correlation in this heterogeneous disorder.   
HSP has been linked to over 50 genetic loci, covering all chromosomes, of which 
only 22 genes have been identified so far (330, 331). Two of the identified disease-
associated genes are DDHD1 and DDHD2 that encode protein products with PA-
phospholipase A1 activity. DDHD1 is localized to chromosome 14q21.1, contains 12 
exons (322) and encodes for the 872 amino acid protein, PA-PLA1. Initial 
characterization identified substantial PA-PLA1 activity in bovine brain and testis that 
corresponds to the two tissues with the highest DDHD1 mRNA expression (332, 333). In 
humans, these two tissues, along with heart and skeletal muscle, additionally contain high 
levels of DDHD2, a more ubiquitously expressed DDHD family member (334-336). 
DDHD2 is both cytosolic and membrane-associated (334, 337). Located on chromosome 
8p11.23 and containing 18 exons, DDHD2 is expressed as two major mRNA transcripts 
that correspond to the full length 711 amino acid protein and another that lacks the 
COOH terminal DDHD phospholipase domain. When patient ddhd2 mutants were 
overexpressed in and partially purified from HEK293T, PA-PLA1 activity was either low 
or absent compared to overexpressed wt DDHD2 (329). Notably, depletion of PA-PLA1 
activity (DDHD1 or DDHD2) in some, but not all cells, can cause mitochondrial 
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elongation (192, 326, 337), presumably due to unopposed fusion. Thus, one might expect 
that the balance between fission and fusion may be disturbed in some cells in patients 
with ddhd1 or ddhd2 mutations with an overall shift towards too much fusion. As active 
fission is a crucial process for clearance of damaged mitochondria by mitophagy, 
unopposed fusion could drive the accumulation of dysfunctional mitochondria (338). 
Consistent with the possible accretion of sub-optimal mitochondria, respiration and ATP 
levels are decreased and cytosolic ROS increased in ddhd1 patient-derived lymphoblasts 
(322). Unfortunately, PA levels and mitochondrial morphology have not been 
documented in either ddhd1 or ddhd2 patient-derived cells (322) but there are no major 
changes in phospholipids in ddhd2-/- mouse brains (339). 
It is unclear whether or not depletion of DDHD1 or DDHD2 can directly affect 
mitochondrial dynamics by accumulating pro-fusogenic PA on the OMM. Given their 
similar substrate specificity, they may have redundant roles in this regard. Still, there 
might be functional differences for these two PA phospholipases that are dictated by their 
expression patterns and subcellular distributions. As such, future studies are needed to 
investigate the potential causative link between dysregulation of PA metabolism on the 
OMM with disease pathogenesis for these subtypes of HSP. 
 
PERSPECTIVES 
Phospholipids are not simply cellular barriers that delineate cells and organelles 
thus allowing biochemical pathways to be compartmentalized and cross-regulated. 
Although predominantly synthesized in the ER, some phospholipids, such as PG and CL, 
are exclusively made in the mitochondrion, while others, such as PE, involve a pathway 
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that begins in the ER but is completed in the cell’s powerhouse. In mitochondria, 
phospholipids are important for an impressive array of functions. Indeed, when 
phospholipid levels, molecular species, or distribution within the mitochondrion is 
affected, as is the case for the diseases discussed herein, mitochondrial dysfunction 
ensues. Barth syndrome was the first known inborn error of mitochondrial phospholipid 
metabolism. Since the identification of TAZ as the causative gene for BTHS, exome 
sequencing and basic research have both contributed to the recent addition of new 
diseases that impinge upon mitochondrial lipid metabolism. We propose to classify these 
disorders as a new category of mitochondrial disease that specifically impacts 
phospholipid homeostasis. The clinical heterogeneity of patient phenotypes reflects the 
variety of functions that phospholipids partake in and their fundamental importance for 
mitochondrial physiology. Future work needs to focus on developing appropriate models 
for these diseases. As exemplified by BTHS, the availability and in-depth 
characterization of such models will contribute enormously to our understanding of each 
disease process and identify potential therapeutic strategies. Further, such basic work 
should help us better understand disease mechanisms and provide explanations for shared 
and distinct phenotypes.  
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FIGURE 2.1 Mammalian cardiolipin biosynthesis. CL biosynthesis likely involves PA sourced from multiple 
pathways. PA can be generated by LPAATs which acylate LPA; LPA can be made using glycerol 3-phosphate 
(G3P) and acyl-CoAs by mitochondrial and ER GPATs. Additionally, PA can be made on the OMM through the 
hydrolysis of CL by MitoPLD. In the OMM, PA recruits the phosphatase lipin-1 which dephosphorylates PA into 
DAG. In turn, DAG may traffic across the OMM and be phosphorylated by AGK forming PA in the context of the 
IMS-side of the IMM. Regardless of where it is made, PA must reach the matrix side of the IMM to gain access 
to the core CL biosynthetic machinery. Here, PA is converted to CDP-DAG by TAMM41, thus providing the 
precursor for the committed step in CL biosynthesis, PGP synthesis by PGS1. PGP is rapidly dephosphorylated 
by PTPMT1 and the produced PG is condensed with CDP-DAG by CLS generating CL. Dashed arrows 
describe uncharacterized steps and pathways.
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FIGURE 2.2 Mammalian cardiolipin remodeling. CL that is synthesized by CLS on the 
matrix-facing leaflet of the IMM can by remodeled by three different pathways. While no single 
enzyme has been demonstrated to be required to initiate CL remodeling in mammals, several 
phospholipases of the iPLA2 family have been demonstrated to have a role in the process. 
Additionally, the submitochondrial localization of the phospholipases and the mechanisms by 
which CL gains access to these enzymes are unknown. After a fatty acyl chain is hydrolyzed 
from CL, generating MLCL, MLCL can be acylated back to CL by acyltransferases or transac-
ylases. MLCLAT1 on the matrix-leaflet of the IMM, TAZ on the IMS-facing leaflets of the OMM 
and IMM, and ALCAT1 on the ER MAM all have the capacity to re-acylate MLCL. The 
acyltransferases, ALCAT1 and MLCLAT1, use acyl-CoAs as an acyl chain donor to acylate 
MLCL. In contrast, the transacylase TAZ uses acyl chains donated from other phospholipids. 
The activity of TAZ is required to establish the steady state physiological CL molecular form. In 
contrast, the CL formed by ALCAT1 is more sensitive to oxidative damage and associated with 
pathologic states. Dashed arrows describe uncharacterized steps and pathways. In the 
phospholipid key, unremodeled CL corresponds to the newly synthesized CL that enters the 
pathway at the point of CLS (black head group). CL can undergo either physiologically-relevant 




























FIGURE 2.3 Inter-organelle and intra-organelle phospholipid trafficking. The existence of ER- and vacuole-mitochondria contacts is highly 
conserved from yeast to humans. By generating closely appositioned membranes, the inter-organelle and intra-organelle tethers are hypoth-
esized to promote movement of lipids across the aqueous cytosol and IMS, respectively. Within the mitochondrion, phospholipid trafficking may 
involve contacts between the OMM and the IMM mediated by MICOS complexes or NM23-H4. In addition, PRELI transports PA from the OMM 
to the IMM. PLS3 activity stimulates CL externalization on OMM. It may directly transport CL from the IMM to the OMM or instead function as a 
scramblase that redistributes CL between both leaflets of the IMM. CL now exposed to IMS-side of IMM would then be transported to the OMM 
by other mechanisms. With the possible exception of EMC, it is presently unclear if any of the known tethers has specificity for a defined 
phospholipid(s); as such, they are shown to promote the flux of phospholipids (PL) in bulk. If a specific phospholipid is impacted by mutations in 
a complex/protein (levels and/or composition), the lipid is indicated. Solid lines indicate known transport mechanisms. Dashed lines describe 
possible trafficking routes and/or highlight transport events whose mechanisms have not been resolved. The ERMES complex is found only in 
yeast and color-coded pink. For the remaining proteins/complexes, those found only in mammals are in blue and those that are likely to be 
conserved across species are colored grey. See text for additional details.
FIGURE 2.4 Biological functions of cardiolipin. As the signature phospholipid of the mito-
chondrion, CL is intimately involved in a number of mitochondrial processes. (A) Anionic CL on 
the IMM can function as a proton trap by attracting (and providing) a local pool of protons that 
can be funneled towards the ATP synthase. Moreover, CL is associated with every OXPHOS 
component and can promote their assembly into respiratory supercomplexes. Such supramo-
lecular assemblies are thought to enhance electron transfer and reduce ROS leakage from the 
electron transport chain. (B) CL associates with dynamin-related GTPases that are intimately 
involved in fusion and fission and (C) contributes to the assembly and function of IMM and 
OMM translocases vital for mitochondrial biogenesis. (D) Besides enhancing OXPHOS by 
stabilizing SCs, CL also promotes the assembly of ATP synthase oligomers that provide a 
structural scaffold required for establishing the characteristic shape of mitochondrial cristae. (E) 
Externalization of CL on the surface of the mitochondrion is involved in signaling the execution 
of either mitophagy or apoptotic cell death. 
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FIGURE 2.5 Potential mechanisms of DCMA mitochondrial dysfunction. (A) Under physi-
ological conditions, DNAJC19 is targeted to TIM17B by MAGMAS and associates with compo-
nents of the TIM23 translocation machinery, forming translocase B. DNAJC19 is homologous to 
yeast Pam18p which stimulates mtHsp70 activity of the PAM (presequence-associated motor) 
complex and stabilizes binding of incoming precursors. Moreover, DNAJC19 also interacts with 
prohibitin-2 (PHB) of the PHB complexes. PHB1/PHB2 oligomers form ring-like complexes that 
are modeled to delineate specialized membrane domains. Functional segregation of CL and 
TAZ in such domains may confer acyl chain specificity to TAZ, allowing it to perform 
physiologically-relevant CL remodeling (green). Thus, DNAJC19 may participate in both mito-
chondrial presequence protein import as well as formation of membrane domains that are 
important for TAZ-based CL remodeling. (B) In the absence of DNAJC19, the ability of the 
TIM23 machinery to import proteins across the IMM may be compromised. Consequently, the 
biogenesis of mitochondrial proteins, such as subunits of respiratory complexes, may be 
reduced. (C) Further, loss of DNAJC19 prevents the PHB complex-based generation of 
privileged membrane domains. In the absence of such domains, TAZ remodeling, which may still 
occur, lacks specificity (red). For clarity, not all components of the TOM, TIM, and PAM com-
plexes are depicted.
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FIGURE 2.6 Potential consequences of the absence of SERAC1 activity. (A) PG that is 
generated on the matrix-leaflet of the IMM is trafficked out of the mitochondrion and remodeled 
by SERAC1 on the ER MAMs. Remodeled PG can subsequently serve as substrate for BMP 
and CL synthesis. BMP in the endosomsal/lysosomal compartments regulates (green arrow) 
cholesterol esterification and trafficking out of the compartment. (B) In the absence of a func-
tional SERAC1, PG is not remodeled and accumulates shorter acyl chain moieties. The 
decrease in acyl chain length somehow reduces overall BMP levels, perhaps because the 
unremodeled PG is a poor precursor for BMP synthesis. Reduced BMP levels in the 
endosome/lysosome impairs cholesterol esterification (inhibition in red) and leads to decreased 
(red arrows) cholesterol efflux. The lack of SERAC1 also changes the steady state composition 
of CL acyl chains. Blue arrows denote enzymatic reactions and lipid movements. Dashed arrows 
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The X–linked disease Barth syndrome (BTHS) is caused by mutations in TAZ; TAZ is the 
main determinant of the final acyl chain composition of the mitochondrial-specific 
phospholipid, cardiolipin. To date, a detailed characterization of endogenous TAZ has 
only been performed in yeast. Further, why a given BTHS-associated missense mutation 
impairs TAZ function has only been determined in a yeast model of this human disease. 
Presently, the detailed characterization of yeast tafazzin harboring individual BTHS 
mutations at evolutionarily conserved residues has identified seven distinct loss-of-
function mechanisms caused by patient-associated missense alleles. However, whether 
the biochemical consequences associated with individual mutations also occur in the 
context of human TAZ in a validated mammalian model has not been demonstrated. Here, 
utilizing newly established monoclonal antibodies capable of detecting endogenous TAZ, 
we demonstrate that mammalian TAZ, like its yeast counterpart, is localized to the 
mitochondrion where it adopts an extremely protease-resistant fold, associates non-
integrally with intermembrane space-facing membranes and assembles in a range of 
complexes. Even though multiple isoforms are expressed at the mRNA level, only a 
single polypeptide that co-migrates with the human isoform lacking exon 5 is expressed 
in human skin fibroblasts, HEK293 cells, and murine heart and liver mitochondria. 
Finally, using a new genome-edited mammalian BTHS cell culture model, we 
demonstrate that the loss-of-function mechanisms for two BTHS alleles that represent 
two of the seven functional classes of BTHS mutation as originally defined in yeast, are 






The boundaries of cells and organelles are marked by membranes that differ in 
their phospholipid and protein compositions. The collection of phospholipids, including 
their associated fatty acyl chains, that establish a defined membrane-bound compartment 
confer unique membrane properties (curvature and rigidity) and contribute to numerous 
functions that occur at/across the membrane surface (transport and signaling) or within 
the space that it confines. As such, changes in membrane lipid composition can directly 
impact numerous fundamental cellular processes. A particularly salient example of the 
importance of proper lipid composition for organelle function is provided by the 
mitochondrion, the powerhouse of the cell, and its signature phospholipid, cardiolipin 
(CL).   
CL is required for a diversity of basic processes that are central to mitochondrial 
biology (1). In fact, CL is of such fundamental importance that mammalian development 
fails in utero in its absence (2). CL is a dimer of two phosphatidic acids linked together 
by a glycerol bridge. CL associates with numerous mitochondrial proteins, including 
every oxidative phosphorylation (OXPHOS) complex/component, many solute carriers, 
and translocases in both the outer and inner mitochondrial membranes (3-5). Collectively, 
these interactions with CL stabilize individual proteins and multisubunit complexes, and 
can stimulate enzyme activity either directly (e.g. serve a catalytic function (6)) or 
secondarily (e.g. promote the assembly of individual respiratory complexes into more 
efficient supercomplexes	   (7-9)). Finally, CL serves as a signal that is detected by CL-




and inner mitochondrial membrane (IMM) fusion (10, 11) to apoptosis and mitophagy 
(12, 13).  
The biosynthesis of CL occurs through a reaction series that is highly conserved 
from yeast to humans (14). With respect to its acyl chain composition, the CL that is 
newly produced is not what accumulates at steady state, which is highly homogeneous 
and characterized by increased acyl chain unsaturation and molecular symmetry (15). The 
steady state form of CL is established by an acyl chain remodeling process that begins 
with the removal of a fatty acyl chain from CL by a deacylase(s), generating 
monolysocardiolipin (MLCL), which is then re-acylated by the evolutionarily conserved 
MLCL transacylase, tafazzin (TAZ)	  (16). Mutations in TAZ result in the X-linked cardio- 
and skeletal myopathy, Barth syndrome (BTHS)	  (17, 18). In the absence of TAZ, there is 
less CL, the remodeling precursor and product, and more MLCL, the remodeling 
intermediate	  (19). Further, the CL that remains has an abnormal acyl chain profile (15, 
20). These BTHS-associated changes in mitochondrial phospholipid composition 
destabilize respiratory supercomplexes, reduce OXPHOS efficiency, increase reactive 
oxygen species production, and impair sarcomere organization	  (21-24).  
BTHS is the founding member of a new class of mitochondrial disorder that 
results from nuclear defects that impact mitochondrial phospholipid metabolism (25). 
Notably, some of the disorders, including dilated cardiomyopathy with ataxia (DCMA), 
Sengers, and MEGDEL syndromes, in this new class of mitochondrial disease share some 
biochemical phenotypes with BTHS. In each case, changes in the acyl chain pattern, 
abundance, and or submitochondrial distribution of CL are postulated to contribute to 




been established and thus the basis for the shared and unique phenotypes of this cohort of 
syndromes is presently unclear.  
Currently, a detailed topological map of tafazzin-based CL remodeling has only 
been drawn in the yeast Saccharomyces cerevisiae. In yeast, all of the steps up to and 
including the initiation of the remodeling process occur on the matrix side of the IMM 
(14). In contrast, yeast Taz1 is anchored to both the IMM and outer mitochondrial 
membrane (OMM) facing the intermembrane space (IMS) by virtue of a membrane 
anchor that protrudes into but not completely through the lipid bilayer (30). Thus, in yeast, 
CL remodeling involves an obligate trafficking step of MLCL from one side of the IMM 
to the other. Further, a yeast BTHS model has been exploited to determine the disease 
pathogenicity of a multitude of patient-associated missense alleles. To date, seven distinct 
pathogenic loss-of-function (LOF) mechanisms have been identified (30-32). Thus at 
present, our understanding of the basic cell biology of this clinically important 
remodeling pathway and the biochemical abnormalities associated with any genetic 
lesion linked to BTHS is based solely on work in yeast.   
Here, we show that mammalian TAZ is localized to the mitochondrion where it 
adopts an extremely protease-resistant fold, associates non-integrally with IMS-facing 
membranes, and assembles in a range of complexes. Even though multiple isoforms are 
expressed at the transcript level, only a single TAZ polypeptide that co-migrates with the 
human isoform lacking exon 5 is detected in mitochondria isolated from human skin 
fibroblasts, HEK293 cells, and murine heart and liver. Utilizing a newly established 
mammalian BTHS cell model, we determined that the two pathogenic mutations tested 




defined in yeast. Interestingly, overexpression of the unstable R57L mutant which lacks 
transacylase activity in vitro, partially rescues the mitochondrial CL and MLCL 
abnormalities of the taz deficient cells in vivo, suggesting that strategies aimed at 
stabilizing this mutant allele could be of therapeutic benefit. 
 
RESULTS 
Mammalian TAZ is localized to the mitochondrion 
The absence of antibodies capable of detecting endogenous TAZ has significantly 
impeded progress in our understanding of BTHS pathogenesis. To overcome this obstacle, 
three TAZ-specific mouse monoclonal antibodies (mAb; 2G3F7, 3D7F11, and 2C2C9) 
were generated. Critically, each mAb detected endogenous TAZ in fibroblast cell extracts 
from healthy controls (C109) but not two BTHS patients (TAZ001 and TAZ003) (Figure 
3.1A). TAZ001 encodes a truncated 50 amino acid protein while TAZ003 has a single 
R57L missense allele in TAZ (20). Using these new reagents, endogenous TAZ co-
fractionated with mitochondria (Figure 3.1B) and was detected in both human and murine 
mitochondria (Figure 3.1C). 
Human TAZ mRNA is present as a number of splice variants (20, 33). To 
determine the capacity of the three mAbs to detect different TAZ isoforms, the epitope 
recognized by each mAb was mapped; each of the three mAbs binds an epitope that is 
present in a different exon (Figure 3.1D). Moreover, they each have the capacity to 
recognize every predicted isoform based on mRNA analyses (20, 33). Following 
immunoprecipitation of TAZ with one mAb (3D7F11), only a single TAZ band was 




extracts (Figure 3.1E). Finally, based on co-migration with assorted human TAZ isoforms 
expressed in taz1Δ yeast (34), all of the cells and tissues surveyed only express TAZ 
lacking exon 5 (TAZ-ex5; exon 5 is missing in rodents so full-length murine TAZ already 
lacks exon 5) (Figure 3.1F). Thus, TAZ-ex5 is likely the major isoform expressed at the 
protein level in vivo. 
Generation of a mammalian BTHS cell model 
To establish a new mammalian BTHS cell culture model, we utilized TALEN-
mediated genome editing in 293 Flp-In cells to introduce genetic lesions within TAZ exon 
1. Two tazTALEN clones were identified that had undetectable levels of TAZ protein 
(Figure 3.2B) and which contained genomic deletions in the targeted locus (Figure 3.2A). 
In both tazTALEN.2 and 19, a proline that is highly conserved in mammals but not in fungi, 
is deleted (Figure 3.S1); in addition, there was a missense mutation (V12A) identified in 
tazTALEN.19 and five additional amino acids removed (amino acids 11-16) in tazTALEN.2. 
Surprisingly, neither deletion altered the overall reading frame of TAZ. Based on in silico 
analyses (Table 2), we hypothesize that Pro13 is either a critical determinant of a non-
bilayer spanning membrane anchor and/or essential for TAZ folding and stability. 
Consistent with these possibilities, proteosomal inhibition with MG132 did not stabilize 
TAZ in either tazTALEN cell line (Figure 3.2C). The lack of protein expression did not 
reflect differences in TAZ mRNA levels (Figure 3.2D). Moreover, the expression of 
representative proteins of each mitochondrial subcompartment and every OXPHOS 
complex was the same in mitochondria isolated from each tazTALEN cell line as WT 
(Figures 3.2E and F). Of note, the expression of PHB2 and DNAJC19, proteins 




as matrix-targeted Su9-DHFR was imported into mitochondria isolated from both 
tazTALEN cells at rates similar to that of WT mitochondria, the membrane potential across 
the IMM is not grossly impaired in the tazTALEN cells (Figures 3.2G and H). 
 Next, the phospholipid composition of mitochondria isolated from WT and 
tazTALEN cells was determined by mass spectrometry. An increased MLCL:CL ratio is a 
biochemical hallmark of TAZ deficiency (35). Importantly, mitochondria from each 
tazTALEN cell contained a significantly increased MLCL:CL ratio (Figure 3.3C) that was 
largely driven by an accumulation of MLCL (Figure 3.3B). The amount of CL was not 
significantly changed (Figure 3.3A). TAZ-based CL remodeling is a major determinant 
of the final acyl chain composition of CL at the steady state, which is typified by the 
inclusion of more unsaturated acyl chains compared to pre-remodeled CL. While there 
were only modest changes in CL acyl chain length in the tazTALEN cells (Figure 3.3E), the 
amount of CL containing fewer double bonds was significantly increased (Figure 3.3F). 
Moreover, the relative abundance of unsaturated acyl chains for CL molecules of a given 
length was consistently lower in tazTALEN than in WT mitochondria (Figures 3.3G-K). In 
addition to its dramatically increased abundance, there were also notable changes in the 
acyl chain profile of the remodeling intermediate MLCL in mitochondria isolated from 
both tazTALEN cells (Figures 3.3L-O). Specifically, MLCL with longer acyl chains that 
contained fewer double bonds accumulated in the absence of TAZ activity. Other 
alterations in the mitochondrial lipidome that were consistent features of mitochondria 
from both tazTALEN cells included an increased abundance of phosphatidylglycerol (PG, 
Figure 3.3D), bis-monoacylglyerol phosphate, reduced levels of phosphatidylinositol, and 




phosphatidylethanolamine, two lipid classes that can be used by TAZ as acyl chain 
donors for MLCL re-acylation (16) (Figures 3.S2-S4). Collectively, these results validate 
the tazTALEN cells as new cellular BTHS models. 
Mammalian TAZ is a membrane protein that assembles in high molecular weight 
complexes 
Yeast Taz1 associates with the IMS-side of the IMM and OMM by virtue of a 
membrane anchor that extends into but not through the lipid bilayer (30). To determine if 
human TAZ is similarly membrane-associated, mitochondrial extracts from 293 Flp-In or 
C109 fibroblasts were sonicated and centrifuged to obtain the pellet, containing 
membrane-associated proteins, and the supernatant, containing soluble proteins. TAZ, 
like TIM23 and TOM20, was detected in the pellet fraction (Figure 3.4A). Next, alkali 
extraction was performed. As expected, the integral proteins TIM23 and TOM20 were 
largely retained in the pellet whereas the peripheral cytochrome c (CYT C) was 
quantitatively released into the supernatant (Figure 3.4B). Like yeast Taz1, human TAZ 
was steadily released into the supernatant as the pH increased, suggesting a similar mode 
of membrane association (Figure 3.4C). Alternatively, analogous to succinate 
dehydrogenase subunit A (SDHA), TAZ membrane association may be determined by an 
interaction with a yet-to-be identified integral membrane protein.  
As yeast Taz1 engages in a range of macromolecular complexes (30, 36), the 
assembly of mammalian TAZ was examined by 2D blue native (BN)/SDS-PAGE. In 
both human and murine mitochondria, TAZ assembled in a range of complexes (Figure 




mitochondrial membranes and engages in macromolecular complexes in a manner that is 
highly reminiscent of its yeast ortholog.  
Mammalian TAZ is highly protease resistant and localized to IMS-facing leaflets 
Next, we determined the submitochondrial localization of TAZ. First, 
mitochondria from 293 Flp-In cells were titrated with increasing amounts of digitonin, 
causing the sequential release of soluble IMS proteins, soluble matrix proteins, 
membrane proteins of the OMM, and finally IMM-embedded proteins into the 
supernatant (Figures 3.5A and B). The fractionation profile of human TAZ overlapped 
with both IMM and OMM proteins (Figure 3.5B) suggesting that like yeast Taz1, human 
TAZ associates with both the IMM and OMM (4, 30, 37).  
Second, a protease-protection assay was performed to determine if human TAZ is 
associated with IMS-facing membranes as predicted based on results in yeast. In brief, 
human and murine mitochondria were incubated in iso-osmotic buffer, low osmotic 
buffer, or low osmotic buffer supplemented with detergent, with each permutation 
performed in the absence or presence of the non-specific protease mixture, pronase E 
(Figure 3.5C). Accordingly, OMM proteins facing the cytosol (e.g. TOM20) are 
accessible to added protease in each condition, residents of the IMS (TIM23; TIM23 is an 
IMM protein with a large domain exposed to the IMS) are degraded by added protease 
following osmotic rupture of the OMM (low osmotic buffer) and detergent solubilization, 
and matrix proteins (GRP75) are only degraded upon addition of detergent with protease. 
Like the matrix marker GRP75, in every source of mitochondria tested, mammalian TAZ 




that mammalian TAZ is localized to the matrix-facing leaflet of the IMM, the opposite 
side of the IMM as yeast Taz1.  
This conclusion, however, is predicated on TAZ being sensitive to protease. Thus, 
another potential explanation for the observed pattern is that perhaps TAZ adopts a 
highly protease-resistant fold that becomes accessible to proteolytic cleavage only in the 
presence of detergent. To test the idea that TAZ is protease-resistant, we compared its 
sensitivity to proteases upon addition of detergent with or without prior heat denaturation 
(Figure 3.5D). When solubilized with SDS, heat denaturation increased the sensitivity of 
TAZ to degradation by each protease. One potential explanation for the resistance of 
TAZ to proteolytic degradation is that it forms aggregates. However, using a sequential 
detergent solubility assay where TAZ was readily solubilized with digitonin (protein 
aggregates resist solubilization even when re-extracted with TX-100), TAZ does not form 
protein aggregates (Figure 3.5E).  
 In light of TAZ’s protease resistance, the assays performed cannot conclusively 
establish the topology of membrane-associated TAZ. Therefore, we performed an in 
organello import assay in which radiolabeled TAZ precursor was incubated with WT 
mitochondria in the presence or absence of a membrane potential and non-imported 
precursor removed with trypsin (Figure 3.5F). Import of TAZ was time-dependent but 
membrane potential-independent. The TAZ precursor was not processed upon import 
consistent with the failure of most in silico programs (Table 3) to predict a mitochondrial 
presequence cleavage site. Critically, 35S-TAZ precursor was readily degraded by trypsin 
following incubation with mitochondria on ice and disruption of the OMM (compare 




disruption of the OMM in the presence of trypsin drastically decreased the 35S-TAZ 
detected (lane 6). Thus, the protease resistance of TAZ observed at steady state occurs 
after it is imported into the mitochondrial IMS. 
To gain further insight into the topology of TAZ, epitopes tags were added to 
either termini of TAZ (CNAP-TAZ and TAZ-3XFLAG for NH2- or COOH-terminal 
tagged TAZ, respectively) (Figure 3.6A). Upon transfection into the tazTALEN.19 cell line, 
each construct was expressed similar to untagged WT TAZ (Figure 3.6B) and 
importantly, rescued the altered MLCL:CL ratio of this TAZ-deficient model (Figures 
3.6C and D). The sensitivity of the appended epitope tags to proteolytic degradation was 
determined in intact mitochondria, following OMM rupture, or in the presence of 
detergent. Like the IMS marker TIM23, which is anchored to the IMM but exposes a 
large domain in the IMS, the NH2-terminal epitope of CNAP-TAZ became sensitive to 
added protease when the OMM was disrupted (Figure 3.6F). In contrast, 3XFLAG added 
to the COOH terminus of TAZ was resistant to proteolytic degradation unless detergent 
was included (Figure 3.6F). Thus, either the COOH terminus of TAZ is in the matrix, 
implying that TAZ has a membrane spanning domain contrary to expectations based on 
its alkali extraction profile (Figures 3.4B and C), or alternatively, the added tag is 
incorporated in the core protease-resistant structure of TAZ. To distinguish between these 
two possibilities, we transfected the tazTALEN.19 cell line with TAZ harboring a COOH-
terminal APEX2 tag (38, 39). APEX2 encodes an engineered ascorbate peroxidase that 
can be used in electron microscopy studies to localize a tagged protein (38, 39). TAZ-
APEX2 was expressed normally and functional based on the restored MLCL:CL ratio 




with H2O2 in the presence of 3,3’-diaminobenzidine (DAB), electron micrographs 
captured DAB staining in the mitochondrial IMS (Figure 3.6G). In contrast, peroxide 
treatment of tazTALEN cells expressing untagged TAZ resulted in micrographs with little 
contrast and no staining. Our combined results indicate that mammalian TAZ adopts a 
highly protease-resistant structure following its import into the mitochondrial IMS where 
it non-integrally associates with mitochondrial membranes with both termini exposed to 
the IMS.  
 The R57L allele encodes an unstable protein 
TAZ003 fibroblasts harbor an R57L missense mutation that was previously 
classified in yeast (K65L) as a temperature-sensitive allele (Figure 3.7A) (20, 32). As 
such, the inability to detect TAZ in TAZ003 cells could provide evidence that like in 
yeast, the R57L allele is intrinsically unstable. To determine if the R57L allele encodes 
an unstable polypeptide, we re-introduced into the two tazTALEN cell lines WT TAZ, R57L, 
and an H69Q TAZ mutant that in yeast encodes a catalytically-null polypeptide (32). The 
5-6 subclones that were isolated per construct per parental cell line displayed little 
variability in TAZ expression for a given TAZ allele (Figure 3.7B). Consistent with the 
possibility that the R57L allele is intrinsically unstable, its steady state expression in 
clones from both tazTALEN cells was dramatically reduced compared to WT TAZ-
expressing cells. The reduced expression was not reflected at the transcript level (Figure 
3.7C), did not result from impaired import into the mitochondrial IMS (Figure 3.7D), and 
was not restored upon proteosomal inhibition (Figures 3.7E and 3.S5A). Moreover, when 




half-life (t1/2) than WT TAZ (Figures 3.7F and 3.S5B). Thus, as previously characterized 
in a yeast BTHS model (32), the R57L BTHS variant encodes an unstable protein. 
The H69Q allele is catalytically-null 
The H69Q mutation disrupts a highly conserved HXXXXD acyltransferase motif. 
When modeled in yeast, the equivalent H77Q mutation results in a protein that behaves 
biochemically and cell biologically like WT Taz1 but that is completely devoid of 
transacylase activity (32). As expected, expression of H69Q in whole cell extracts (Figure 
3.7B) and isolated mitochondria (Figure 3.8A) was similar to WT TAZ. The H69Q allele 
was imported into the mitochondrial IMS (Figure 3.8B) and assembled in complexes 
(Figures 3.8C and 3.S5C) just like WT TAZ. The preserved complex formation of the 
H69Q mutant indicates that TAZ assembly is insensitive to increased MLCL or changes 
in CL acylation. To directly measure the transacylase activity of WT and mutant TAZ, 
isolated mitochondria were incubated with 14C-labeled lyso-PC and its conversion to PC 
monitored (Figure 3.8D). Overexpression of WT TAZ resulted in dramatically increased 
transacylase activity. In stark contrast, mitochondria overexpressing H69Q (or R57L) 
lacked any detectable transacylase activity above background. Finally, while WT TAZ 
restored the MLCL:CL ratio of both tazTALEN cell lines to normal, overexpression of the 
H69Q mutant did not (Figures 3.8E-G). Therefore, the H69Q variant encodes a 
catalytically inactive polypeptide in both mammals and yeast. Intriguingly, 
overexpression of the R57L mutant, which was devoid of transacylase activity in vitro 
(Figure 3.8D) did partially improve the MLCL:CL ratio of both tazTALEN cell lines in vivo 
(Figures 3.8E-G) indicating that prior to its degradation, it retained some residual 




3.S5C). Collectively, these results suggest that the LOF mechanisms that underlie certain 
missense mutations are conserved in yeast and mammalian BTHS models.  
 
DISCUSSION 
We have determined that CL remodeling is organized in topologically similar 
ways in mammals and yeast. Like in yeast, mammalian TAZ is localized to the IMS-
facing leaflets of the OMM and IMM. Thus, the main determinant of the final CL acyl 
chain pattern, TAZ, resides on the opposite side of the IMM as the CL biosynthetic 
machinery. In yeast, the lipase that functions upstream of Taz1, Cld1, is peripherally 
associated with the matrix side of the IMM (40). At present, the identity and detailed 
localization of the mammalian lipase(s) that functions upstream of human TAZ to initiate 
CL remodeling has not been defined. The rationale for the localization and topology of 
TAZ-based CL remodeling in yeast and mammals is presently unclear but is presumed to 
be important for it to function properly. Notably, besides dictating the final acyl chain 
pattern of CL, the physiological functions of this conserved remodeling pathway remain 
elusive (41). 
Overall, our work suggests that human and yeast TAZ, whose polypeptides are 
only 18% identical and 41% conserved, are remarkably similar biochemically. Not only 
is their submitochondrial localization the same, yeast and mammalian TAZ also interact 
with mitochondrial membranes in a similar manner which in yeast involves a membrane 
anchor that extends into but not completely through the lipid bilayer (30). Further, both 
yeast and mammalian TAZ assemble in a range of complexes that appear qualitatively 




with itself but does interact with the ATP synthase as well as the major mitochondrial 
ADP/ATP carrier, Aac2 (36). Thus, it is possible that these interactions will be 
evolutionarily conserved. However, it is important to mention that the vast majority of 
the yeast Taz1 interactome remains undocumented and the noted interactions between 
yeast Taz1 and the ATP synthase or Aac2 are clearly sub-stoichiometric. The 
composition of all of the mammalian TAZ-associated complexes is similarly unknown 
but is something we are actively investigating.  
Critically, another feature shared between yeast and mammalian TAZ are the LOF 
mechanisms associated with distinct pathogenic mutations. Using a novel BTHS cell 
model, the LOF mechanism for the two tested pathogenic mutations were conserved as 
modeled in yeast or human TAZ. In patient-derived TAZ003 cells, the protein product of 
the R57L allele is undetectable. When overexpressed in tazTALEN cells, the R57L mutant 
localized properly and assembled normally (Figures 3.S5A-C), but accumulated to a 
much lesser extent and had a significantly shorter half-life than WT TAZ. The 
corresponding yeast mutant, K65L, is a temperature-sensitive allele that becomes 
unstable and loses activity at non-permissive temperature (32). Interestingly, even though 
the R57L allele lacked in vitro activity, its overexpression did improve the MLCL:CL 
ratio in both tazTALEN cells (Figure 3.7G). Therefore, small molecules capable of 
stabilizing the R57L mutant could increase its activity and thus represent viable 
therapeutic options. Importantly, dysfunctional conservation extends to the H69Q 
mutation. In yeast, the corresponding H77Q mutant is identical to WT Taz1 in every way 
tested except that it is devoid of transacylase activity (32). As predicted from yeast, the 




TAZ is a promiscuous transacylase that can utilize a range of lyso-lipid substrates 
and phospholipid acyl chain donors. Moreover, TAZ itself lacks intrinsic acyl chain 
specificity which raises the obvious question of how a non-specific enzyme can generate 
CL that typically has a specific collection of acyl chains. Recent experiments have 
suggested that the physical state of phospholipid membranes can affect the substrate 
specificity of TAZ. Under experimental conditions that mimic high membrane curvature, 
have an increased proportion of non-bilayer lipids, or perturbed bilayer states, TAZ gains 
the capacity to generate the physiologically-relevant CL molecular form that contains 
four attached 18:2 linoleic acids (42). In mitochondria, such privileged lipid domains may 
be delineated by the recently described prohibitin/DNAJC19 complexes (28). The ring-
shaped prohibitin complexes, composed of PHB1 and PHB2 subunits and including 
DNAJC19 (28), form protein and lipid scaffolds within the IMM that contribute to cristae 
morphogenesis and cell proliferation (43). Surprisingly, knockdown of either PHB2 or 
DNAJC19, which do not interact with TAZ, changes the acyl chain pattern of CL similar 
to TAZ depletion (28). Depletion of either protein with TAZ does not prevent the 
accumulation of MLCL. These findings suggest that PHB/DNAJC19 complexes 
participate in CL remodeling after the process is initiated. Since MLCL does not 
accumulate, TAZ is still active when PHB2 or DNAJC19 expression is reduced. 
Although both completely traverse the IMM bilayer, the majority of the DNAJC19 
polypeptide resides in the matrix. Thus, how PHB/DNAJC19 complexes could modulate 
TAZ specificity remains unclear based on the submitochondrial localization and 
interfacial membrane association of TAZ as defined previously in yeast and here in 




tempting to speculate that PHB/DNAJC19 complexes sequester TAZ within membrane 
domains with physical properties (high membrane curvature) that confer acyl chain 
specificity to TAZ. While the exact details of how PHB/DNAJC19 complexes modulate 
the specificity of TAZ-mediated CL remodeling is undefined, the functional relationship 
between PHB/DNAJC19 complexes and TAZ is underscored by the fact that mutations in 
DNAJC19 result in DCMA, a disease that shares many clinical features with BTHS (25, 
26). Our results thus establish a framework to dissect the functional relationship between 
PHB/DNAJC19 complexes and TAZ which may in turn reveal the basis for the shared 
and distinct phenotypes of BTHS and DCMA. 
 
MATERIALS AND METHODS 
Molecular Biology 	  
The human TAZ ORF lacking exon 5 was amplified by PCR using cDNA from 
HeLa cells and subcloned first into pBSK (Stratagene) and then into pcDNA5/FRT 
(Invitrogen). The R57L and H69Q mutations were introduced into the parental 
pcDNA5/FRThTAZ plasmid via overlap extension (44). TAZ with an NH2 terminal 
CNAP tag (45) or COOH terminal 3XFLAG or APEX2 tags were introduced into the 
parental pcDNA5/FRThTAZ plasmid via overlap extension (44). For TAZAPEX2, 
pcDNA3APEX2-NES (39), a gift from Alice Ting (Addgene plasmid # 49386), was used 
as template. For in vitro transcription/translation, WT TAZ and the R57L and H69Q 
alleles were subcloned into pSP64. The sequence of every construct was verified by DNA 
sequencing. The TALEN binding pair recognizes sequences in TAZ exon1 that are 




Technologies). The two constructs, which are fused to the truncated Fok1 nuclease, were 
subcloned into pcDNA3.1 and pEF6/V5-HisA (Life Technologies) generating 
pcDNA3TAZ1-R and pEF6ATAZ1-L, respectively. 
Cell Culture 	  
All cells were grown at 37°C, 5% CO2. Control (C109) and BTHS patient 
fibroblasts (TAZ001 and TAZ003) (20) were maintained in DMEM (Cellgro) containing 
10% fetal bovine serum (FBS, Hyclone), 2 mM L-glutamine (Gibco), and 50 units/L 
penicillin-streptomycin (Gibco). HEK293 Flp-In cells (Invitrogen) were grown in 
DMEM containing 10% FBS, 2 mM L-glutamine, and 100 µg/ml zeocin (Invitrogen). To 
establish a BTHS cell model, 293 Flp-In cells grown in medium lacking antibiotic but 
supplemented with 50 µg/ml uridine, were transfected with a 1:1 ratio of pCDNA3TAZ1-
R and pEF6ATAZ1-L using FuGENE 6 (Promega), selected with 0.5 mg/ml G418 and 5 
µg/ml blasticidinS (Cellgro) for 1 week, and single colonies isolated by ring cloning. 
Individual clones were maintained in the same medium as used for the parental 293 Flp-
In cells and the inclusion of uridine found to not be essential. Whole cell extracts derived 
from candidate clones were harvested and analyzed by SDS-PAGE and immunoblot. 
Stable tazTALEN rescue cell lines were generated by co-transfecting the two tazTALEN cell 
lines with pOG44 (expressing the Flp-recombinase) and the relevant pcDNA5/FRT 
plasmid (WT, CNAP-TAZ, TAZ-3XFLAG, TAZ-APEX2, R57L, H69Q) at a ratio of 9:1 
using FuGENE 6. Transfected cells were selected using 200 µg/ml hygromycin B 
(Invitrogen), individual clones recovered by ring cloning, expanded, and screened by 
immunoblot. Equal numbers of individual clones per construct were combined to 




pooled population was derived from at least 5 individual clones except for tazTALEN.19 
overexpressing CNAP-TAZ which was established from 3 clones. Mycoplasma 
contamination was routinely monitored and not detected.  
Purification of recombinant human TAZ 	  
The entire open reading frame of TAZ lacking exon5 was cloned into the pET28a 
vector (Novagen) downstream of the 6xHis tag, induced at 37°C for 4 hours with 1 mM 
IPTG in C41 (DE3) Escherichia coli, and inclusion bodies separated from native protein 
extracts by centrifugation at 22,000 ×g for 1 hour at 4°C. Lipids and debris were removed 
from the inclusion bodies by resuspending the pellet with 7-10 mls of wash buffer (50 
mM Tris-HCl, pH 7.0, 2.5 mM EDTA, 1 M urea, 1% (v/v) Triton X-100) per gram of 
cells using a dounce homogenizer followed by centrifugation at 22,000 ×g for 30 minutes 
at 4°C. This wash step was repeated three times until the supernatant was clear. A final 
wash was performed using wash buffer lacking urea and Triton X-100. The final 
recovered protein pellet was resuspended using a dounce homogenizer with 4 ml of 
extraction buffer (50 mM HEPES-KOH, pH 7.5, 5 mM EDTA, 8 M guanidine-HCl, 2 
mM β-mercaptoethanol) per gram of cells and clarified by centrifugation at 100,000 ×g 
for 1 hour at 4°C. The solubilized inclusion bodies were mixed 1:1 with ddH2O, His6-
TAZ purified using Ni2+ agarose (Qiagen), and bound material recovered under 
denaturing conditions.  
Antibodies	  
Custom monoclonal antibodies against human TAZ-ex5 were produced by 




3D7F11, and 2G3F7 – that secrete TAZ-reactive antibodies were established. Antibodies 
against the following proteins were: GRP75 (Antibodies Inc. 75-127); β-actin (A5441) 
and TIMM9 (WH0026520M1) (Sigma); topoisomerase I (Developmental Studies 
Hybridoma Bank CPTC-TOP1-1-S); calreticulin 3 (sc-134295) and TOM20 (sc-11415) 
(Santa Cruz); HLA-B (Epitomics 2389-1); TIM23 (611332), CYCS (556433), 
SMAC/DIABLO (612246), and cyclin D1 (556470) (BD); UQCRC2 (ab14745), ACO2 
(ab129069), VDAC1 (ab15895), and COX4 (ab16056) (Abcam); SDHA (Invitrogen 
4592000); PHB2 (BioLegend 611802); DNAJC19 (ProteinTech 12096-1-AP); and 
NDUFB6 (Molecular Probes, discontinued). F1β was a kind gift from Dr. Peter Pedersen 
(Johns Hopkins School of Medicine) and the ANT2/5H7 (46) antibody was raised against 
the yeast ADP/ATP carrier, Aac2, but conveniently cross-reacts with human and murine 
ANT2. Goat anti-rabbit or mouse secondary antibodies conjugated to horseradish 
peroxidase were also used (31460 and 62-6520; Pierce). 
Whole cell extraction	  	  
Confluent culture dishes were washed twice with ice-cold PBS and lysed with 
RIPA lysis buffer (1% (v/v) Triton X-100, 20 mM HEPES-KOH, pH 7.4, 50 mM NaCl, 1 
mM EDTA, 2.5 mM MgCl2, 0.1% (w/v) SDS) spiked with 1 mM PMSF for 30 minutes at 
4°C with rotation. Insoluble material was removed by centrifugation for 30 minutes at 
21,000 ×g at 4°C, the supernatant collected, and protein quantified using a bichichronic 





SDS-PAGE and immunoblotting was performed as previously described (47). 
Images were captured with a Fluorchem Q (Cell Biosciences, Inc) quantitative digital 
imaging system and quantitation performed using the indicated software. Images were 
processed in Adobe Photoshop with only linear adjustments in contrast and brightness 
and assembled in Adobe Illustrator.  
Preparation of subcellular fractions	  
Fibroblasts and 293 Flp-In cells were seeded onto four 150 mm×25 mm tissue-
culture dishes and allowed to expand to confluency. Two days prior to mitochondrial 
isolation, the cells were switched from dextrose- to galactose-based media (DMEM 
without glucose, Gibco; supplemented with 10 mM galactose, Sigma). Mitochondria 
were isolated on ice (with ice-cold buffers) using a protocol adapted from (48). Briefly, 
after aspirating spent media from dishes, cells were scraped off in PBS and centrifuged at 
600 ×g for 10 minutes. After washing the cells once more with PBS, the pelleted cells 
were resuspended in 3 ml isolation buffer (IBc, 10 mM Tris-MOPS, 1 mM EGTA/Tris, 
pH 7.4, 200 mM sucrose) and homogenized with 40-45 strokes in a motor-driven tightly 
fitting Teflon Potter-Elvehjem at 1,600 rpm. Cell lysates were then centrifuged twice at 
600 ×g for 10 minutes; the resulting pellet is the nuclear fraction. Mitochondria were 
recovered from the supernatant by centrifugation at 7,000 ×g for 10 minutes. The 
mitochondrial pellet was resuspended to a volume that fits a 1.5 ml microcentrifuge tube; 
after an additional 7,000 ×g spin, a 10,000 ×g clarifying spin was performed to obtain 
crude mitochondria. The supernatant from the prior 7,000 ×g spin contains cytosolic, 
lysosomal, and ER fractions which were further sub-fractionated as follows. Lysosomes 




of IBc. The remaining supernatant was centrifuged at 40,000 ×g for another 30 minutes to 
obtain plasma membranes. Further centrifugation of the obtained S40 (100,000 ×g for 1 
hour) resulted in the isolation of ER (pellet) and cytosolic fractions (supernatant). Heart 
and liver mitochondria from 10-12 week old female FVB mice were isolated on ice using 
a protocol adapted from (49, 50). Briefly, tissues were rinsed with ice-cold CP1 (100 mM 
KCl, 50 mM MOPS, pH 7.4, 5 mM MgSO4, 1 mM EGTA, 1 mM ATP), minced with 
scissors and washed several times with CP1 before resuspension in CP2 (CP1 
supplemented with 2 mg/ml BSA). Tissues were then homogenized using a Polytron 
(three 2.5 second pulses on medium setting; Fisher PowerGen 1000 large bore 
homogenizer). The homogenate was centrifuged at 580 ×g for 7 minutes at 4°C and the 
resultant supernatant contained either liver mitochondria or in the case of heart tissue, 
subsarcolemmal mitochondria (SSM), while the pellet contained heart interfibrillar 
mitochondria (IFM). Liver and SSM supernatants were repeatedly centrifuged at 580 ×g 
until there were no visible cell/debris pelleting. A final clarifying spin at 3,000 ×g for 7 
minutes was performed before resuspending the mitochondrial pellets in KME (100 mM 
KCl, 50 mM MOPS, 1 mM EGTA). To extract IFM mitochondria, the pellet was 
resuspended in CP1 containing 5 mg trypsin per gram tissue with mixing, for 10 minutes 
on ice. The trypsin was inactivated with an equivalent volume of CP2 before 
centrifugation at 7,500 ×g for 7 minutes at 4°C. For our purposes (to maximize heart 
mitochondrial yield) the resultant pellet was resuspended in CP2, clarified with a 3,000 
×g spin before being resuspended in KME and combined with the SSM mitochondria. 
Organellar and mitochondrial fractions were quantitated using a BCA assay. 




used immediately, aliquoted, snap frozen with liquid N2, and stored at -80°C for 
downstream analyses.  
Epitope-Mapping 
A peptide scan consisting of 15mer peptides with an 11 amino acid overlap 
between adjacent peptides that spans the entire 262 amino acid TAZ protein was 
generated by JPT Peptide Technologies. The membrane was moistened with methanol 
prior to immunoblotting and the membrane subsequently regenerated with 100 mM β-
mercaptoethanol, 1% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.7, two more times to map 
epitopes bound by the different TAZ monoclonal antibodies. The epitopes recognized by 
each of the three monoclonal antibodies were determined by densitometry analysis of the 
immunoreactive PepSpots.  
Immunoprecipitation	  
The TAZ monoclonal antibody, 3D7F11, or normal mouse serum was conjugated 
to protein G-sepharose using the Seize X Protein A Immunoprecipitation kit and protocol 
(Pierce). Confluent T75 cm2 flasks of the indicated cells were lysed with 1 ml RIPA lysis 
buffer and protein extracts quantified as described above. 1.5 mg cellular extract per cell 
line was diluted to 1 ml with protease inhibitor-spiked lysis buffer and rotated with 90 µl 
normal mouse serum-conjugated beads for 1 hour at 4°C. After centrifugation at 376 ×g 
for 5 minutes at 4°C, the pre-cleared lysates were transferred to tubes containing 90 µl 
3D7F11-conjugated beads and rotated at 4°C for 4 hours. Following low speed 
centrifugation as before, unbound extract was collected for analysis and the bound 




per wash) twice with Wash Buffer (0.1% (v/v) Triton X-100, 20 mM HEPES-KOH, pH 
7.4, 50 mM NaCl, 1 mM EDTA, 2.5 mM MgCl2, 0.1% (w/v) SDS; 1 ml per wash), twice 
with High Salt Wash Buffer (0.1% (v/v) Triton X-100, 20 mM HEPES-KOH, pH 7.4, 
500 mM NaCl, 1 mM EDTA, 2.5 mM MgCl2, 0.05% (w/v) deoxycholate; 1 ml per wash) 
and once with Low Salt Wash Buffer (0.1% (v/v) Triton X-100, 20 mM HEPES-KOH, 
pH 7.4, 1 mM EDTA, 2.5 mM MgCl2, 0.05% (w/v) deoxycholate; 1 ml per wash). To 
elute bound material, three sequential elutions were performed using 0.1 M glycine, pH 
2.8, and the pooled eluates were neutralized with 50 µl 1 M Tris-Cl, pH 8.0. Eluates were 
transferred to a spin column (Pierce 1824826) and centrifuged for 2 minutes at 376 ×g to 
reduce resin carry-over. Finally, the unbound extracts (pre-clear and IP beads) and eluates 
were TCA-precipitated (20% (v/v) TCA with 0.07% (v/v) deoxycholate) for 1 hour on ice, 
the pellet fractions resuspended in a 1:1 mix of 2X reducing sample buffer and 0.1 M 
NaOH, and boiled for 5 minutes.  
Genotyping tazTALEN cells	  
Genomic DNA was extracted using the Gentra Puregene Cell Kit (Qiagen) and 
the genomic region surrounding the target site (exon1 extending into exon2, 
encompassing the ATG) was PCR amplified, digested with XbaI/HindIII (NEB), and 
ligated into pBSK(-). Transformants were analyzed by Sanger sequencing. As 293 cells 
are hypotriploid, sequences of at least 10 individual clones for each of the two tazTALEN 





Total RNA was isolated from WT, tazTALEN, and tazTALEN overexpressing TAZ 
alleles using the PureLink RNA Mini Kit with DNase treatment (Invitrogen). 25 ng of 
RNA was analyzed in 20 µl reactions using the EXPRESS One-Step SYBR GreenER 
qRT-PCR Kit (Life Technologies) with 7500 Real-Time PCR Systems (Applied 
Biosystems) according to the manufacturer’s instructions. Each reaction, including non-
template controls, was performed at least in duplicate with a minimum of three different 
biological replicates and contained 50 nM ROX and 200 nM each of forward and reverse 
gene-specific primers designed with Primer3 (51). The reaction conditions were as 
follows: 5 minutes at 50°C, 2 minutes at 95°C, followed by 40 two-temperature cycles 
(15 seconds at 95°C and 1 minute at 60°C) and melt curve profiling. Expression of TAZ 
was analyzed by the comparative CT (ΔΔCT) method (XTest/XGAPDH=2-ΔΔCT) with GAPDH as 
an endogenous reference gene. Values were represented as mean ΔΔCT ± SEM or fold 
change (2ΔΔCT) ± SD relative to TAZ expression in 293 Flp-In cells (Prism 6). 
Import	  
Radiolabeled precursors were produced using an SP6 Quick Coupled 
Transcription/Translation system (Promega) spiked with Easy-Tag L-35S-methionine 
(PerkinElmer). Radiolabeled precursors were incubated in import buffer (20 mM 
HEPES-KOH, pH 7.4, 250 mM sucrose, 80 mM KOAc, 5 mM MgOAc, 10 mM 
succinate, and 5 mM methionine) with freshly isolated mitochondria for the indicated 
amount of time at 37°C or 4°C, as specified. To dissipate the mitochondrial proton-
motive force, mitochondria were pre-incubated with 1 µM valinomycin and 5 µM 
carbonyl cyanide m-chlorophenyl hydrazine for 5 minutes at 37°C. Import was stopped 




indicated, the OMM was ruptured as already described in the presence of 20 μg/ml 
trypsin. Following 30 minutes on ice, 100 μg/ml soybean trypsin inhibitor was added and 
mitochondria were re-isolated by centrifugation at 21,000 ×g for 5 minutes at 4°C. 100% 
of each time point and 5% of imported precursors were resolved on 12% SDS-PAGE gels 
and analyzed by phosphoimaging. 
Lipidomics	  
A defined amount of internal standards (0.1 nmol of CL(14:0)4, 0.2 nmol of 
BMP(14:0)2, 2.0 nmol of PC(14:0)2, 0.1 nmol of PG(14:0)2, 5.0 nmol of PS(14:0)2, 0.5 
nmol of PE(14:0)2, 1.0 nmol of PA(14:0)2, 2.0 nmol of SM(14:0)2, 0.02 nmol of 
LPG(14:0), 0.1 nmol of LPE(14:0), 0.5 nmol of LPC(14:0), 0.1 nmol of LPA(14:0) 
(Avanti Polar Lipids) dissolved in 120 µl of chloroform/methanol (1:1, v/v)) and 1.5 ml 
of chloroform/methanol (1:1, v/v) were added to 1 mg mitochondria. Subsequently, the 
mixture was sonicated in a water bath for 5 minutes, followed by centrifugation at 15,000 
×g for 5 minutes. The organic layer was transferred to a glass vial and dried under a 
nitrogen steam at 60°C. Subsequently, the residue was dissolved in 200 µl of 
chloroform/methanol/water (50:45:5, v/v/v) containing 0.01% of NH4OH, and 10 µl of 
the solution was injected into the liquid chromatography-mass spectrometry (LC/MS) 
system. LC/MS analysis was performed as described in (35). In negative mode, mass 
spectra of phospholipid molecular species were obtained by continuous scanning from 
m/z 380 to 1500 with a scan time of 2 seconds. In positive mode, mass spectra of PC, 
LPC and SM were obtained by continuous scanning for product ions with m/z 184 from 
m/z 400 to 1000. Mass spectra for PE, LPE and PE plasmalogens were obtained by 




converted to mzXML format using msConvert (52) for the negative scan data and 
ReAdW for the positive specific scan data. Details on the metabolic data pre-processing 
pipeline will be described elsewhere (manuscript in preparation). Briefly, the dataset was 
processed using a semi-automated xcms-based metabolomics workflow (53) written in 
the R language and statistical environment (http://www.r-project.org/). The workflow 
comprises pre-processing (peak-finding and quantification), identification of metabolites, 
isotope correction, normalization/scaling based on internal added standards and statistical 
analysis of the results. 
Membrane association assays	  
Sonication experiments utilized 0.2 mg mitochondria and were performed in the 
absence of KCl as described (40). The supernatant and membrane fractions were 
separated by ultracentrifugation at 175,000 ×g using a TLA120.1 rotor for 30 minutes at 
4°C. Carbonate extraction was performed as described (30) except that 0.5 ml of 0.1 M 
Na2CO3 at the indicated pH was added to 0.1 mg mitochondria, and following 30 minutes 
on ice, the pellet and supernatant fractions were separated by centrifugation at 175,000 
×g for 15 minutes at 4°C using a TLA120.1 rotor. 
Blue native (BN) gel electrophoresis	  
Mitochondria were solubilized for 30 minutes on ice in 20 mM HEPES-KOH, 
10% glycerol, 50 mM NaCl, 1 mM EDTA, 2.5 mM MgCl2, pH 7.4 supplemented with 
1% (w/v) (mouse tissues) or 1.25 % (w/v) (human cells) digitonin (Biosynth International, 
Inc) and protease inhibitors. Extracts were clarified by centrifugation for 30 minutes at 




Digitonin fractionation assay	  
Digitonin-based submitochondrial localization was adapted from (40). In brief, 
0.1 mg mitochondria were resuspended in 50 µl SEHK buffer (250 mM sucrose, 5 mM 
EDTA, pH 7.0, 10 mM HEPES-KOH, pH 7.4, 200 mM KCl) supplemented with 0-0.5% 
digitonin and 1 mM PMSF. Following a brief vortex on level 1, samples were incubated 
for 2 minutes on ice and solubilization stopped by adding 450 µl cold SEHK buffer. 
Solubilized proteins were separated from the membrane pellets by centrifugation at 
100,000 ×g for 10 minutes at 4°C. After the supernatant was TCA-precipitated, the 
membrane and supernatant-derived pellets were resuspended in equal volumes of 
reducing sample buffer.  
Protease-based assays	  
Freshly isolated mammalian mitochondria (0.2 mg) from cells or tissues were 
resuspended in iso-osmotic IBc or KME buffers, respectively. To rupture the OMM, 
mitochondria (0.2 mg) were resuspended in 5 mM Tris-Cl, pH 7.5 for 30 minutes on ice; 
0.5% (v/v) deoxycholate was added to further solubilize the IMM. Each of these 
conditions was performed in the absence and presence of 125 µg/ml pronase E. Pronase 
was inhibited with 5 mM PMSF and samples precipitated with 20% (v/v) TCA and 
0.07% (v/v) deoxycholate, incubated at 60°C for 5 minutes followed by an hour on ice. 
Samples were centrifuged at 21,000 ×g for 10 minutes at 4°C, washed with 1 ml of cold 
acetone, resuspended in a 1:1 mix of 2X reducing sample buffer:0.1M NaOH and boiled 
for 5 minutes. To determine sensitivity to assorted proteases following heat denaturation, 
mitochondria (0.2 mg) were resuspended in 5 mM Tris-Cl, pH 7.5 containing 0.1% (v/v) 




0.1% SDS containing 250 µg/ml pronase E, 200 µg/ml proteinase K, or 40 µg/ml trypsin 
added. Following a 30 minute incubation on ice, pronase E and proteinase K were 
inhibited with 5 mM PMSF and trypsin with 100 µg/ml soybean trypsin inhibitor. Every 
sample was precipitated with 20% (v/v) TCA and 0.07% (v/v) deoxycholate, incubated at 
60°C for 5 minutes followed by an hour on ice. Samples were centrifuged at 21,000 ×g 
for 10 minutes at 4°C, washed with 1 ml of cold acetone, resuspended in a 1:1 mix of 2X 
reducing sample buffer:0.1M NaOH and boiled for 5 minutes.  
Protein aggregation assay	  
Protein aggregation was determined in mitochondria (0.2 mg) isolated from 293 
Flp-In cells exactly as previously described (31). 
Phospholipid labeling and analyses	  
Cells were seeded onto 60 mm dishes or 6 well plates and allowed to grow to 50-
70% confluency at 37°C, 5% CO2. Following aspiration, regular media spiked with 2.5 
µCi/ml 32Pi was added and the cells incubated at 37°C, 5% CO2 for 24 hrs. Cells were 
washed twice with ice cold 1X PBS, detached in 0.8 ml IBc buffer using a cell scraper, 
transferred to a microfuge tube, collected at 600 ×g 5 min at 4oC, and resuspended in 0.1 
ml IBc buffer. Phospholipids were extracted from equal amounts of labeled cells, 
determined by liquid scintillation, as described (30) except that 0.9% (w/v) NaCl was 
used to initiate phase separation instead of ddH2O. Samples were resuspended in 
chloroform, loaded onto ADAMANT TLC plates (Machery-Nagel), resolved once in 
chloroform:ethanol:H2O:trimethylamine (30:35:7:35, v/v/v/v), and phospholipids 





Cells were seeded onto 100 mm dishes and allowed to grow to ~70% confluence 
before fixing with 3.0% formaldehyde and 1.5% glutaraldehyde in 0.1 M sodium 
cacodylate, 5 mM CaCl2, 2.5% (w/v) sucrose, pH 7.4, for 1 hour at RT. Cells were 
washed three times for 15 minutes each with 0.1 M sodium cacodylate, 2.5% (w/v) 
sucrose, pH 7.4, and another three times for 5 minutes each with 50 mM Tris-HCl, 7.5% 
(w/v) sucrose, pH 7.4, prior to labeling with 0.5 mg/mL DAB and 0.015% H2O2 in 50 
mM Tris-HCl, 7.5% (w/v) sucrose, pH 7.4 for 20 to 60 minutes. The labeling reaction 
was stopped by rinsing cells twice with 50 mM Tris-HCl, 7.5% (w/v) sucrose, pH 7.4, 
and once with 0.1 M sodium cacodylate, pH 7.4, 5 mM CaCl2, 2.5% (w/v) sucrose, 
before scraping cells into needle tubes. Cells were pelleted progressively by spinning 
from 3,000 rpm to 12,000 rpm over the course of an hour and the pellet was post-fixed in 
1% OsO4, 1% potassium ferrocyanide in 0.1 M sodium cacodylate, 5 mM CaCl2, pH 7.4 
for 45 minutes at RT. The pellets were washed thoroughly with 0.1 M sodium cacodylate, 
pH 7.4, 5 mM CaCl2, 2.5% (w/v) sucrose several times until solution becomes clear, 
dehydrated through a graded series of ice-cold ethanol, and subsequently embedded in 
Epon resin. Sections were cut on a Reichert Ultracut T ultramicrotome and observed on 
an FEI Tecnai 12 transmission electron microscope at 100 kV. Images were captured 
with a Soft Imaging System Megaview III digital camera and figures were assembled in 
Adobe Photoshop with only linear adjustments in contrast and brightness. 
Cycloheximide chase	  
Cell culture medium lacking antibiotics but containing 100 µg/ml cycloheximide 




times, cells were solubilized with 100 µl 1% (w/v) SDS and diluted to 0.5% SDS, 1% β-
mercaptoethanol with 2% (v/v) β-mercaptoethanol. After denaturing the lysates at 100°C 
for 10 minutes, protein was quantified using the Bradford method (Bio-Rad). 
Transacylation assay	  
The transacylase assays were performed as previously described (16, 32) using 1 
nmol of 1-[14C]palmitoyl-2-lyso-PC (0.05 mCi; PerkinElmerLife Sciences) per reaction 
in 0.2 ml reaction buffer (10 mM β-mercaptoethanol, 0.5 mM EDTA, 50 mM Tris, pH 
7.4). To initiate the reactions, ~125 µg mitochondria (the exact amount was determined 
by the BCA assay) were added, the reactions vortexed on high for 1 second, and 
incubated with shaking at 220 rpm for 5 minutes at 37°C. Lipid extraction, thin layer 
chromatography separation, image acquisition and analyses were executed as described 
(32).  
Data analysis	  
Band densitometry analyses were performed using Quantity One (Bio-Rad) or 
Image J (54). With the exception of the data in Fig 2D and 7D, statistical analyses were 
performed using SigmaPlot 11 software (Systat Software) and all comparisons performed 
by t test or one-way analysis of variance with Holm-Sidak pairwise comparisons. For Fig 
2D and 7D, comparisons were performed using one-way analysis of variance with 
Geisser-Greenhouse correction Tukey’s multiple comparison test available in the Prism 6 
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Table 2: Predicting membrane anchors in TAZ. In silico prediction of membrane 
anchors using different program algorithms. Some programs have algorithms that predict 
the existence of membrane domains but do not define the residues involved. Most of the 
listed algorithms perform searches for transmembrane stretches; however, because our 
experimental evidence is not consistent with TAZ containing a transmembrane region, we 
will refer to these stretches as potential membrane anchors. Membrane anchors that were 
weakly predicted are in paranthesis. 
Human Mouse Zebrafish Fly Yeast References 
Philius a 14-35; (168-183) Globular Globular 134-156 Globular (55) 









TMHMM v2.0 15-35 15-35 No 136-158 No (57) 
HMMTOP 9-28 15-34 No 135-158 26-44 (58) 
MINNOU 15-41 16-40 15-40 135-158 22-47 (59) 
Phobius b 15-34 15-34 Non-cytoplasmic 135-158 26-47 (60) 







TOPCONS 15-35 15-35 16-36 92-112 7-27 (62) 
OCTOPUS 15-35 15-35 15-35 92-112 7-27 (63) 
SCAMPIseq 15-35 15-35 No No No (64) 
SCAMPImsa 15-35 15-35 15-35 92-112 7-27 (64) 
PRODIV 16-36 16-36 16-36 92-112 10-30 (65) 
PRO 16-36 16-36 16-36 No 10-30 (65) 








waveTM 7-35 16-40 7-35 135-158 29-44 (67) 
TopPred II d 11-31 15-35 (19-39, 169-189) 
139-159; 
(226-246) 27-47 (68) 









98, 112-135) (69) 
a transmembrane regions with a confidence score greater than 0.5 is listed followed by regions with scores below 0.5 in 
parentheses 
b non-cytoplasmic (or cytoplasmic) means that the prediction contains no membrane helices but provides the most probable 
location and orientation of transmembrane helices in the sequence 
c all proteins were predicted to be non-transmembrane proteins using reference library 32 with long output; however, using the 
hydropathy scores generated from the query sequence, segments containing hydrophobicity scores greater than 2 are chosen 
and presented; segments containing amino acids that score greater than 3 are listed first followed by those segments than 
have scores of only 2+ in parentheses 
d transmembranes predicted with certainty are listed followed by putative membrane-spanning segment in parentheses 
e significant transmembrane regions are listed followed by weakly predicted stretches in parentheses 
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Table 3: Mitochondrial targeting sequences cannot be conclusively defined in any of 
the TAZ orthologs. In silico prediction of mitochondrial targeting peptides present 
within various TAZ orthologs using different program algorithms. Note that in some 
programs, the algorithm predicts the presence or absence, or probability, of a targeting 































Not pred (71) 
PSORT II 
(Gavel) c None found C-24 C-32 C-51 None found (72) 
PSORT II 
(kNN) d 8.7% 17.4% 17.4% 17.4% 30.4% (73) 









Predotar f 0.03 0.34 0.00 0.34 0.00 (75) 
iPSORT g None found None found None found None found None found (76) 











a predicts the subcellular localization of proteins based on the predicted presence of chloroplasts transit peptide (cTP), 
mitochondrial targeting peptide (mTP) or secretory pathway signal peptide (SP) 
b the probability that the protein will be exported to the mitochondria is indicated, along with the potential cleavage site (C-#), if 
available 
c searches for consensus patterns around mitochondrial targeting peptide cleavage sites (C-#) 
d k-nearest neighbor algorithm for assessing the probability that the query is localized to the mitochondria  
e predicts cleavage sites of mitochondrial targeting peptides (prediction score) 
f provides a probability estimate as to whether the sequence contains a mitochondrial (shown), plastid or ER targeting 
sequence 
g searches for N-terminal sorting signals and predicts whether or not it contains a signal peptide, a mitochondrial targeting 
peptide, or a chloroplast transit peptide 
h predicts putative mitochondrial presequences (probability score), cleavage site(s) (C-#), and the mitochondrial protease that is 
likely involved 
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FIGURE 3.1 One isoform of TAZ is expressed and localized to mitochondria in mammalian 
cells and tissues. [See next page for figure legends.] 
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FIGURE 3.1 One isoform of TAZ is expressed and localized to mitochondria in mammalian 
cells and tissues. (A) Whole cell extracts (50 μg) from healthy control (C109) and BTHS patient 
fibroblasts (TAZ001 and TAZ003) were immunoblotted with three different mAbs generated 
against recombinant human TAZ. (B) Subcellular fractions (50 μg) derived from C109 cells 
immunoblotted as indicated. (C) Mitochondrial extracts (50 μg) from the indicated source immu-
noblotted with the TAZ mAbs. (D) The epitope recognized by each TAZ mAb was determined by 
peptide array. The exon that harbors each epitope is indicated. (E) TAZ was immunoprecipitated 
with 3D7F11 from 1.5 mg of the indicated cell extracts. 50 μg starting material and non-binding 
flow through and 100% of bound material (Preclear and IP) were immunoblotted using 2C2C9. 
(F) Whole cell extracts from WT or taz1Δ yeast transformed as indicated and mitochondrial 
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FIGURE 3.2 Generation of a BTHS cell culture model 
using TALEN-mediated genome editing. (A) TALEN-
mediated disruption of TAZ in 293 Flp-In cells introduces 
nucleotide deletions that result in an in-frame deletion in 
tazTALEN.2 and a missense and in-frame deletion in tazTALEN.19. 
(B) Whole cell extracts from the indicated cells grown in 
dextrose or galactose-based media were resolved by SDS-
PAGE and immunoblotted. (C) Wt 293 Flp-In and tazTALEN 
-
resolved by SDS-PAGE and immunoblotted for the indicated 
proteins. Cyclin D1, a target of the ubiquitin-proteasome 
pathway (78), is used as a positive control. (D) Relative 
mRNA levels of TAZ in wt (293 Flp-In) and each tazTALEN cell. 
expression level, which was set to 0. [See next page for F-H 
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In organello Import In organello Import
FIGURE 3.2 Generation of a BTHS cell culture model using TALEN-mediated genome 
editing. (E) Mitochondria (50 μg) from the designated source were immunoblotted as listed. (F) 
Protein expression in (E) was quantified by densitometry and normalized to wt levels (mean ± 
SEM; n = 3). Significant differences are indicated. (G) In organello import of radiolabeled 
[35S]-Su9-DHFR into wt 293 Flp-In and tazTALEN mitochondria in the presence or absence of a 
membrane potential. Following import, mitochondria were osmotically ruptured, treated with 
trypsin, resolved by SDS-PAGE, and bands detected by phosphoimaging. P, precursor (5% of 
precursor protein + 100 μg mitochondria); p, precursor; m, mature. (H) The percentage of 
precursor imported at each time point was calculated (mean ± SEM; n = 3). See also Fig S3.1 
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* p < 0.001
** p < 0.01










acyl chain length:double bonds acyl chain length:double bonds acyl chain length:double bonds
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FIGURE 3.3 tazTALEN cells have altered mitochondrial CL and 
MLCL profiles as determined by high-perfomance liquid 
chromatography-mass spectrometry. [See next page for 
figure legends.]
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FIGURE 3.3 tazTALEN cells have altered mitochondrial CL and MLCL profiles as determined 
by high-perfomance liquid chromatography-mass spectrometry. The relative amounts of CL 
(A), MLCL (B), and PG (D) was determined by high-performance liquid chromatography-mass 
spectrometry. (C) The ratio of MLCL:CL as determined from (A and B). The abundance of CL (E) 
and MLCL (L) of a given acyl chain length (E,L) or containing the indicated number of double 
bonds (F, M), was determined as a percentage of the total amount of CL or MLCL. The distribu-
tion of double bonds per acyl chain length for CL (G-K) and MLCL (N-O) expressed as a percent 
of the sum of all species of the indicated length. All data are the mean ± SEM (n  = 3). Significant 
differences are indicated. See also Figures 3.S2-3.S4.
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 293 C109





























































































































FIGURE 3.4 Membrane association and assembly of TAZ. (A) Mitochondria were sonicated 
and equal volumes of the pellet (P) and TCA-precipitated supernatant (S) fractions were 
immunoblotted as indicated. SM, starting material. (B) Mitochondria were incubated in 0.1 M 
Na2CO3 of the listed pH. Integral proteins (P) were separated from released proteins (S) by 
ultracentrifugation and equal volumes of each were immunoblotted as indicated. (C) Quantified 
band intensities of the P and S fractions were plotted as the percentage of total protein released 
into the supernatant for each pH (mean ± SEM; n = 3 (C109) or 4 (293)). (D) Mitochondria from 
control and BTHS fibroblasts (450 μg), 293 Flp-In cells (200 μg), and mouse heart and liver 
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FIGURE 3.5 Mammalian TAZ is protease resistant and associates with IMS-facing leaflets. 
[See next page for F and figure legends.]
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Heat Denaturation


























Protein Aggregation In organello Import: wt TAZ
Temp (oC) 37 4
OMM Ruptured - - - - + + +
Trypsin + + + + + -+
+ ∆Ψ + -+ + + ++
Time (min) P 5 10 20 20 20 2020
Lane: 1 2 3 4 5 6 7 8
FIGURE 3.5 Mammalian TAZ is protease resistant and associates with IMS-facing leaflets. 
(A) Mitochondria were titrated with increasing amounts of digitonin to differentially solubilize 
mitochondrial compartments. After centrifugation, equal volumes of the pellet (P) and superna-
tant (S) fractions were resolved by SDS-PAGE and immunoblotted. (B) Quantified band intensi-
ties for two markers per compartment were combined and plotted as the percent detected in 
supernatant (mean ± SEM; n = 7). (C) Mitochondria, osmotically ruptured mitoplasts, or 
detergent-solubilized mitochondria from the indicated source were incubated without or with 
protease, resolved by SDS-PAGE, and immunoblotted. (D) Mitochondria were solubilized with 
0.1% (w/v) SDS and where indicated, heated at 95°C for 5 minutes prior to adding pronase E, 
proteinase K, or trypsin. Equal volumes of each sample were resolved by SDS-PAGE and 
immunoblotted. (E) Mitochondria were solubilized with digitonin and fractionated into a superna-
tant (S1) and pellet (P1) by centrifugation. Material not extracted by digitonin (P1) was further 
solubilized with TX–100 and separated into a supernatant (S2) and pellet (P2) by centrifugation. 
Fractions were resolved by SDS–PAGE and immunoblotted as indicated. (F) In organello import 
of radiolabeled [35S]-TAZ into 293 Flp-In mitochondria at the indicated temperature in the pres-
ence or absence of a membrane potential. Following import, mitochondria were treated with 
trypsin, resolved by SDS-PAGE, and bands detected by phosphoimaging. Where indicated, 
mitochondria were osmotically ruptured in the presence or absence of trypsin. P, precursor (5% 
of precursor protein + 100 μg mitochondria). 
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FIGURE 3.6 Both termini of TAZ are in the IMS. (A) 























































In organello Import: R57L
Temp (oC) 37 4
OMM Ruptured - - - - + + +
Trypsin + + + + + -+
+ ∆Ψ + -+ + + ++
Time (min) P 5 10 20 20 20 2020
|Q16635-3|HUMAN       51  YELIEKRGPATPLITVSNHQSCMDD  75
|Q91WF0|MOUSE 51  YELIENRGPATPLITVSNHQSCMDD  75
|Q6PUS0|ZEBRAFISH     51  LNLVDERPQDTPLITVCNHQSCMDD  75
|Q9V6G5|FLY 170 IQLITKRPKGIPLVTVSNHYSCFDD 233
|Q06510|YEAST 59  TALERSKRENRGLMTVMNHMSMVDD  83
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FIGURE 3.7 The R57L allele is highly unstable. 
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In vivo Degradation: Cell Extracts
F
FIGURE 3.7 The R57L allele is highly unstable. (A) Sequence alignment of TAZ from the 
indicated species encompassing human Arg57 and His69 (highlighted) and the HXXXXD motif 
(underlined). (B) Whole cell extracts (20 μg) from 5-6 clones transfected with the indicated TAZ 
alleles were immunoblotted. (C) Relative mRNA levels of TAZ analyzed by the comparative CT 
(ΔΔCT) method, represented as mean fold change (2ΔΔCT) ± SD n ≥ 4 relative to 293 Flp-In TAZ 
expression. (D) In organello import of radiolabeled precursor R57L TAZ into freshly isolated 293 
Flp-In mitochondria as described in Fig. 3.5F. (E) tazTALEN cells overexpressing WT, R57L and 
H69Q alleles were incubated for 4 hours with 20 μM of the proteasome inhibitor, MG132. 40 μg 
of whole cell lysates were resolved by SDS-PAGE and immunoblotted for the indicated proteins. 
(F) Whole cell extracts (20 μg) were collected after incubation with cycloheximide for the 
indicated times, and the amount of TAZ remaining assessed by immunoblot. The half-lives of the 




















































































































































































































In organello Import: H69Q
Temp (oC) 37 4
OMM Ruptured - - - - + + +
Trypsin + + + + + -+
+ ∆Ψ + -+ + + ++
Time (min) P 5 10 20 20 20 2020
FIGURE 3.8 The H69Q mutant is catalytically dead. (A) 
Mitochondria (20 μg) from 293 Flp-In, tazTALEN, and tazTALEN 
cells overexpressing WT, R57L and H69Q alleles were 
immunoblotted as indicated. (B) In organello import of 
radiolabeled precursor H69Q TAZ into freshly isolated 293 
Flp-In mitochondria as described in Fig. 3.5F. (C) Assem-
bly of H69Q as determined by 2D BN/SDS-PAGE. (D) 
Lyso-PC to PC transacylase activities were determined in 
mitochondria isolated from 293 Flp-In, tazTALEN, and 
tazTALEN cells overexpressing the indicated TAZ alleles 
(mean ± SEM, n = 3). Significant differences are indicated. 
n.s., not significant. The relative amounts of CL (E) and
MLCL (F), and the subsequent MLCL:CL ratio (G), in 
tazTALEN cells overexpressing WT, R57L, and H69Q were 
determined as previously described. See also Figure 
3.S5.
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Q91WF0   10   ---------PAVPRLT------WTLA--SSVVM-GLVGTYSCFW--  35
Q16635-3   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
B2KIJ8   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
Q4KLG6   10   ---------PAVPRLT------WTLA--SSVVM-GLVGTYSCFW--  35
Q6IV82   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
Q6IV84   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
Q6IV78   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
Q6IV76   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
A9CB62   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
L5KEI0   10   ---------PAVPPVT------WTLA--SSVVM-GLVGTYSCFW--  35
L8Y8H8    0   ----------------------------------------------  0
Q6IV77   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
Q6IV83   10   ---------PAVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
C3PSZ4   10   ---------PSVPPLT------WTLA--SSVVM-GLVGTYSCFW--  35
G3IBK7   10   ---------PAVPRLT------WTIA--SSVVM-GLVGTYSCFW--  35
G5BFK7    0   ----------------------------------------------  0
G9KSH0   10   ---------PAVPRFT------WTLA--SSVVM-GLVGTYSCFW--  35
A0A091DW33   1   --------------------------------M-GLVGTYSCFW--  11
A0A091UIX9   0   ----------------------------------------------  0
R4GIL6    0   ----------------------------------------------  0
G1KMR1   10   ---------PQAPYLP------WTLA--SRLIM-GLVGTYSCFW--  35
T1DID2   10   ---------PQAPSLA------WNLA--SRVIM-GLVGTYSCFW--  35
T2B2H9   10   ---------PTCPRLP------YTLT--SNLVM-GLVGTYSWLW--  35
C0HAQ4   10   ---------PQCPQLA------WKVT--STLVM-GVVGSYSYFW--  35
Q28HD1   10   ---------PARPCLS------RHVT--STVVM-GLVGTYSWIW--  35
Q7ZXM1   10   ---------PGRARLA------RHVS--STLVT-GLVGTYSWAW--  35
C1BLX4   10   ---------PQCPLLP------WRIS--SSLVM-GMVGTYSYFW--  35
Q6PUS0   10   ---------PQCPRLG------WRIS--SRVVM-GMVGSYSYLW--  35
V9LBI1   10   ---------CGSRTLS------GRLT--STVVT-GLVGTYSRVW--  35
E3TG56   10   ---------PQCPRLG------WRIS--SSFVM-GMVGSYSYLW--  35
S4R9W7    0   ----------------------------------------------  0
A0A087U3B0  21   ---------LQNFSL-------WQLG--SAVVI-PAVGILSKIM--  45
T1G6N1   15   ---------FSFG---------WKLA--SRLTM-GAVGLTSKFF--  37
C3XWE9   13   ---------PGP--L-------WNVA--STLTV-AAVGGFSKLM--  35
C1BN32   20   ---------DEP--A-------WSLR--SRFIV-SAVGIASKLW--  42
W4YTE8   14   ---------PGV--I-------WKIA--SQATI-CTTYLLSKFW--  36
A0A068Y6L5   1   ---------KRS-LG-------QRVF--HKIPI-AMVASLVKLA--  44
A0A068XNR3   0   ----------------------------------------------  0
G7YAZ1    0   ----------------------------------------------  0
G4VCR7   13   ---------TSY-LP-------RKIL--QSLTY-SFMGLASKIA--  36
E9I7S1   12   ---------SLNGFL-------WRLS--SRFII-SAVGFIGKFI--  36
E1ZW45   15   ---------PSR--L-------WNIA--SSITF-AAVGIVSKII--  37
E2C008   15   ---------PSR--L-------WNIA--SSITF-AAVGIFSKII--  37
V9IAC3    0   ----------------------------------------------  0
A0A067QT85  15   ---------PSR--L-------WNLA--SSITF-AAVGIFSKII--  37
W8AUM7   15   ---------PSG--L-------WYIA--SQIAI-TAVGLLAKFV--  37
A0A034W091  15   ---------PSG--L-------WYIA--SQIAI-TAVGLFAKFV--  37
Q9V6G5   132  ---------PSK--F-------WYVV--SQFVV-SAVGIFSKVV--  154
I1FU24   26   ----------TFGLK-------WRLR--QLPFF-MSGHALCKLY--  49
A0A077WSP27  0   SSLPKFIEKRYDPKWQGENGWLWRAG--STLVV-GGVGMVSKIV--  110
T2MD68   26   SQEHRIIQ--KRNSLGF------KLQ--STLWI-SAVGCVGKILVD  60
E9BY93   99   ---------PSL--L-------WRAA--SQLFV-GAVGWWSILM--  121
U9UP66   44   DG-GKMILKPSTNRF-------WNFA--SWCAI-TSCVFICKFF--  76
A0A075ARW3   1   ---------------------------------------------M  1
Q5JK25   94   FYRKKVGK--EVDGIED------SVI--FRSLQ-ALAVPL---IGN  125
D7U9V3   64   FYRKRVGK--DIGAEED------SVF--VRMLQ-ALAVPV---IGN  95
M8B5M9    0   ----------------------------------------------  0
I1J340   25   ---------AGY--L-------RGVP--RAAVI-ASVGSVAKAY--  47
G9C3A1   22   --------AGRAGHLGG-------VP--RAVVI-AAVGAVAKAY--  47
M0SDS9    7   ---------AEH--L-------GGIP--RALVV-LAVGAFAKTV--  29
C5YA07   24   ---------AGH--L-------GGLP--RAAVF-AAVGAFAKAY--  46
W1PUD7   11   ---------ANH--L-------GGLP--RRLLF-GTVGAFAKLF--  33
A0A068U0Q8  12   ---------GNH--L-------RGIP--RKAIF-MAVGAFAKAV--  34
D2IJL9    0   ----------------------------------------------  0
A0A022QDI1  10   ---------RDH--L-------GGVP--RKLIF-MAAGAFSKTV--  32
K4B7G8   12   ---------ANH--L-------GGIP--RKVVI-TAIGTFAKAV--  34
D8QZ96    7   ---------PSH--L-------SGAP--RRIAI-FTIGSLARIA--  29
M1UV50   148  CAVASRQAAPVPDSYQMLDVGSGRSF--LNALTIAGVGIPSKLL--  189
R7QQN6   111  ---KNNTYVPTPPLS-----GNGGLG--TSMIS-GIVGSFSKVL--  143
M2XZC9   121  ---ASFKEPPEP--------GNGASM--RNLVTIGIVASLSSGI--  151
A0A087SL77  22   ----------------------GSLG--RSLTL-GVVAWGCKML--  40
D8TRK1    0   ----------------------------------------------  0
A0A096P842  26   ----------------------GSLG--RQAVL-GVVALTGKAI--  44
K8EDG9   37   ----------------------GTIG--RTFVL-SAVALFSKAL--  55
C1MT17    1   -------------------------------VL-GVVSRFSRFV--  12
A0A058Z2V2  42   STSQPLLR-PSLHSALLRRDLTWRAA--SRATL-GLVSVLTAAC--  81








sp|Q16635-3|TAZ HUMAN Isoform 3 of Tafazzin OS Homo sapiens
tr|Q4KLG6|Q4KLG6 RAT Protein Taz OS Rattus norvegicus
sp|Q6IV82|TAZ PONPY Tafazzin OS Pongo pygmaeus
tr|A9CB62|A9CB62 PAPAN Tafazzin (Predicted) OS Papio anubis
tr|L8Y8H8|L8Y8H8 TUPCH Tafazzin OS Tupaia chinensis
tr|B2KIJ8|B2KIJ8 RHIFE Tafazzin (Predicted) OS Rhinolophus ferrumequinum
sp|Q6IV76|TAZ ERYPA Tafazzin OS Erythrocebus patas
sp|Q6IV83|TAZ GORGO Tafazzin OS Gorilla gorilla gorilla
sp|Q6IV78|TAZ SAISC Tafazzin OS Saimiri sciureus
tr|L5KEI0|L5KEI0 PTEAL Tafazzin OS Pteropus alecto
sp|Q6IV84|TAZ PANTR Tafazzin OS Pan troglodytes
sp|Q6IV77|TAZ MACMU Tafazzin OS Macaca mulatta
tr|Q91WF0|Q91WF0 MOUSE Tafazzin OS Mus musculus
tr|C3PSZ4|C3PSZ4 DASNO Tafazzin (Predicted) OS Dasypus novemcinctus
tr|G3IBK7|G3IBK7 CRIGR Tafazzin OS Cricetulus griseus
tr|A0A091DW33|A0A091DW33 FUKDA Tafazzin OS Fukomys damarensis
tr|G9KSH0|G9KSH0 MUSPF Tafazzin (Fragment) OS Mustela putorius furo
tr|G5BFK7|G5BFK7 HETGA Tafazzin OS Heterocephalus glaber
tr|T1DID2|T1DID2 CROHD Tafazzin-like protein OS Crotalus horridus
tr|G1KMR1|G1KMR1 ANOCA Uncharacterized protein OS Anolis carolinensis
tr|R4GIL6|R4GIL6 CHICK Uncharacterized protein OS Gallus gallus
tr|A0A091UIX9|A0A091UIX9 NIPNI Tafazzin (Fragment) OS Nipponia nippon
tr|T2MD68|T2MD68 HYDVU Tafazzin OS Hydra vulgaris
tr|C0HAQ4|C0HAQ4 SALSA Tafazzin OS Salmo salar
tr|T2B2H9|T2B2H9 ANDDA Tafazzin OS Andrias davidianus
tr|Q28HD1|Q28HD1 XENTR Tafazzin OS Xenopus tropicalis
tr|Q7ZXM1|Q7ZXM1 XENLA MGC54019 protein OS Xenopus laevis
tr|C1BLX4|C1BLX4 OSMMO Tafazzin OS Osmerus mordax
tr|Q6PUS0|Q6PUS0 DANRE Tafazzin OS Danio rerio
tr|V9LBI1|V9LBI1 CALMI Tafazzin-like protein OS Callorhynchus milii 
tr|S4R9W7|S4R9W7 PETMA Uncharacterized protein (Fragment) OS Petromyzon marinus
tr|E3TG56|E3TG56 ICTPU Tafazzin OS Ictalurus punctatus
tr|A0A077WSP2|A0A077WSP2 9FUNG Uncharacterized protein OS Absidia idahoensis
tr|I1FU24|I1FU24 AMPQE Uncharacterized protein OS Amphimedon queenslandica
tr|T1G6N1|T1G6N1 HELRO Uncharacterized protein OS Helobdella robusta
tr|A0A087U3B0|A0A087U3B0 9ARAC Tafazzin (Fragment) OS Stegodyphus mimosarum
tr|C1BN32|C1BN32 CALRO Tafazzin OS Caligus rogercresseyi
tr|C3XWE9|C3XWE9 BRAFL Putative uncharacterized protein OS Branchiostoma floridae
tr|W4YTE8|W4YTE8 STRPU Uncharacterized protein OS Strongylocentrotus purpuratus
tr|E9I7S1|E9I7S1 DAPPU Putative uncharacterized protein (Fragment) OS Daphnia pulex  
tr|E1ZW45|E1ZW45 CAMFO Tafazzin-like protein OS Camponotus floridanus 
tr|E2C008|E2C008 HARSA Tafazzin-like protein OS Harpegnathos saltator
tr|V9IAC3|V9IAC3 APICE Tafazzin OS Apis cerana
tr|A0A067QT85|A0A067QT85 ZOONE Tafazzin-like protein OS Zootermopsis nevadensis 
sp|Q9V6G5|TAZ DROME Tafazzin homolog OS Drosophila melanogaster
tr|A0A034W091|A0A034W091 BACDO Tafazzin-like protein OS Bactrocera dorsalis 
tr|W8AUM7|W8AUM7 CERCA Tafazzin OS Ceratitis capitata
tr|A0A058Z2V2|A0A058Z2V2 9EUKA Uncharacterized protein OS Fonticula alba
tr|G4VCR7|G4VCR7 SCHMA Putative taz protein (Tafazzin) OS Schistosoma mansoni 
tr|G7YAZ1|G7YAZ1 CLOSI Monolysocardiolipin acyltransferase (Fragment) OS Clonorchis sinensis 
tr|A0A068Y6L5|A0A068Y6L5 ECHMU Tafazzin OS Echinococcus multilocularis 
tr|A0A068XNR3|A0A068XNR3 HYMMI Tafazzin OS Hymenolepis microstoma
tr|Q5JK25|Q5JK25 ORYSJ Tafazzin isoform-like OS Oryza sativa subsp. japonica
tr|D7U9V3|D7U9V3 VITVI Putative uncharacterized protein OS Vitis vinifera 
tr|A0A075ARW3|A0A075ARW3 9FUNG Tafazzin domain-containing protein OS Rozella allomycis
tr|F4P165|F4P165 BATDJ Putative uncharacterized protein OS Batrachochytrium dendrobatidis 
tr|U9UP66|U9UP66 RHIID Uncharacterized protein OS Rhizophagus irregularis 
tr|A0A068U0Q8|A0A068U0Q8 COFCA genomic scaffold scaffold 7 OS Coffea canephora 
tr|A0A022QDI1|A0A022QDI1 ERYGU Uncharacterized protein OS Erythranthe guttata 
tr|D2IJL9|D2IJL9 9SOLA Putative uncharacterized protein (Fragment) OS Phrodus microphyllus 
tr|K4B7G8|K4B7G8 SOLLC Uncharacterized protein OS Solanum lycopersicum
tr|W1PUD7|W1PUD7 AMBTC Uncharacterized protein OS Amborella trichopoda 
tr|M0SDS9|M0SDS9 MUSAM Uncharacterized protein OS Musa acuminata 
tr|M8B5M9|M8B5M9 AEGTA Tafazzin-like protein OS Aegilops tauschii 
tr|G9C3A1|G9C3A1 9ORYZ Putative tafazzin OS Oryza officinalis
tr|I1J340|I1J340 BRADI Uncharacterized protein OS Brachypodium distachyon 
tr|C5YA07|C5YA07 SORBI Putative uncharacterized protein Sb06g032070 OS Sorghum bicolor 
tr|D8QZ96|D8QZ96 SELML Putative uncharacterized protein OS Selaginella moellendorffii 
tr|E9BY93|E9BY93 CAPO3 Acyltransferase OS Capsaspora owczarzaki
tr|M2XZC9|M2XZC9 GALSU Acyltransferase OS Galdieria sulphuraria 
tr|M1UV50|M1UV50 CYAME Similar to acyltransferase Tafazzin OS Cyanidioschyzon merolae 
tr|R7QQN6|R7QQN6 CHOCR Stackhouse genomic scaffold scaffold 74 OS Chondrus crispus 
tr|K8EDG9|K8EDG9 9CHLO Uncharacterized protein OS Bathycoccus prasinos 
tr|C1MT17|C1MT17 MICPC Predicted protein (Fragment) OS Micromonas pusilla
tr|A0A096P842|A0A096P842 OSTTA Tafazzin OS Ostreococcus tauri 
tr|D8TRK1|D8TRK1 VOLCA Putative uncharacterized protein OS Volvox carteri 
tr|A0A087SL77|A0A087SL77 AUXPR Tafazzin-like protein OS Auxenochlorella protothecoides 



















































































FIGURE 3.S1 Pro13 is conserved within mammals and some vertebrates but not fungi, bacteria, or plants. [Figure continued on 
next page.]
Q06510   16   AY-------PRRSPLWR-----FLSY--STSLL-TFGVSKLLLF--  44
U6DXC2   10   ---------PAVPPFT------WTLA--SSVVM-GLVGTYSCFW--  35
U1M5P8   16   ---------PRRSSLL------FKIC--SNIVL-TSVFLASKLL--  41
E1ZDY1   21   ----------------------GELG--RSATL-GLVSLFSKLV--  39
D7G278    1   ---------------MTPVAV---LS--RAV-LFGLNNTRL-----  20
K0TQ94   66   EEIFCSSEPSPWSREHVPVLL--EWS--RRI-SIGLTTLAIRLF--  104
D0N7X6   53   TEV-----FPEW-------LH--DLA--RVP-LFGAATLASKFY--  79
M4C1L9   26   AEI-----FPEW-------LH--NVA--RVP-LFGAATLISKVC--  52
K3WZT1   44   TK------FPEW-------AH--NMG--RVP-VFLAATTAAKVY--  69
A0A024GSB4  368  DKE---QVFPGW-------LH--NVG--RVP-TVMAATAVSKMY--  396
A0A024T9Q2  45   NH--TRDRFPAY-------VS--AAA--RSV-LFYPATLVSKVY--  74
T0PXF3   45   QHVATRDRLPAV-------FY--SAA--RSTFLFYPATLVAKVY--  77
E5S5V3    9   ----NLLE--TINNMHS------KLA--RSIVI-CAVGCV---MLT  36
A8NYD4    1   -----------------------MAAFFSSLTV-ASVGLTCKSF--  20
A0A098VQ42   0   ----------------------------------------------  0
Q5KM36    0   ----------------------------------------------  0
M7XLK9    1   -----------------------MGS-----VP-LVVGAFSKLF--  15
A9V7R4   40   ------DLLDQYPRLSK------ALST-CSFTL---FGLATKLL--  67
Q74ZE5   16   EY-------PRQSVLWQ-----WASH--GTCMA-TIAASKAFLK--  44
Q59X35   51   DY-------PRTNPFWN-----LASH--ATCLF-MITGSKIILN--  79
G2X8Z2   13   --------------LA------WRLS--SSVVM-GLTGAISRAF--  33
N4VQ06    0   ----------------------------------------------  0  
C0ND77   13   --------------SF------WKGC--SAATM-YMVVAACRAF--  33
R1GF56    0   ----------------------------------------------  0
K9FFC1   12   --------------LP------WRAL--SNTTM-WGVAGLCRGF--  32
Q5AZA5    0   ----------------------------------------------  0  
B0XTQ7   16   --------------LP------WRAL--SATTI-FGVAALCRSF--  36
Q54DX7   15   QICD-------IP--KP------QFL--SKGVF-TLVGVLCKFW--  40
D3BH06    0   ----------------------------------------------  0
F4PHF2    3   RIVNNPIF---VP--QP------KTL--SKLAF-TTVGLTCKAW--  32
E4WZU5    0   ----------------------------------------------  0
F8B3W0    4   ------------------------LV--YKPVI-RFALGF------  16
A1KCH8   27   AWTPFAAL--LYPLLPE------RLG--RRIGR-RAITTVFR--IY  99
S9QJT5    8   ------------------------VV--GKLLI-FFAQFI------  20
G3JGQ1    0   ----------------------------------------------  0
E9F2P0    0   ----------------------------------------------  0
Q8DNY1   13   ---------------GD------RMF--YTYLR-GLVVLL------  28
U6ZYN6   248  TQIPAYAK--EWMHGDE------TVV--TLILT-VFSVGIAV-GSM  280
I8U793   246  TQFPNFTK--SHLAGDN------TVV--TALLV-AFSVGVGI-GSM  278
H3ZC81   246  TQFPNFTK--SHLAGDN------TVV--TALLV-AFSVGVGI-GSM  278






tr|D7G278|D7G278 ECTSI Lyso-phosphatidylcholine acyltransferase OS Ectocarpus siliculosus 
tr|K0TQ94|K0TQ94 THAOC Uncharacterized protein OS Thalassiosira oceanica 
tr|A0A024T9Q2|A0A024T9Q2 9STRA Uncharacterized protein OS Aphanomyces invadans 
tr|T0PXF3|T0PXF3 9STRA Uncharacterized protein OS Saprolegnia diclina
tr|A0A024GSB4|A0A024GSB4 9STRA Ac Nc2 contig OS Albugo candida 
tr|K3WZT1|K3WZT1 PYTUL Uncharacterized protein OS Pythium ultimum 
tr|D0N7X6|D0N7X6 PHYIT Tafazzin-like protein OS Phytophthora infestans
tr|M4C1L9|M4C1L9 HYAAE Uncharacterized protein OS Hyaloperonospora arabidopsidis 
tr|E4WZU5|E4WZU5 OIKDI scaffold set scaffold scaffold 5 OS Oikopleura dioica 
sp|Q54DX7|TAZ1 DICDI Putative lysophosphatidylcholine acyltransferase OS Dictyostelium discoideum 
tr|F4PHF2|F4PHF2 DICFS Tafazzin family protein OS Dictyostelium fasciculatum
tr|D3BH06|D3BH06 POLPA Tafazzin isoform 8-like protein OS Polysphondylium pallidum 
tr|U1M5P8|U1M5P8 ASCSU Tafazzin OS Ascaris suum 
tr|E5S5V3|E5S5V3 TRISP Tafazzin OS Trichinella spiralis 
tr|M7XLK9|M7XLK9 RHOT1 Tafazzin OS Rhodosporidium toruloides 
tr|A9V7R4|A9V7R4 MONBE Predicted protein OS Monosiga brevicollis 
tr|A8NYD4|A8NYD4 COPC7 Tafazzin-PC OS Coprinopsis cinerea
tr|Q5KM36|Q5KM36 CRYNJ Tafazzin exon 5 and exon 9 deleted OS Cryptococcus neoformans 
sp|Q06510|TAZ1 YEAST Lysophosphatidylcholine acyltransferase OS Saccharomyces cerevisiae 
tr|Q74ZE5|Q74ZE5 ASHGO AGR254Cp OS Ashbya gossypii
tr|Q59X35|Q59X35 CANAL Uncharacterized protein OS Candida albicans 
tr|R1GF56|R1GF56 BOTPV Putative tafazzin protein OS Botryosphaeria parva 
tr|Q5AZA5|Q5AZA5 EMENI Tafazzin (AFU orthologue AFUA 2G13960) OS Emericella nidulans
tr|B0XTQ7|B0XTQ7 ASPFC Tafazzin OS Neosartorya fumigata 
tr|K9FFC1|K9FFC1 PEND2 Tafazzin OS Penicillium digitatum 
tr|C0ND77|C0ND77 AJECG Tafazzin OS Ajellomyces capsulatus 
tr|G2X8Z2|G2X8Z2 VERDV Tafazzin OS Verticillium dahliae 
tr|N4VQ06|N4VQ06 COLOR Tafazzin OS Colletotrichum orbiculare 
tr|A0A098VQ42|A0A098VQ42 9MICR Tafazzin OS Microsporidia 
tr|A1KCH8|A1KCH8 AZOSB Putative phospholipid biosynthesis acyltransferase OS Azoarcus sp. 
tr|S9QJT5|S9QJT5 9RHOB 1-acyl-sn-glycerol-3-phosphate acyltransferase OS Thalassobacter arenae 
tr|E9F2P0|E9F2P0 METAR Tafazzin OS Metarhizium anisopliae 
tr|G3JGQ1|G3JGQ1 CORMM Tafazzin OS Cordyceps militaris
tr|F8B3W0|F8B3W0 FRADG Phospholipid/glycerol acyltransferase OS Frankia symbiont
sp|Q8DNY1|PLSC STRR6 1-acyl-sn-glycerol-3-phosphate acyltransferase OS Streptococcus pneumoniae 
tr|U6DXC2|U6DXC2 NEOVI Tafazzin OS Neovison vison 
tr|U6ZYN6|U6ZYN6 9PSED 1-acyl-sn-glycerol-3-phosphate acyltransferase OS Pseudomonas sp.
tr|I8U793|I8U793 9ALTE Major facilitator superfamily permease OS Alishewanella agri
tr|J2IDY2|J2IDY2 9ALTE Major facilitator superfamily permease OS Alishewanella aestuarii









































FIGURE 3.S1 Pro13 is conserved within mammals and some vertebrates but not fungi, bacteria, or plants. Sequence alignment of TAZ 
from humans and other organisms using COBALT (Papadopoulos and Agarwala, 2007). Only a section of the alignment encompassing human 
Pro13 is shown which is highlighted in yellow. The residues affected by TALEN-mediated disruption of 293 Flp-In cells are noted in blue in the 
sequence corresponding to human TAZ-ex5. Aligned sequences are then ordered according to the phylogenic tree on the left. Organisms high-
lighted in green are those for which a BTHS (animal or cell) model is currently available. The evolutionary history was inferred by using the Maxi-
mum Likelihood (ML) method based on the JTT matrix-based model (Jones et al., 1992). The bootstrap consensus tree inferred from 500 repli-
cates is taken to represent the evolutionary history of the taxa analyzed (Felsenstein, 1985). Branches corresponding to partitions produced in 
less than 50% bootstrap replicates are collapsed. The percentage of replicate trees in which the associated taxa clustered together in the boot-
strap test is shown next to the branches. Initial tree(s) for the heuristic search were obtained by applying the Neighbor-Joining method to a matrix 
of pairwise distances estimated using a JTT model. The analysis involved 118 amino acid sequences. All positions with less than 95% site cover-
age were eliminated. That is, fewer than 5% alignment gaps, missing data, and ambiguous bases were allowed at any position. There were a total 



















































































































































FIGURE 3.S2 Increased bis-monoacylglyerol phosphate (BMP) and decreased phosphati-
dylinositol (PI) in tazTALEN mitochondria. The relative amounts of the indicated lipids in tazTALEN 
compared to wt 293 Flp-In cells. All data are the mean ± SEM (n = 3). Significant differences are 
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FIGURE 3.S3 tazTALEN cells contain modest changes in acyl chain composition of the TAZ 
substrates, PE and PC. [See next page for L-S and figure legends.] 
183
FIGURE 3.S3 tazTALEN cells 
contain modest changes in acyl 
chain composition of the TAZ 
substrates, PE and PC. The acyl 
chain length, the number of 
double bonds, and the acyl chain 
length:double bond ratio for the 
indicated lipid species was 
determined as indicated in Figure 
3.5. All data are the mean ± SEM 
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acyl chain length:double bonds
***
FIGURE 3.S4 Altered BMP acylation in mitochondria from 
tazTALEN cells. The acyl chain length, the number of double bonds, 
and the acyl chain length:double bond ratio for the indicated lipid 
species were determined as indicated in Figure 3.5. All data are 
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FIGURE 3.S5 The unstable R57L allele and the catalytically-null H69Q mutant assemble in 
high molecular weight complexes. (A) tazTALEN.19 cells overexpressing WT, R57L and H69Q 
alleles were incubated for 4 hours with 20 μM of MG132. 40 μg of whole cell lysates were 
resolved by SDS-PAGE and immunoblotted for the indicated proteins. (B) Mitochondrial extracts 
from 293 Flp-In and tazTALEN cells overexpressing WT, R57L, or H69Q (200 μg) were solubilized 
with digitonin, resolved by 2D BN/SDS-PAGE, and immunoblotted for TAZ. (C) The R57L allele 
has a relatively short half-life. Whole cell extracts (20 μg) were collected after incubation with 
cycloheximide for the indicated times, and the amount of TAZ remaining assessed by immunob-
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FUTURE DIRECTIONS 
 The fortuitous development of antibodies against endogenous human and rodent 
tafazzin (TAZ) in our lab has enabled the biochemical and cell biologic characterization 
of human TAZ detailed in the previous chapter. Mammalian TAZ is localized to IMS-
facing leaflets of the outer (OMM) and inner (IMM) mitochondrial membranes, just like 
its yeast counterpart. The protein is membrane associated, likely in an interfacial manner, 
with both termini protruding into the IMS. Based on its extreme protease-resistance, the 
entire protein, including appendages added to the C-terminus, adopts a tightly-folded 
final structure. Having characterized the TAZ monoclonal antibodies and the cell biology 
of TAZ, we sought to establish a BTHS cell model whereby the loss-of-function 
mechanisms can be systematically dissected biochemically, at the protein level. Using 
TALEN-mediated genome editing in HEK293 Flp-In cells, tazTALEN mutants were 
obtained that lacked detectable TAZ protein or activity. In these backgrounds, WT, R57L, 
and H69Q TAZ alleles were introduced by FLP recombination at the FRT site. 
Importantly, expression of WT TAZ in tazTALEN cells restored the MLCL:CL ratio that is 
a hallmark of the disease to wt 293 levels. In contrast, the expression of the pathogenic 
R57L and H69Q alleles could not restore the lipid abnormalities in tazTALEN cells to WT 
TAZ levels. In fact, the mutant alleles exhibited phenotypes that were consistent with that 
of equivalent mutations when modeled in yeast (1); H69Q is catalytically-dead, as 
expected, and R57L is functional but unstable with a short half-life. The corresponding 
K65L in yeast is temperature-sensitive (1). These observations are intriguing and suggest 
that for certain pathogenic mutations, such as R57L, drugs that can maximize the mutant 
allele’s residual activity by stabilizing the polypeptide structure or retarding its 
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accelerated turnover may provide viable treatment options. Moreover, these results 
confirm that our BTHS cell model can serve as a convenient platform that can be used to 
further interrogate the mechanisms that underlie the spectrum of BTHS patient mutants.  
 The beauty of science and the process of discovery is that every question 
answered represents the beginning of many more that will emerge. So while we 
demonstrate that the subcellular localization of mammalian TAZ and the loss of function 
mechanisms of the R57L and H69Q alleles are conserved with its yeast counterpart, our 
characterization of TAZ is but one piece of a larger puzzle. Can the other patient 
mutations be recapitulated and studied in our tazTALEN system? What is the respiratory 
capacity of tazTALEN cells relative to the parental 293, or that of tazTALENs expressing WT 
versus mutant alleles? How do TAZ mRNA expression compare to that of steady state 
protein levels? Is there a correlation? And if not, is TAZ expression regulated 
translationally or post-translationally? Does TAZ interact with other proteins? How may 
these interactions, if they exist, affect TAZ function? These are but a few of the questions 
that arise with the end of the previous chapter. Below are potential directions, grouped 
thematically, that can be pursued. 
Function 
To address some of the immediate issues that were beyond the capacity of 
Chapter 2, a logical next step would be to subject tazTALENs expressing WT- or mutant 
TAZ to a battery of tests (including, and not limited to, ATP turnover, proton leak, 
maximal respiratory capacity, substrate preference) for respiratory function. It has been 
noted by several groups that taz models contain destabilized respiratory supercomplexes 
(2-4) and reduced electron transport chain activities (5) that likely compromise energetic 
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output. Indeed, the expression of WT TAZ in our tazTALEN system is able to rescue the 
lipid defect that defines the syndrome, however, by quantifying the respiratory function 
in our novel BTHS cell model lacking TAZ protein and function, a baseline respiratory 
capacity can be established to investigate how other pathogenic BTHS missense 
mutations influence energy production. Using classical methods such as the oxygen 
electrode and individual respiratory activity assays, the effect of various taz lesions can 
be assessed. For instance, oxygen consumption by mitochondria can be monitored in cells 
after the selective permeabilization of the plasma membrane with minute levels of 
digitonin and upon the addition of respiratory complex-linked substrates (6, 7). In this 
manner, the rate of oxygen consumption becomes a measure of the electron flux through 
the system. Cells with defective TAZ have respiratory impairments (3, 5, 8-10); therefore, 
it is expected that respiratory defects will be revealed with the use of an oxygen electrode 
or with the Extracellular Flux instrument for high throughput analysis. Alternative 
methods to confirm the respiratory defect could also involve in-gel activity assays. 
Respiratory activities can be followed colorimetrically by supplying exogenous substrates 
or artificial electron donors to native gels providing insight into both function and 
assembly. 
 The major ADP/ATP carrier in yeast, Aac2p, interacts with a number of protein 
complexes as well as respiratory supercomplexes. Notably, these interactions are CL-
dependent and functionally important; when CRD1 (cardiolipin synthase) is ablated, 
Aac2p’s interactions with respiratory supercomplexes are destabilized and respiratory 
functionality is decreased (11, 12). In Δtaz1 yeast, Aac2p’s interaction with the 
respiratory supercomplex is reduced or destabilized, and while there is respiratory 
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dysfunction, it is less severe than in the complete absence of CL (11). Therefore, we 
sought to study the assembly of adenine nucleotide translocases (ANT; orthologous to 
ADP/ATP carrier) in our novel TAZ deficient mammalian model. Preliminary results 
suggest that the MLCL:CL imbalance in the tazTALEN cells may compromise ANT2’s 
high molecular weight interactions (data not shown). This suggests that a portion of the 
mammalian ANT2 interactome is either dependent on the acyl chain composition of CL 
and/or sensitive to elevated levels of MLCL since the relative CL levels are not different 
between WT 293 and the tazTALEN cells. As ANT2 and other ANT isoforms are necessary 
for ADP/ATP flux between the mitochondria and the rest of the cell (13), the metabolic 
consequences of this quarternary defect need to be further investigated. The resultant 
baseline analyses will provide the framework by which we can systematically, and 
veritably, define the degree of energetic dysfunction that is a consequence of a particular 
patient allele (and its lipid aberrations).  
Characterizing mutants 
When R57L and H69Q alleles were overexpressed in our tazTALEN cell model, the 
cells phenocopied Δtaz1 yeast that expressed the equivalent K65L and H77Q mutations. 
This provides proof-of-principle for the use of our cell model in characterizing other 
known pathogenic mutations. R57L, an unstable protein, and the catalytically-null H69Q 
are mutations that cover two types of loss-of-function mechanisms from a list of seven 
described using 21 missense mutations that are identical or conserved between yeast and 
humans (1, 14). The loss-of-function mechanisms additionally include: non-functional 
truncated products resulting from frameshifts or aberrant splicing; mislocalized within 
mitochondria and aggregation-prone; aberrantly assembled; hypomorphic alleles with 
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residual transacylase activity; and unable to engage in stable productive assemblies. A 
variant(s) from each class can be selected and studied for conserved loss-of-function 
mechanisms. For instance, mutations that are described to be mislocalized and/or 
aggregation-prone when modeled in yeast can be confirmed with APEX2 tagging and 
subsequent electron microscopy, hypomorphic alleles can be subject to transacylase 
assays, while native PAGE can reveal aberrant TAZ assemblies. Further, our tazTALEN 
system can be used to characterize other pathogenic alleles that cannot be modeled in 
yeast due to lack of sequence conservation (ClustalOmega alignment of yeast Taz1p and 
human TAZ revealed an 18.878% identity; Figure 4.1).  
Role of modifying factors 
It has become clear from the numerous case studies of BTHS patients and those 
afflicted with other mitochondrial diseases that strict genotype-phenotype correlations do 
not always exist (15, 16). Modifying factors such as age, gender, genetic and (epigenetic) 
modifiers (17, 18), degree of mitochondrial DNA (mtDNA) penetrance (or mosaicism), 
and mtDNA haplotype likely act as key determinants of BTHS pathogenicity and disease 
progression. It has been demonstrated by several groups that mtDNA haplotypes can 
define gene expression (19) and contribute significantly to the predisposition to and 
severity of mitochondrial diseases (20). Although technically challenging, the 
introduction of various taz alleles into cybrids harboring mtDNA of different haplotypes 
may be required to draw solid genotype-phenotype relationships in BTHS pathogenesis.  
Structure 
Another defining feature of TAZ, which has only complicated our analyses, is its 
protease-resistance. Mammalian TAZ can be degraded by pronase E, a protease mixture, 
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only after the addition of detergent to mitochondria. When human TAZ was 
heterologously expressed in Δtaz1 yeast, a similar protease accessibility profile was 
observed (Figure 4.2) and bolstered our original interpretation of TAZ’s 
submitochondrial localization, which placed the protein on the matrix-facing leaflet of the 
matrix. However, this conclusion was arrived at using a classical biochemical approach 
that requires the target protein to be protease sensitive in order to interrogate its topology. 
Unfortunately, TAZ happens to be resistant to numerous proteases and behaves as a 
tightly folded protein. When endogenous or overexpressed TAZ is boiled in the presence 
of detergent prior to protease treatment, TAZ becomes more easily degraded, 
demonstrating that if TAZ is first denatured by heat and remains unfolded in the presence 
of detergent, TAZ becomes susceptible to proteolytic degradation. Interestingly, yeast 
Taz1p also contains a core structure that is resistant to proteinase K degradation (up to 1 
mg/ml) in the presence of 0.1% Triton X-100 (21), pointing to structural conservation 
across eukaryotes.  
It is curious as to why TAZ is so obstinate to proteolysis (protease treatment and 
overall turnover) despite numerous cleavages that are allowed by thermolysin (85 
cleavage sites), proteinase K (141 sites), and trypsin (33 sites) when the PeptideCutter 
algorithm was used (22). For instance, proteins that can resist the action of proteinase K 
are rare as this serine protease exhibits broad substrate specificity and potent proteolytic 
activity in the presence of detergents and over a wide pH range. Exceptions include the 
well-known Protease-resistant protein, PrP, pathogenic aggregates such as α-synuclein, 
and the protease itself. Since (endogenous) TAZ is not present in aggregates and 
participates in a range of high molecular weight interactions, TAZ’s intrinsic resistance 
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towards proteases likely has functional implications. Perhaps TAZ needs to remain 
tightly folded as a consequence of its localization and function; it is anchored to the 
membrane but exposed to the soluble IMS. Further, it catalyzes the transfer of fatty acyl 
chains between phospholipids at the interface of the hydrophobic core of the membrane 
bilayer and the hydrophilic lipid head groups. As TAZ needs to function dynamically at 
this water-lipid interface on multiple fronts it may be critical that the protein remains 
ordered, folded, and resistant to changes in the electrostatic environment to ensure 
function. For example, residues participating in disulfide bonding and metal coordination 
in copper and zinc superoxide dismutases, which are critical for function, are largely 
SDS-resistant, characteristics that likely evolved as a way to preserve structural integrity 
and function in the face of its oxidatively damaging substrates (free radicals, superoxide 
anions, etc). 
Unfortunately, a structure for TAZ is lacking and antibodies against endogenous 
TAZ have been unavailable (until now), precluding structure-function analyses that 
would be helpful in dissecting the mechanisms underlying the various loss-of-function 
mutations. A cursory examination of full-length human TAZ using ProtParam (22) shows 
that behind leucine (11.0%) and glycine (7.5%), proline (7.2%) is the third most abundant 
amino acid represented in TAZ’s sequence (Figure 4.3). Prolines in peptide chains can 
influence the conformation and folding of the peptide backbone by virtue of its unique 
cyclic and imino structure. As a result, its rigidity prevents it from occupying many of the 
main-chain conformations that can be adopted by other amino acids. Further, there is 
evidence that suggests that di-proline motifs in the C’ terminus of a protein (TAZ has two 
di-prolines, one close to each termini of the protein) or prolines, in general, may decrease 
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the proteins susceptibility to proteolytic enzymes (23, 24). In fact, of the 38 proteases 
tested by PeptideCutter, none are predicted to cleave TAZ’s di-proline pair (22); proline 
endopeptidases have been reported to cleave di-proline bonds, but only substrates whose 
sequences do not exceed 30 amino acids (25). Thus, the preponderance of prolines is 
striking and worth investigating as they may be involved in conferring TAZ its unique 
structural characteristics.  
Membrane association 
 Another aspect of TAZ that remains elusive are the amino acids that mediate the 
protein’s membrane association. As TAZ does not contain an N’ terminal targeting signal 
and does not undergo processing during mitochondrial import, the protein is likely 
targeted to its final localization via hydrophobic stretches that may act as internal stop-
transfer signals. As mentioned briefly in Chapter II, algorithms that are commonly used 
to predict transmembrane (TM) domains show conflicting results for TAZ. In the absence 
of any solid structural data, it could be helpful to generate deletions in regions of the 
protein that exhibit high hydrophobicity (TM-like) to arrive at residues involved in 
membrane interactions. Subsequently, carbonate extraction and/or digitonin fractionation 
of the various TM mutants, along with APEX2-tagging, if need be, can be performed to 
zero in on TAZ’s putative “membrane anchor(s)”. In yeast, mutations modeled at V223D, 
V224R, and I226P are thought to disrupt a hydrophobic stretch of the protein that may be 
involved in membrane anchoring, resulting in mutant Taz1 proteins that are partially 
mistargeted to the mitochondrial matrix, aggregation-prone, and fail to function (14, 21). 
As these mutants can be translated and properly imported, at least in yeast, residues at the 
equivalent human positions, I209, L210, and L212, should be mutagenized and 
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introduced into tazTALEN cells to assess the phospholipid and metabolic consequences of 
these mutations. Besides systematically mutating and/or deleting portions of the protein 
to identify sequences important for membrane association, other modes of membrane 
association such as myristoylation, prenylation, and palmitoylation should also be 
explored. TAZ contains two cysteines, Cys33 and Cys118, that are predicted to be 
palmitoylated (26). Further, Cys33 is invariant between yeast and humans. Notably, 
BTHS patients harboring Cys118 missense mutations exist (27, 28) and since the residue 
is not conserved between yeast and humans, would serve as an ideal candidate to 
investigate using our tazTALEN system. 
An interesting idea to consider is the effect of TAZ mislocalization or “re-
localization” within the mitochondrion. TAZ’s current placement on the IMS-facing 
leaflet of the IMM and/or OMM is difficult to reconcile with CL’s predominance in the 
matrix-facing leaflet, the site of its biosynthesis. On the surface, it seems energetically 
costly to flip-flop CL across the IMM for multiple rounds of remodeling by an enzyme 
that does not exhibit intrinsic substrate specificity (29). Thus, it may be worthwhile to 
investigate the effects of a matrix-localized TAZ that would place the protein in the same 
compartment as the core CL biosynthetic machinery. A starting point might involve 
mutating the I209, L210, and L212 residues to less disruptive amino acids such as alanine 
(i.e. “targeted” alanine scanning mutagenesis). Since the introduction of charged or 
kinked residues within and/or flanking the hydrophobic “anchor” may actually repel 
membrane association or disrupt TAZ’s overall protein fold and stability (in addition to 
causing its mislocalization), mutagenesis to alanine may reveal ameliorated phenotypes.  
TAZ interactions 
205 
In yeast, Taz1p has been shown to interact with the major ADP/ATP carrier, 
Aac2p, and the ATP synthase, both of which are key components in the supply and flux 
of energy intermediates across the mitochondrial IM (30). However, in mammals, not 
much is known about TAZ’s interactome. Using the STRING database that includes 
known and predicted protein interactions, be it direct or indirect, a query for human TAZ 
revealed hits such as phospholipases, PLA2G6 and PLA2G4A, as well as HADHB, 
DNAJC19, and OPA3 (31). Most of the listed interactions are identified by textmining 
published abstracts rather than actual experimentation and therefore, would need to be 
interrogated using biochemical and cell biological techniques such as 
immunoprecipitation, co-expression, and or proteomics. Interestingly, of the multiple 
large-scale mammalian mitochondrial proteomes that are available in the literature (32-
41), only one study (42) was able to identify TAZ as a component and resident of the 
mitochondrion, and only in mouse liver mitochondria. In hindsight, the lack of TAZ in 
these proteomic studies might hark back to TAZ’s inherent structural stability and 
resistance towards tryptic digests (and therefore preclude peptide identification by 
MS/MS).  
For a more directed approach at identifying proteins that interact with TAZ, cells 
expressing CNAP-TAZ or TAZ-3XFLAG can be used. As their expression restores the 
lipid aberrations in tazTALEN cells, TAZfunction is not adversely affected by either added 
tag. The N’ terminal CNAP-tag (containing His and Protein C epitopes) appended onto 
TAZ has been successfully used to define the yeast Aac2p interactome (12) and the 
human ANT1 and ANT2 interactome (data not shown). In the latter experiment, cells 
expressing tagged and untagged ANTs were differentially cultured in either labeled 
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“heavy” medium or unlabeled “light” medium; mitochondrial lysates were affinity 
purified and mixed prior to gel resolution and subsequent LC-MS/MS. By coupling 
SILAC (stable isotope labeling of amino acids in cell culture) labeling with conventional 
MS/MS-based proteomics, quantitative levels of hits can be obtained and non-specific 
hits can be largely eliminated (43). If somehow digitonin-solubilized TAZ adversely 
affects protein binding (in light of evidence suggesting that TAZ’s specificity is 
determined by the physical state of its lipid macroenvironment (29)), APEX2-tagged 
TAZ constructs that are already generated and characterized can be used. The engineered 
peroxidase tag is capable of biotinylating in vivo proteins proximal to TAZ in the 
presence of biotin-phenol and H2O2 (34). The labeled proteins can then be enriched with 
the use of streptavidin-conjugated resin. Presumably, the high binding affinity of biotin 
for streptavidin would allow for the identification of partners that may otherwise be 
transient interactions or present at low abundance. The limitation of the APEX2 
proteomic approach is that the peroxidase is highly promiscuous and lacks specificity, as 
such, not all proteins can be labeled and if identified, might not be true interactors but 
highly abundant and/or reactive proteins (44). Another issue that has to be considered is 
whether or not appending the APEX2 tag onto the highly folded and protease resistant C’ 
termini would affect APEX2’s function and hamper accessibility to proximal proteins 
due to steric hindrance.  
TAZ expression and regulation 
TAZ expression has been largely documented on the mRNA level (45-47); in 
humans, at least 6 alternatively spliced isoforms (FL, -ex5, -ex7, -ex5,7, -ex6,7, and –
ex5,6,7) are thought to exist (47, 48). When TAZ mRNA expression was surveyed in a 
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variety of tissues, the mRNA expression pattern was similar for most isoforms except for 
TAZ-ex6,7 (overall low abundance) and did not necessarily correlate to tissues that are 
primarily affected in BTHS pathology (i.e. heart and skeletal muscle) (48). Further, when 
various TAZ isoforms were expressed in BTHS patient fibroblasts, none of the isoforms, 
individually, were able to thoroughly rescue the lipid defect (though there is a slight 
improvement) (48), pointing to functional contributions of each of the spliced variants. 
However, in Δtaz1 yeast, only the heterologous expression of human TAZ variant lacking 
exon 5 can restore the lipid defects; full-length human TAZ can only partially restore the 
CL profile (49).  
As is, the relative importance of each splice variant remains unclear. Thus, using 
our TAZ mAbs, which conveniently recognize epitopes in three different exons, the 
relationship between mRNA expression and steady state protein levels can be explored. 
In our tazTALEN system, TAZ mRNA levels are unchanged between wt 293 and tazTALEN 
cells despite the absence of a protein product in the latter. mRNA analysis of TAZ splice 
variants in patient fibroblasts show a wide spectrum of transcript levels – some alleles 
have increased mRNA expression that might be caused by transcriptional upregulation 
but other alleles had unaffected, decreased, or even absent TAZ transcript levels (48). 
These results suggest that TAZ is unlikely to be regulated at the transcriptional level, like 
that posited for CL metabolism (50, 51), as there seems to not be any conclusive 
transcriptional upregulation in the absence of TAZ activity. 
If TAZ is not regulated at the transcriptional level, translational and post-
translational mechanisms could be in play. Importantly, TAZ-ex5 is the only variant 
expressed in 293 cells and its reintroduction into tazTALEN.2 and .19 clearly rescued the 
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MLCL:CL imbalance. Even though our quantitative RT-PCR did not distinguish between 
the different TAZ mRNA that might be present, isoform-specific primers can be designed 
to determine the relative expression of each variant in 293 cells. If multiple TAZ isoforms 
are present and yet only TAZ-ex5 is translated, translational regulation of TAZ clearly 
exists, perhaps in a tissue-specific manner. Regardless of the mRNA transcripts that are 
present, the absence of functional TAZ in our tazTALEN system can provide a clean 
background to evaluate the individual contributions of each isoform when overexpressed.  
Currently, it remains to be determined if TAZ undergoes any form of PTM. Using 
PTM prediction algorithms, 9 phosphorylated sites (NetPhos 2.0, (52)), 6 glycation sites 
(NetGlycate, (53)), 9 C’ terminal mannosylation sites (NetCGlyc, (54)), and ubiquination 
at position 135 (CPLM, (55)) were identified. Using an antibody against acetylated lysine 
motifs, K149 of human TAZ was identified as acetylated based on proteomic discovery-
mode mass spectrometry (56). While the existence and functional relevance of these 
candidate sites are unknown, for instance, acylation in mitochondria may be a chemical 
event facilitated by alkaline pH and acyl-CoA concentrations in the matrix rather than an 
enzyme-dependent event (57), unconventional PTMs are still worth considering. 
Glycation is hypothesized to participate in mitochondrial pathologies (58) and 
mannosylation could be mediated by mitochondrial mannoysltransferases that are 
activated by phospholipids such as CL (59). Even carbamylation, which occurs on 
mitochondrial glutamate dehydrogenase and increases susceptibility to proteinases (60), 
could be a potential regulatory modification. No N’ terminal acetylation (61), 
myristoylation (Myristoylator, (62)), or prenylation sites (PrePS, (63)) were predicted.  
Final words 
209 
Named after the masochistic Italian comic who finds immense joy in beating his 
jockstrap with a water bottle, TAZ has certainly lived up to its name. During my graduate 
career coddling and prodding this enigmatic lipid remodeler, TAZ and I have had a 
tumultuous relationship filled with excitement, novelty, joy, confusion, deceit, and finally 
acceptance (pun intended). But at the end of all of it, I can only thank TAZ for taking me 
on an unforgettable scientific adventure. If there is anything that I have learned it is that: 
“Do not believe in anything simply because you have heard it. Do 
not believe in anything simply because it is spoken and rumored by many. 
Do not believe in anything simply because it is found written in your 
religious books. Do not believe in anything merely on the authority of 
your teachers and elders. Do not believe in tradition because they have 
been handed down for many generations. But after observation and 
analysis, when you find that anything agrees with reason and is 
conducive to the good and benefit of one and all, then accept it and live 
up to it.” 
– Hindu Prince Gautama Siddharta, the founder of Buddhism,
563-483 BC) 
Q16635|TAZ_HUMAN       -----------------MPLHVKWPFPAVPPLTWTLASSVVMGLVGTYSCFWTKYMNHLT 43
Q06510|TAZ1_YEAST      MSFRDVLERGDEFLEAYPRRSPLWRFLSYSTSLLTFG----VSKLLLFTCYNVKLNGFE- 55
* * :      *:.    :. :  ::*: .*   .  
Q16635|TAZ_HUMAN       VHNREVLYELIEKRGPATPLITVSNHQSCMDDPHLWGILKLRHIWNLKLMRWTPAAADIC 103
Q06510|TAZ1_YEAST      ----KLETALERSKRENRGLMTVMNHMSMVDDPLVWATLPYKLFTSLDNIRWSLGAHNIC 111
::   * ..:     *:** ** * :*** :*. *  : : .*. :**: .* :**
Q16635|TAZ_HUMAN       FTKELHSHFFSLGKCVPVCRG-AEFFQAENEG-KGVLDTGRHMPGAGKRREKGDGVYQKG 161
Q06510|TAZ1_YEAST      FQNKFLANFFSLGQVLSTERFGVGPFQGSIDASIRLLSPDDTLDLEWTPHSEVSSSLKKA 171
* ::: :.*****: : . *  .  **.. :.   :*.    :    . :.: ..  :*.
Q16635|TAZ_HUMAN       MDFILEKLNHGDWVHIFPEGKVN-----MSSEFLRFKWGIGRLIAECHLNPIILPLWHVG 216
Q06510|TAZ1_YEAST      YS-PPIIRSKPSWVHVYPEGFVLQLYPPFENSMRYFKWGITRMILEATKPPIVVPIFATG 230
.      .: .***::*** *      :...:  ***** *:* *.   **::*:: .*
Q16635|TAZ_HUMAN       MNDVLPNSPP-------YFPRFGQKITVLIGKPFSALPVLERLRAENKSAVEMRK----- 264
Q06510|TAZ1_YEAST      FEKIASEAVTDSMFRQILPRNFGSEINVTIGDPLNDDL-IDRYRKEWTHLVEKYYDPKNP 289
::.:  ::            .**.:*.* **.*:.    ::* * * .  **        
Q16635|TAZ_HUMAN       -ALTDFIQ--EEFQHLKT-QAEQLHNHLQPGR---------------------------- 292
Q06510|TAZ1_YEAST      NDLSDELKYGKEAQDLRSRLAAELRAHVAEIRNEVRKLPREDPRFKSPSWWKRFNTTEGK 349
*:* ::  :* *.*::  * :*: *:   *
Q16635|TAZ_HUMAN       -------------------------------- 292
Q06510|TAZ1_YEAST      SDPDVKVIGENWAIRRMQKFLPPEGKPKGKDD 381
FIGURE 4.1 Clustal Omega (1.2.1) alignment of human and yeast tafazzin. Sequences 
corresponding to yeast.Taz1p (Q06510) and full-length human TAZ (Q16635) were retrieved 
from Uniprot and aligned using CLUSTAL O(1.2.1). The epitopes recognized by each of the three 
mAbs are highlighted within the sequence alignment. Characterized and uncharacterized BTHS 
mutants are noted in various colors.  
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FIGURE 4.2 Protease accessibility of human TAZ lacking exon 5 






















FIGURE 4.3 Amino acid compositions of human and yeast tafazzin.The relative 
contributions of each amino acid to the final protein.The outer ring represents the amino 
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After biosynthesis, an evolutionarily conserved acyl chain remodeling process generates 
a final highly homogenous and yet tissue-specific molecular form of the mitochondrial 
lipid cardiolipin. Hence cardiolipin molecules in different organisms, and even different 
tissues within the same organism, contain a distinct collection of attached acyl chains. 
This observation is the basis for the widely accepted paradigm that the acyl chain 
composition of cardiolipin is matched to the unique mitochondrial demands of a tissue. 
For this hypothesis to be correct, cardiolipin molecules with different acyl chain 
compositions should have distinct functional capacities and cardiolipin that has been 
remodeled should promote cardiolipin-dependent mitochondrial processes better than its 
unremodeled form. However, functional disparities between different molecular forms of 
cardiolipin have never been established. Here we interrogate this simple but crucial 
prediction utilizing the best available model to do so, Saccharomyces cerevisiae. 
Specifically, we compare the ability of unremodeled and remodeled cardiolipin, which 
differ markedly in their acyl chain composition, to support mitochondrial activities 
known to require cardiolipin. Surprisingly, defined changes in the acyl chain composition 
of cardiolipin do not alter either mitochondrial morphology or oxidative phosphorylation. 
Importantly, preventing cardiolipin remodeling initiation in yeast lacking TAZ1, an 
ortholog of the causative gene in Barth syndrome, ameliorates mitochondrial dysfunction. 
Thus, our data do not support the prevailing hypothesis that unremodeled cardiolipin is 
functionally distinct from remodeled cardiolipin, at least for the functions examined, 
suggesting alternative physiological roles for this conserved pathway. 
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INTRODUCTION 
Cardiolipin (CL), a mitochondrial phospholipid with two phosphate headgroups 
and four acyl chains, is required for the optimal function of numerous mitochondrial 
processes, including oxidative phosphorylation (OXPHOS) (Acehan et al., 2011; 
Claypool et al., 2008b; Eble et al., 1990; Fry and Green, 1980; Fry and Green, 1981; 
Gomez and Robinson, 1999; Koshkin and Greenberg, 2000; Koshkin and Greenberg, 
2002; Pfeiffer et al., 2003; Schwall et al., 2012; Sedlak and Robinson, 1999; Zhang et al., 
2002; Zhang et al., 2005), protein import (Gebert et al., 2009; Jiang et al., 2000; Marom 
et al., 2009; van der Laan et al., 2007), establishment of cristae morphology (Claypool et 
al., 2006; Mileykovskaya and Dowhan, 2009), fission and fusion (Ban et al., 2010; 
DeVay et al., 2009; Montessuit et al., 2010), and apoptosis (Gonzalvez et al., 2008; 
Ostrander et al., 2001). Despite limited acyl chain specificity of the CL biosynthetic 
enzymes (de Kroon et al., 2013; Houtkooper et al., 2006), the acyl chain composition of 
CL within an organism or cell type displays a remarkable degree of homogeneity 
(Schlame et al., 2005). This is achieved via acyl chain remodeling that is initiated by a 
lipase(s), generating monolyso-CL (MLCL, CL lacking one acyl chain), and completed 
by a transacylase or an acyltransferase which reacylates MLCL (Claypool and Koehler, 
2012). 
Mutations in the MLCL transacylase tafazzin cause Barth syndrome, resulting in 
cardiac and skeletal myopathy, cyclic neutropenia, and respiratory chain defects (Barth et 
al., 1983; Bione et al., 1996; Schlame and Ren, 2006). In Barth syndrome patients and 
models of Barth syndrome, CL levels are decreased, MLCL accumulates, and the 
remaining CL contains an altered acyl chain composition (Gu et al., 2004; Schlame et al., 
2003; Soustek et al., 2011; Valianpour et al., 2005; Whited et al., 2012; Xu et al., 2006a), 
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although which lipid alteration either individually or in combination leads to 
mitochondrial dysfunction has not been thoroughly investigated.   
While the pathophysiological importance of defective CL remodeling is firmly 
established, the physiological importance of this pathway represents a largely 
unaddressed issue that is preventing a comprehensive molecular understanding of how 
this evolutionarily conserved and clinically relevant process promotes mitochondrial 
function. The most widely accepted hypothesis is based on the highly intriguing 
observation that the final homogeneous molecular form of CL varies between organisms 
or even between tissues within the same organism (Cheng et al., 2008; Schlame et al., 
2005). As such, it is postulated that CL molecules with different acyl chain compositions 
are functionally distinct, and that the molecular form of CL specifically fits the demands 
of its host cell (Cheng et al., 2008; Houtkooper et al., 2009; Kiebish et al., 2012; Schlame 
et al., 2002). However, as of yet, this provocative hypothesis has not been directly tested 
in any model organism.  
 At present, yeast are not merely the best, but also the only model available 
capable of directly comparing the functionality of distinct molecular forms of CL in 
otherwise isogenic cells. Three CL remodeling pathways have been identified in higher 
eukaryotes, although their relative contribution to establishing the final molecular form of 
CL is unclear (Claypool and Koehler, 2012; Schlame, 2013). In contrast, yeast only 
undergo tafazzin-mediated CL remodeling. Recently, the phospholipase that initiates CL 
remodeling was identified in yeast as Cld1p (Beranek et al., 2009). Cld1p has no 
homolog in higher eukaryotes; however its function, the removal of an acyl chain from 
CL to form MLCL, is conserved. A similar phenomenon is seen with the 
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phosphatidylglycerolphosphate phosphatase in CL biosynthesis: the yeast (Gep4p) and 
mammalian (PTPMT1) enzymes are phylogenetically unrelated despite catalyzing the 
same reaction (Osman et al., 2010; Zhang et al., 2011a). A calcium-independent 
phospholipase A2 has been identified as a CL phospholipase in flies (iPLA2-VIA) and 
mammals (iPLA2γ) (Malhotra et al., 2009; Mancuso et al., 2007; Schlame et al., 2012b).  
However, murine iPLA2γ is not the lipase that provides the substrate MLCL utilized by 
tafazzin (Kiebish et al., 2013). Consequently, the exact role of these lipases in CL 
remodeling is unclear. Therefore, in higher eukaryotes, not only are there multiple 
potential CL remodeling pathways, but additionally, a complete inventory of all of the 
involved players has not been established. As such, it is currently not possible to compare 
the functionality of distinct molecular forms of CL in metazoans.   
 In contrast, Cld1p localizes exclusively to mitochondria and is the only lipase that 
initiates tafazzin-mediated CL remodeling in yeast (Baile et al., 2013; Beranek et al., 
2009). Here, we utilized Δcld1 yeast to determine if cardiolipin molecules with different 
acyl chain compositions—in this case unremodeled versus remodeled cardiolipin—have 
distinct functional capacities, a central prediction of the prevailing hypothesis.  
Unexpectedly, unremodeled CL functioned as well as remodeled CL in maintaining 
mitochondrial morphology and promoting OXPHOS. Further, mutating CLD1, and thus 
preventing the initiation of CL remodeling, was able to suppress the defects of Δtaz1 
yeast. Thus, we conclude that in yeast, unremodeled CL can support known CL-




CLD1 functions upstream of TAZ1 in CL remodeling 
The initial characterization of CLD1 revealed that Δcld1 and Δcld1Δtaz1 yeast 
contained identical mitochondrial phospholipid profiles (Beranek et al., 2009), indicating 
that CLD1 is epistatic to TAZ1 (the yeast homolog of tafazzin) in the same pathway. In 
contrast, growth on respiratory media, where ethanol and glycerol are the only available 
carbon sources thus requiring ATP generated by OXPHOS, suggested that CLD1 
functions in a pathway parallel to, or distinct from, TAZ1 (Beranek et al., 2009). 
In an attempt to resolve this, we analyzed CL biosynthesis and remodeling 
mutants in multiple independent yeast strains. As expected, in mitochondria isolated from 
yeast lacking cardiolipin synthase (Δcrd1), CL was absent and its precursor PG 
accumulated (Figure A.1). Importantly, the same phospholipid profile was seen in the 
double mutant, Δcrd1Δcld1, indicating that CLD1 functions after CRD1, in one pathway. 
The Δcld1 mutant displayed a lipid profile similar to that of wild type, while Δtaz1 
resulted in a reduction of CL and an accumulation of MLCL. The double mutant 
Δcld1Δtaz1 phenocopied Δcld1 and wild type. Thus, in agreement with previous studies 
(Baile et al., 2013; Beranek et al., 2009), analysis of mitochondrial phospholipids 
indicates that CLD1 functions upstream of TAZ1 and downstream of CRD1 in the CL 
remodeling pathway. 
The placement of CLD1 between CRD1 and TAZ1 was also analyzed by growth 
on respiratory media (Figure A.2). Δcrd1 yeast displayed a growth defect, and both 
Δcrd1Δcld1 and Δcrd1Δtaz1 mimicked this phenotype, confirming that CRD1 is 
upstream of both CLD1 and TAZ1. Δtaz1 yeast also displayed a growth defect on 
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respiratory media, but only at elevated temperature. Consistent with Berenak et al, Δcld1 
yeast grew as well as wild type, but in contrast to their results, our analysis showed that 
Δcld1Δtaz1 did not exhibit a growth defect and phenocopied Δcld1. To rule out strain-
specific differences, this epistasis analysis was confirmed in two additional genetic 
backgrounds (Figures A.1 and A.2). Therefore, CLD1 functions upstream of TAZ1 in a 
single biochemical pathway. 
Δcld1 mitochondria contain unremodeled CL 
CL from Δcld1 yeast was previously shown by GC/MS to contain more C16:0 fatty 
acyl chains than wild type at the expense of C18:1 and C16:1 (Beranek et al., 2009). This is 
consistent with the presence of unremodeled CL in Δcld1 mitochondria, and prompted us 
to analyze more comprehensively the acyl chain composition of CL in remodeling 
mutants by shotgun lipidomics (Figures A.3A and Tables 4 and 5). The acyl chain 
composition of CL from Δcld1 or Δtaz1 mitochondria was clearly altered compared to 
wild type, and the CL species that accumulated in Δcld1 were similar to that of 
Δcld1Δtaz1, consistent with CLD1 functioning upstream of TAZ1. 
Unremodeled CL in yeast is characterized in part by saturated acyl chains of 
increased heterogeneity. To quantify this, the molecular species of CL from each strain 
was categorized by the number of saturated acyl chains, and expressed as the percent of 
total CL (Figure A.3B). CL from wild type mitochondria contained mostly unsaturated 
fatty acyl chains; only 8% contained one saturated acyl chain while the remaining 92% of 
CL contained no saturated acyl chains. In contrast, only 20% of CL from Δcld1 contained 
no unsaturated acyl chains, whereas 51% and 28% of CL contained one or two saturated 
acyl chains, respectively. 
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Interestingly, the presence of CL with no saturated acyl chains in both Δcld1 and 
Δtaz1 mitochondria suggests that either an alternate (albeit minor) CL remodeling 
pathway exists, or instead that a subpopulation of newly synthesized CL already contains 
four unsaturated acyl chains. While the relative amounts of mature (e.g. a remodeled-like 
acyl chain composition) CL vary between Δcld1 and Δtaz1 mitochondria, the absolute 
amounts are similar (Figures A.3C and D), implying that Cld1p is able to specifically 
deacylate unremodeled CL. This is further supported by the molecular species of MLCL 
present in Δtaz1; although 28% of CL in Δcld1 contains 2 saturated acyl chains, none of 
the molecular forms of MLCL in Δtaz1 contained 2 saturated acyl chains (Figure A.3E 
and Table 5), suggesting that Cld1p preferentially removes saturated acyl chains from 
CL. 
Thus, we have provided the most extensive analysis to date of the CL acyl chain 
composition in CL remodeling mutants. CL molecules from Δcld1 yeast contain more 
saturated acyl chains than wild type, consistent with unremodeled CL. Accordingly, 
Δcld1 is a genetic tool to determine if CL molecules with different acyl chain 
compositions are functionally distinct in a strain that is otherwise isogenic to wild type 
yeast. 
CL remodeling is not required to maintain mitochondrial morphology 
Altered mitochondrial morphology has been observed in Δcrd1 and Δtaz1 yeast 
(Claypool et al., 2008a; Mileykovskaya and Dowhan, 2009). To determine what role, if 
any, CL remodeling plays in the establishment and/or maintenance of mitochondrial 
morphology, CL remodeling mutants were analyzed by EM (Figures A.4 and A.5). 
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 No overt morphological differences were observed between mitochondria in wild 
type and Δcld1 yeast (Figure A.4A). Surprisingly, the morphology of mitochondria in 
Δcrd1 and Δtaz1 also appeared unaffected, although measurement of mitochondrial 
membranes indicated that both mutants contained longer cristae membranes than wild 
type or Δcld1 (Figures A.4B and C). Additionally, no difference in the number of 
aberrant mitochondria, which display exaggerated cristae, was observed between wild 
type and any CL remodeling mutant (Figures A.4D and E). 
 To confirm these results, mitochondria from CL remodeling mutants derived from 
the W303 genetic background were also analyzed (Figure A.5). While no remarkable 
morphological defects were observed (Figure A.5A), mitochondria from Δcrd1 and Δcld1 
(but not Δtaz1) yeast displayed longer cristae membranes than wild type, and all of the 
mutants displayed longer OMM membranes than wild type (Figures A.5B and C). 
Additionally, in the W303 background, no aberrant mitochondria were observed in wild 
type (Figures A.5D and E), unlike the mutants which contained a small fraction of 
aberrant mitochondria. 
 The mitochondrial morphology in Δcrd1, Δcld1, and Δtaz1 yeast remained largely 
unperturbed, although subtle differences were noted. Importantly, studies which 
previously reported abnormal mitochondrial morphology in Δcrd1 and Δtaz1 yeast never 
reported the penetrance of the observed defects (Claypool et al., 2008a; Mileykovskaya 
and Dowhan, 2009). Furthermore, our results indicate that the genetic background 
contributes to mitochondrial morphology. Thus, we conclude that there is not a general 
morphological phenotype in mitochondria lacking either remodeled CL or CL entirely. 
CL remodeling is not required for optimal OXPHOS function 
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CL is required for the optimal function of respiratory complexes (Fry and Green, 
1980; Fry and Green, 1981; Gomez and Robinson, 1999; Koshkin and Greenberg, 2000; 
Koshkin and Greenberg, 2002; Schwall et al., 2012; Sedlak and Robinson, 1999), as well 
as for the stability of respiratory supercomplexes (Claypool and Koehler, 2012; Claypool 
et al., 2008b; Pfeiffer et al., 2003; Zhang et al., 2002; Zhang et al., 2005). Respiratory 
supercomplexes, which in yeast consist of two copies of complex III and either one 
(III2IV) or two (III2IV2) copies of complex IV, increase the efficiency of electron flux 
through the electron transport chain via substrate channeling (Cruciat et al., 2000; 
Lapuente-Brun et al., 2013). Thus, we used Δcld1 to determine the ability of 
unremodeled CL to support OXPHOS. 
In Δcrd1 (and Δcrd1Δcld1) mitochondria, respiratory supercomplexes were 
destabilized due to the absence of CL, as seen by the decreased abundance of the III2IV2 
supercomplex and the resultant increase in the III2IV supercomplex, as well as the 
liberated complex III dimer and free complex IV (Figure A.6A). Additionally, the 
ADP/ATP carrier (Aac2p) did not assemble into higher molecular weight complexes, 
including with respiratory complexes, in the absence of CL (Claypool et al., 2008b). In 
Δtaz1, respiratory supercomplex stability was not affected, although the association of 
Aac2p with the supercomplex was diminished. In Δcld1 however, the stability of 
respiratory supercomplexes, including those containing Aac2p, was preserved, indicating 
that the acyl chain composition of CL does not affect respiratory supercomplex stability. 
We further investigated the role of the molecular form of CL in OXPHOS by 
measuring the rate of O2 consumption in isolated mitochondria. The P/O ratio (a measure 
of OXPHOS efficiency) in Δcld1 mitochondria was indistinguishable from wild type, but 
 232 
was decreased in Δcrd1, Δcrd1Δcld1, and Δtaz1 mitochondria (Figure A.6B). Likewise, 
no change in the respiratory control ratio (RCR; a measure of OXPHOS coupling) was 
observed in Δcld1 compared to wild type (Figure A.6C). Notably, the OXPHOS defects 
observed in Δtaz1 mitochondria were suppressed after the additional deletion of CLD1. 
As an alternative method to measure OXPHOS function, we tracked the 
membrane potential (Δψm) of isolated mitochondria using the potentiometric fluorescent 
probe TMRM (Figure A.6D). Δψm was established via NADH addition, and state 3 
respiration was induced by adding ADP, which caused a transient depolarization due to 
the utilization of the proton gradient to drive ADP/ATP transport by Aac2p and ATP 
production by complex V. After the ADP was consumed, the inner membrane repolarized 
and state 4 respiration resumed. Δcld1 and Δcld1Δtaz1 mitochondria were able to 
repolarize at rates identical to wild type, whereas Δcrd1, Δcrd1Δcld1 and Δtaz1 
mitochondria repolarized more slowly (Figure A.6E). Taken together, these results 
indicate that OXPHOS coupling is not dependent on the acyl chain composition of CL 
that is generated by tafazzin-mediated remodeling. 
Interestingly, the individual state 3 and state 4 respiration rates in Δcrd1 and 
Δtaz1 mitochondria were higher than in wild type (Figure A.7A), which is consistent with 
some reports, but different from others (Claypool et al., 2008b; Jiang et al., 2000; 
Koshkin and Greenberg, 2000; Koshkin and Greenberg, 2002; Ma et al., 2004). This 
observation potentially could be due to a lower steady-state Δψm for mitochondria from 
these strains which, due to respiratory control, would result in higher respiration rates 
(e.g. easier to pump protons against a lower electrochemical potential); but relative Δψm 
measurements in Δcrd1 and Δcrd1Δcld1 mitochondria were not significantly different 
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from wild type (Figure A.7B). However, TMRM time traces revealed that immediately 
after establishing the Δψm, Δcrd1, Δcrd1Δcld1, and Δtaz1 mitochondria began to 
depolarize, whereas those from the other strains maintained a high Δψm (Figure A.6D). 
This depolarization may originate from breaches in the inner membrane permeability 
barrier that, although not large enough to resolve on measurements of relative steady-
state Δψm (Figure A.7B), could be resolved on individual traces (Figure A.6D). To 
identify the source of the putative proton leak, we tested the effects of inhibiting two key 
OXPHOS components, complex V using oligomycin and Aac2p using 
carboxyatracyloside (Figure A.7C); both of which create regulated aqueous conduits in 
the membrane and require CL for assembly (Acehan et al., 2011; Claypool et al., 2008b). 
The lack of transient depolarization after ADP addition confirmed the efficacy of both 
oligomycin and carboxyatracyloside. Interestingly, both inhibitors curtailed the 
immediate depolarization in Δcrd1, Δcrd1Δcld1 and Δtaz1 mitochondria, suggesting that 
in these strains, the time-dependent decrease in Δψm was mediated by proton leak through 
complex V and Aac2p. 
When respiration was analyzed under uncoupled conditions to measure maximum 
electron transport capacity, a small but significant decrease in mitochondria lacking 
CRD1 was measured, but no decrease was seen in Δtaz1 or Δcld1 (Figure A.8A).  
Measurement of individual complex III and complex IV activities revealed that the defect 
was specific to complex III (Figures A.8B and C), consistent with CL participating in its 
catalytic mechanism (Wenz et al., 2009). Further, the steady state abundance of 
respiratory complex subunits (as well as other mitochondrial proteins) was not affected in 
any mutant (Figure A.8D). Thus, unremodeled and remodeled CL, which differ 
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significantly in their acyl chain composition, have the same capacity to promote the 
expression, assembly, and activity of the OXPHOS system.  
 
DISCUSSION 
Despite the pervasiveness of the hypothesis that CL remodeling establishes a 
molecular form of CL that is optimized to support mitochondrial function, direct 
evidence for this proposition is lacking. Using Δcld1 yeast, which cannot initiate CL 
remodeling, we have provided the most comprehensive comparison to date of the 
intrinsic functional capacity of distinct molecular forms of CL—remodeled vs. 
unremodeled CL—in otherwise isogenic cells.Our data indicate that in yeast 
unremodeled and remodeled CL are equally able to maintain mitochondrial morphology 
and promote OXPHOS and are thus at variance with the prevailing model that CL 
remodeling is critical for mitochondrial function. Still, it is possible that the acyl chain 
composition in mammals plays a larger role in controlling OXPHOS function than in 
yeast and that this capacity has been a relatively recent addition to the functionality of 
this remodeling pathway. Consistent with this possibility is that cardiolipin remodeling 
attributed to acyl-CoA:lysocardiolipin acyltransferase-1, which localizes to the 
endoplasmic reticulum, is associated with mitochondrial dysfunction (Cao et al., 2004; 
Cao et al., 2009; Li et al., 2010). Alternatively, mitochondrial processes other than 
OXPHOS that are presently not known and thus not interrogated in the present study, 
may be dependent on a specific CL acyl chain composition.   
Our results, however, suggest that CL remodeling evolved to achieve other 
biological outcomes instead of simply establishing a tissue-specific molecular form of 
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CL. The ability to remodel CL acyl chains may be more important than the establishment 
of a specific molecular form. CL is susceptible to oxidative damage due to its tight 
association with respiratory complexes, the major sites of reactive oxygen species 
production in a cell (Kim et al., 2011). Thus, CL remodeling may be used as a repair 
mechanism that removes and replaces damaged acyl chains, restoring OXPHOS capacity 
(Baile et al., 2013; Musatov, 2006). Indeed, increased oxidative damage is observed in 
Δtaz1 yeast and Barth syndrome lymphoblasts (Chen et al., 2008; Gonzalvez et al., 
2013). Why then, do most tissues/organisms contain only a few molecular forms of CL? 
Tafazzin has no acyl chain specificity (Xu et al., 2006b). Thus, the acyl chain 
composition of remodeled CL may instead reflect the acyl chain composition of the 
surrounding lipids in the microenvironment containing tafazzin (Schlame et al., 2012a). 
Additionally, when compared to Δcld1, the acyl chain composition of CL in Δtaz1 
suggests that saturated acyl chains are the preferred substrate of Cld1p. As such, the 
specificity of the lipase may also contribute to the final molecular form of CL in a given 
tissue/cell (Zhang et al., 2011b). 
These results have important implications regarding the pathological causes of 
Barth syndrome. Great emphasis has been placed on the altered CL acyl chain 
composition, but Barth syndrome patients (and models) also exhibit decreased levels of 
CL with concurrent increases in MLCL (Gu et al., 2004; Schlame et al., 2003; Soustek et 
al., 2011; Valianpour et al., 2005; Whited et al., 2012; Xu et al., 2006a). Our data suggest 
that the absolute levels of lipids (either decreased CL or increased MLCL) and/or the 
absence of an active remodeling pathway may exert a larger role in contributing to the 
disease state than simple changes in the final acyl chain composition. These conclusions 
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have therapeutic implications. For instance, if alterations in the levels of CL and MLCL 
are the major drivers of mitochondrial dysfunction, than therapies promoting the 
accumulation of CL and/or depletion of MLCL may alleviate the symptoms of Barth 
syndrome. An obvious target to inhibit is the lipase that initiates CL remodeling, as we 
have shown that the Δcld1Δtaz1 yeast strain phenocopies wild type. Interestingly, Barth 
syndrome patient lymphoblasts treated with the iPLA2 inhibitor bromoenol lactone 
partially corrects the MLCL:CL ratio, as does knocking out iPLA2 in TAZ-/- flies 
(Malhotra et al., 2009). However, this strategy is currently hampered in patients since the 
relevant lipase(s) that functions upstream of tafazzin has not been molecularly identified 
(Kiebish et al., 2013). Thus further investigation into the basic biology of CL remodeling 
is required before plausible treatments can be realized. 
 
MATERIALS AND METHODS  
Yeast strains and growth conditions  
All yeast strains used in this study were isogenic to GA74-1A (MATa, his3-11,15, 
leu2, ura3, trp1, ade8 [rho+, mit+]) except where indicated, and have been described 
previously (Baile et al., 2013; Claypool et al., 2008a; Claypool et al., 2008b; Jarosch et 
al., 1996), except Δcrd1Δcld1, which was generated by replacing the entire open reading 
frame of CLD1 with HIS3MX6 and CRD1 with TRP1 (Wach et al., 1994). Strains derived 
from W303 (MATa, ade2-1, ura3-1,15, his3-11, trp1-1, can1-100 [rho+, mit+]) were 
generated by replacing CRD1 with TRP1, CLD1 with HIS3MX6, and/or TAZ1 with 
URA3MX. Strains derived from PTY144 (MATα, leu2-3,112, ura3-52, trp1-Δ1, lys2, 
his3::hisg [rho+, LYS2]) (Thorsness et al., 2002) were generated by replacing CRD1, 
CLD1, or TAZ1 with HIS3MX6, except Δcld1Δtaz1 in which CLD1 was replaced with 
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HIS3MX6 and TAZ1 with URA3MX. Yeast were grown in rich lactate media (1% yeast 
extract, 2% tryptone, 0.05% dextrose, 2% lactic acid, 3.4 mM CaCl2-2H2O, 8.5 mM 
NaCl, 2.95 mM MgCl2-6H2O, 7.35 mM KH2PO4, 18.7 mM NH4Cl, pH 5.5), except for 
growth analysis where overnight YPD (1% yeast extract, 2% peptone, 2% dextrose) 
cultures were spotted on synthetic media (0.17% yeast nitrogen base, 0.5% ammonium 
sulfate, 0.2% complete amino acid mix with either 2% dextrose or 3% glycerol/1% 
ethanol). Genetic knockouts constructed for this study were generated by replacing the 
entire open reading frame of the gene using PCR-mediated gene replacement (Wach et 
al., 1994). 
Multidimensional mass spectrometry-based shotgun lipidomic analysis of 
mitochondrial lipids 
 A modified Bligh and Dyer procedure was used to extract lipids from each yeast 
mitochondrial preparation.  Each lipid extract was reconstituted with a volume of 200 
µl/mg mitochondrial protein in chloroform/methanol (1:1; v/v). Internal standards for 
quantification of individual molecular species of lipid classes were added prior to lipid 
extraction (Christie and Han, 2010). Shotgun lipidomics analyses were performed with a 
QqQ mass spectrometer (Thermo Fisher Scientific TSQ Vantage, San Jose, CA) 
equipped with an automated nanospray device (Triversa Nanomate, Advion Biosciences, 
Ithaca, NY) and operated with Xcalibur software as previously described (Han et al., 
2008). Identification and quantification of lipid molecular species were performed using 
an automated software program as previously described (Yang et al., 2009). 
Electron Microscopy  
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 Cells were harvested and fixed in 3% glutaraldehyde contained in 0.1 M Na 
cacodylate, pH 7.4, 5 mM CaCl2, 5 mM MgCl2, and 2.5% (w/v) sucrose for 1 hour at 
room temperature with gentle agitation; spheroplasted; embedded in 2% ultra low 
temperature agarose (prepared in water); cooled; and subsequently cut into small pieces 
(~1mm3). The cells were then post-fixed in 1% OsO4, 1% potassium ferrocyanide 
contained in 0.1 M Na cacodylate, 5mM CaCl2, pH 7.4 for 30 minutes at room 
temperature. The blocks were washed thoroughly 4X with ddH20, 10 minutes total; 
transfered to 1% thiocarbohydrazide at room temperature for 3 minutes; washed in 
ddH2O (4X, 1 minute each); and transferred to 1% OsO4, 1% potassium ferrocyanide in 
0.1 M Na cacodylate, pH 7.4 for an additional 3 min at room temperature. The cells were 
washed 4X with ddH2O (15 minutes total); en bloc stained in Kellenberger’s uranyl 
acetate (UA) for 2 hr to overnight; dehydrated through a graded series of ethanol; and 
subsequently embedded in Spurr resin. Sections were cut on a Reichert Ultracut T 
ultramicrotome; post-stained with UA and lead citrate; and observed on an FEI Tecnai 12 
TEM at 100kV. Images were recorded with a Soft Imaging System Megaview III digital 
camera; and figures were assembled in Adobe Photoshop with only linear adjustments in 
contrast and brightness. 
Assessment of Δψm  
The lipophilic cationic dye tetramethylrhodamine methyl ester (TMRM, 
Molecular Probes), which accumulates in mitochondria in accordance with a Nernstian 
distribution, was used in quench mode. 2 ml samples of mitochondria (0.1 mg 
mitochondrial protein per ml) in measurement buffer (MB; 20 mM Tris-HCl, pH 7.2, 20 
mM KCl, 3mM MgCl2, 4mM KH2PO4 and 250 mM sucrose) containing 50 nM TMRM 
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(from DMSO stocks, final DMSO concentration 1.0% (v/v)) were added to stirred 
cuvettes. TMRM emission (λex 547 nm; λem 570 nm; slits at 4 nm) was measured over a 
time course that included the successive addition of: (i) respiratory substrate (2 mM 
NADH) at 100 s; (ii) 45 µM ADP, pH 7.5 at 300 s and 700 s, and (iii) 2.5 µM 
valinomycin at 1000 s to completely dissipate the potential. The relative measure of Δψm 
was based on the difference in fluorescence intensity (ΔF) prior to respiratory substrate 
addition and after establishment of the maximal Δψm. The time dependence of return to 
state 4 respiration following the initiation of a phosphorylation cycle was calculated 
graphically (Kaleidagraph) as the time between ADP addition and stable re-establishment 
of the maximal Δψm. Carboxyatractyloside and oligomycin, each at final concentration of 
10 µM were incubated with mitochondria at 4˚C for 5 min either separately or together. 
After incubation, TMRM emission was measured over a time course as described above. 
Complex III and complex IV activity measurements  
Complex III and IV activities were measured as described (Tzagoloff et al., 1975) 
with a few modifications. To measure complex III activity, 1-25 µg mitochondria 
solubilized in 0.5% (w/v) n-dodecyl β-D-maltoside were added to reaction buffer (50 mM 
KPi, 2 mM EDTA, pH 7.4) with 0.008% (w/v) horse heart cytochrome c and 1 mM 
potassium cyanide. The reaction was started by adding 100 µM decylubiquinol, and the 
reduction of cytochrome c followed at 550 nm. Complex IV activity was measured by 
adding mitochondrial extracts to reaction buffer with 0.008% (w/v) ferro-cytochrome c 
and following cytochrome c oxidation at 550 nm. 
Antibodies  
 240 
Most antibodies used in this study were generated in our laboratory or the Schatz 
(J. Schatz, University of Basel, Basel, Switzerland) or Koehler (C. Koehler, University of 
California, Los Angeles, Los Angeles, CA) laboratories and have been described 
previously (Baile et al., 2013; Claypool et al., 2006; Daum et al., 1982; Maccecchini et 
al., 1979; Ohashi et al., 1982; Poyton and Schatz, 1975; Riezman et al., 1983; Whited et 
al., 2012). Other antibodies used were mouse anti-Aac2p clone 6H8 (Panneels et al., 
2003), and horseradish peroxidase-conjugated (Thermo Fisher Scientific) or fluorescent-
conjugated (Pierce) secondary antibodies. 
Miscellaneous  
Isolation of mitochondria, preparation of yeast cell extracts, blue native-PAGE, 
mitochondrial respiration, phospholipid analysis, and immunoblotting were performed as 
previously described (Claypool et al., 2008a; Claypool et al., 2006; Claypool et al., 
2008b). Statistical comparisons were performed by one-way analysis of variance 
compared to wild type using SigmaPlot 11 software (Systate Software, San Jose, CA). 
All graphs show the mean ± SEM. 
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FIGURE A.1. CLD1 is epistatic to TAZ1 in the CL remodeling pathway by mitochondrial 
phospholipid analysis. (A) Mitochondrial phospholipids from the indicated strains derived from 
GA74-1A were labeled with 32Pi and separated by TLC. (B) Quantification of (A).  n = 5-6. *** p < 
0.001  Mitochondrial phospholipids from the indicated strains derived from (C) PTY144 and (D) 
W303 were analyzed as in (A).  Whole cell extracts from the indicated strains derived from (E) 
PTY144 and (F) W303 were immunoblotted. * indicates a non-specific cross reaction of the Cld1p 
antisera.  PA, phosphatidic acid; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PS, 
phosphatidylserine; PI, phosphatidylinositol; PC, phosphatidylcholine.
 244 
 
FIGURE A.2. CLD1 is epistatic to TAZ1 in the CL remodeling pathway by respiratory 
growth analysis. 1:4 serial dilutions of the indicated strains derived from (A) GA74-1A, (B) 
PTY144, or (C) W303 were spotted on the indicated media and incubated at 30°C or 37°C. 
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FIGURE A.3. Δcld1 contains unremodeled CL. (A) The acyl chain composition of CL was 
determined by multidimensional mass spectrometric array analysis. n=3 (B) CL was categorized 
by the number of saturated acyl chains and expressed as a % of the total CL. (C) Quantification 
of the total amount of CL per mg of protein. (D) CL was categorized by the number of saturated 
acyl chains and expressed as the amount of CL per mg protein. (E) The acyl chain composition of 





FIGURE A.4. Mitochondrial morphology is not affected by unremodeled CL in GA74 yeast. 
Mitochondria from the indicated strains derived GA74 were analyzed by TEM. (A) Representative 
micrographs from the indicated strains. m = mitochondria, n = the nucleus. Bars = 0.5 µm. (B) 
Quantification of cristae length per mitochondrion. (C) Quantification of OM length per 
mitochondrion. (D) Quantification of aberrant mitochondria for each strain, defined as the 
appearance of exaggerated cristae >0.5 µm in length. Number of mitochondria analyzed is 
indicated for each strain. (E) Examples of mitochondria with exaggerated cristae. Bars = 0.5 µm. * 





FIGURE A.5. Mitochondrial morphology is not affected by unremodeled CL in W303 yeast. 
Mitochondria from the indicated strains derived GA74 were analyzed by TEM. (A) Representative 
micrographs from the indicated strains. m = mitochondria.  Bars = 0.5 µm. (B) Quantification of 
cristae length per mitochondrion. (C) Quantification of OMM length per mitochondrion. (D) 
Quantification of aberrant mitochondria for each strain, defined as the appearance of exaggerated 
cristae >0.5 µm in length. Number of mitochondria analyzed is indicated for each strain. (E) 





FIGURE A.6. OXPHOS function is not affected by unremodeled CL. (A) Mitochondria were 
solubilized with digitonin, separated by blue native-PAGE (top panels), and immunoblotted for 
Cyt1p (complex III), Cox2p (complex IV), Atp2p (complex V), and Aac2p. Bottom panels are 
immunoblots following SDS-PAGE which serve as loading controls. (B and C) Respiration 
measured in the presence of 2 mM NADH. n = 6-9. (B) P/O ratios. (C) Respiratory control ratios. 
(D) Representative TMRM time traces of mitochondria isolated from the indicated yeast strains 
following the addition of 2 mM NADH (to establish the Δψm) and two sequential additions of 45 
µM ADP to induce phosphorylation cycles, manifest as transient depolarizations. (E) The average 
times required for the re-establishment of maximal (state 4) Δψm following ADP addition for the 





FIGURE A.7. Mitochondrial proton leak is increased in the absence of CL. (A) Respiration of 
isolated mitochondria measured in the presence of NADH (state 4) or NADH and ADP (state 3). 
*** p < 0.001 (B) The relative membrane potentials from 5 independent experiments were plotted 
(circles). The mean ± SEM are displayed as black bars. (C) Membrane potential of the indicated 
strains measured in the presence of oligomycin (left), carboxyatractyloside (middle), or oligomycin 





FIGURE A.8. The individual components of OXPHOS are not affected by unremodeled CL. 
(A) Uncoupled respiration measured in the presence of 2 mM NADH and 10 µM CCCP. (B) 
Complex III and (C) complex IV activity, measured in DDM mitochondrial extracts. ** p < 0.01 (D) 
Mitochondrial proteins from the indicated strains were separated by SDS-PAGE and 
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(Physiology), Johns Hopkins University School of Medicine, 
Baltimore, MD 
  Mentor: Steven M. Claypool, Ph.D.  
09/2005 – 05/2009 B.A., Chemistry and Art History cum laude, Williams College, 
Williamstown, MA 
   Mentor: Amy M. Gehring, Ph.D. 





04/2010 – 12/2015  Graduate research. Lab of Steven M. Claypool, Ph.D. Department 
of Physiology, JHUSOM 
01/2010 – 03/2010 Research rotation. Lab of Svetlana Lutsenko, Ph.D. Department of 
Physiology, JHUSOM 
09/2009 – 12/2009 Research rotation. Lab of Geraldine Seydoux, Ph.D, Department of 
Molecular Biology and Genetics. JHUSOM 
Summers 2007, 2008 Summer Research Assistant. Lab of Amy M. Gehring, Ph.D., 
Department of Chemistry, Williams College 
09/2008 – 06/2009 Senior Thesis research. Lab of Amy M. Gehring, Ph.D., 
Department of Chemistry, Williams College  
Summers 2005, 2006 Summer Intern. Lab of Dr. Hao-Hueng Chang, M.D., Department 





07/2012 – 06/2014 American Heart Association Pre-doctoral Fellowship, Mid-Atlantic 
Affiliate 
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Honors and awards 
2015 Best Poster Award. Gordon Research Conference on Molecular and Cellular 
Biology of Lipids. The same poster was awarded the Best Poster Award 
(presented by and awarded to Claypool SM) at the Lipids – In vivo dynamics, 
Protein Partners, and Signaling Section of the American Society for Biochemistry 
and Molecular Biology 2015 Annual Meeting. 
2014  Poster Travel Award. 7th International Barth Syndrome Scientific, Medical and 
Family Conference. 




 Lu YW, Acoba MG, Kandasamy S, Sathappa M, Alder NN, Claypool SM. The 
role of CL-binding motifs in mediating heterologous interactions of mitochondrial 
carriers. Manuscript in preparation. 
Lu YW, Galbraith L, Herndon JD, Lu YL, Pras-Raves M, Vervaart M, van 
Kampen A, Luyf A, Koehler CM, Gottlieb E, Vaz FM, Claypool SM. Defining functional 
classes of Barth syndrome mutation in humans. In revision at Human Molecular Genetics. 
Bhattacharjee A, Duffy M, Robinson E, Conrad-Antoville A, Lu YW, Mangels C, 
Capps T, Vogt S, Murphy MP, Lutsenko S, Ralle M. Activity of menkes disease protein 
ATP7A is essential for redox balance in the mitochondria. In revision at Journal of 
Biological Chemistry. 
Lu YW, Claypool SM. Disorders of phospholipid metabolism: an emerging class of 
mitochondrial disease due to defects in nuclear genes. Frontiers in Genetics (Invited 
review). 2015 Feb 3; 6: 3. [PMCID: PMC4315098] 
 Baile MG, Lu YW, Claypool SM. The topology and regulation of cardiolipin 
biosynthesis and remodeling in yeast. Chemistry and Physics of Lipids (Invited review). 
2014 Apr; 179: 25-31. [PMCID: PMC3947685] 
 Baile MG, Sathappa M, Lu YW, Pryce E, Whited K, McCaffery JM, Han X, 
Alder NN, Claypool SM. Unremodeled and remodeled cardiolipin are functionally 
indistinguishable in yeast. Journal of Biological Chemistry. 2014 Jan 17; 289(3): 1768-78. 
[PMCID: PMC3894353] 
Lu YW, San Roman AK, Gehring AM. Role of phosphopantetheinyl transferase 
genes in antibiotic production by Streptomyces coelicolor. Journal of Bacteriology. 2008 
Oct; 190(20): 6903-8. [PMCID: PMC2566214] 
 
 
Oral Presentation – National conferences 
 
04/2015 Selected speaker. Topological differences but dysfunctional conservation 
of cardiolipin remodeling. Navigating Lipid Research in Baltimore: from 
Cell to System, 2nd Annual Meeting, Carnegie Institution, Baltimore, MD 
06/2014 Selected speaker. Biochemical characterization of human and murine 
Tafazzin. 7th International Barth Syndrome Scientific, Medical and Family 
Conference, Biennial Meeting, Clearwater, FL 
 
	   267 
Oral Presentations – Local meetings 
 
10/2014 Selected speaker. Biochemical characterization of human and murine 
Tafazzin. Annual BCMB Graduate Program Retreat, Baltimore MD 
02/2012 The role of cardiolipin in defining the interactome of the ADP/ATP carrier. 
Johns Hopkins Yeast Club. JHUSOM, Baltimore, MD 
01/2012 The role of cardiolipin in defining the interactome of the ADP/ATP carrier. 




    
Lu YW, Galbraith L, Gottlieb E, Vaz FM, Claypool SM. 2014. Topological 
Difference but Dysfunctional Conservation of Cardiolipin Remodeling in Yeast and 
Mammals. Molecular & Cellular Biology of Lipids, Gordon Research Conference, 
Waterville Valley, NH, July 26-31. 
Lu YW, Galbraith L, Gottlieb E, Vaz FM, Claypool SM. 2014. Biochemical 
characterization of human and murine Tafazzin. 7th International Barth Syndrome 
Scientific, Medical and Family Conference, Clearwater, FL, June 23-28. 
Lu YW, Baile MG, Huang TC, Pandey A, Claypool SM. 2013. The role of 
cardiolipin in defining the mammalian ANT interactome. American Society for 





01/2016 – 03/2016 Teaching Assistant for ME:340.703 Cell Structure and Dynamics. 
Department of Cell Biology, JHUSOM, Baltimore, MD 
 Supervisor: Hiromi Sesaki Ph.D. 
01/2015 – 03/2015 Teaching Assistant for ME:340.703 Cell Structure and Dynamics. 
Department of Cell Biology, JHUSOM, Baltimore, MD 
 Supervisor: Hiromi Sesaki Ph.D. 
01/2014 – 03/2014 Teaching Assistant for ME:340.703 Cell Structure and Dynamics. 
Department of Cell Biology, JHUSOM, Baltimore, MD 
 Supervisor: Peter Espenshade Ph.D. 
10/2013 Teaching Assistant for ME:800.600 Cell Physiology block of 
Scientific Foundations of Medicine (first year medical student core 
curriculum), Department of Cell Biology, JHUSOM, Baltimore, 
MD 
 Supervisor: Erika Matunis Ph.D. 
02/2008 – 05/2009 Laboratory Teaching Assistant for CHEM 151: Concepts of 
Chemistry and CHEM 256: Introduction to Physical and Inorganic 
Chemistry. Department of Chemistry, Williams College, 
Williamstown, MA 
 Supervisor: Enrique Peacock-Lopez Ph.D. 
 




09/2014 – 12/2014 Thomas Lin (JHU undergraduate) 
01/2015 – present Michelle Acoba (Cellular and Molecular Physiology rotation 
student and a now graduate student in the Claypool Lab) 
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